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Abstract 
Nanoparticles are thought to present a unique hazard to human health. Furthermore, the 
increasing use of nanomaterials in consumer products has not been accompanied by relevant 
risk assessments. It is conceivable that skin flexion may assist the translocation of 
nanoparticles across the stratum corneum. However, current in vitro methodology to study 
dermal absorption involves the exclusive use of immobile skin within diffusion cells. 
Therefore, a novel skin-flexing diffusion cell system (“CutaFlex™”) was developed to 
incorporate reproducible skin flexing (2 flexes min
-1
; 6 mm maximum amplitude). The initial 
aims of this Thesis were to characterise the CutaFlex
™
 system to eliminate the possibility of 
flexion-induced (experimental) skin damage, demonstrate equivalence with historical 
permeability data to model compounds and assess the effect of skin flexing on barrier 
disruption. Subsequent work aimed to investigate the hypothesis that nanoparticles require 
dermal flexion to penetrate intact skin.  In supporting these aims, this Thesis also performed 
work to assess the correlation between direct measurements of skin barrier function (using 
tritiated water) and transepidermal water loss (TEWL), the effect of flexing on the 
performance of topical skin protectants (barrier creams) and to further validate in vitro 
diffusion cell measurements against in vivo data acquired under identical conditions. 
The results demonstrated that skin flexing did not alter skin barrier function and that the 
CutaFlex
™
 system was in general agreement with historical measurements of skin 
permeability. Furthermore, controlled chemical or physical damage to the stratum corneum 
was not exacerbated by skin flexing. Skin flexion did not facilitate the dermal absorption of a 
range of nanoparticles (quantum dots). However, differences in the partitioning of 
nanoparticles into the stratum corneum were observed (independent of the degree of flexing), 
with greater amounts of negatively charged nanoparticles found in the superficial layers of 
the stratum corneum in comparison with positive or neutral nanoparticles.  Flexing had a 
modest effect on the performance of a skin barrier cream which was limited to low dose 
applications; an effect tentatively ascribed to flexion-induced movement of cream to 
previously untreated areas.  A poor correlation was found between 
3
H2O water permeability 
and TEWL flux. Most importantly, there was excellent agreement between in vitro skin 
permeability studies and in vivo studies (which used a surrogate measure of skin 
permeability).   
To summarise, the data in this Thesis has led to the development and characterisation of a 
novel diffusion cell (CutaFlex
™
), capable of simultaneously flexing skin whilst performing 
dermal absorption measurements comparable with the OECD-compliant models. 
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1.1 Anatomy Of The Skin 
The skin is the largest organ of the human body and a very important line of defence 
against harmful factors present in the external environment. As a veneered structure, 
the three primary layers of the skin are represented by the outer epidermis, dermis 
and inner hypodermis (Figure 1.1). The epidermis is further subdivided into the 
stratum corneum, stratum granulosum, stratum spinosum and stratum basale layers 
and is responsible for protection against xenobiotics, micro-organisms and certain 
types of radiation (Monteiro-Riviere, 1991). The dermis provides elasticity as well as 
structural and immunological support for the epidermis (Monteiro-Riviere, 1996). As 
the innermost layer, the hypodermis functions as insulation and in energy 
metabolism. On the whole, the stratum corneum is a good but imperfect barrier 
against the absorption of xenobiotics as well as reducing ‘insensible’ water loss to 
the environment (Chilcott, 2008). In addition to physical barrier importance, other 
crucial roles of the skin include temperature regulation, endocrine and apocrine 
modulation, metabolism and neurosensory roles (Monteiro-Riviere, 1996). The 
viable epidermis measures approximately 50-100 µm, the dermis 1-2 mm and the 
hypodermis 1-2 mm (Schaefer and Redelmeier, 1996). An average human adult 
weighing approximately 65 kg will have a skin surface area of approximately 18,000 
cm
2
 (Schaefer and Redelmeier, 1996). This is a large area in terms of potential 
exposure, but much smaller than the lung and gastrointestinal tract, organs that are 
associated with the exchange or absorption of xenobiotics. 
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Figure 1.1: Skin Structure And Appendages. The outermost layer of the skin is the epidermis, this is followed by the dermis and lastly, the 
hypodermis. Appendages such as hair follicles, sebaceous glands and sweat glands exist in the integument. Beneath the downgrowths of 
epidermis (rete ridges) exists a network of capillaries in the dermis which are connected to arteries and veins that exist in the deeper part of the 
dermis. A network of nerve fibres also exist in the dermis (Viegas, 2014). 
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1.1.1 The Epidermis 
The epidermis is responsible for limiting transcutaneous water loss, immune-
surveillance, protection against solar radiation and temperature regulation. The 
protective element of the skin begins with the stratum corneum (horny layer), as well 
as the thin film that lies on top of this layer known as the acid mantle. The acid 
mantle is made up of sebum, corneocyte debris and remnant material from sweat 
(Chilcott, 2008). Sebum is the principal part of the acid mantle and is mainly 
composed of triglycerides, wax esters, and squalene in which the composition and 
secretion of these components differ by anatomical region (Kligman, 1963). 
Although hard to measure, the stratum corneum has been acknowledged as having an 
acidic pH, as low as 5.0 (Katz and Poulson, 1971), whereas the pH of the viable 
epidermis has been measured as around 7.4 (Sage et al., 1993, Aly et al., 1978).  
The stratum corneum is on average 5-20 µm thick (Lademann, 1988). This layer is 
composed of approximately 15 cell layers, which can increase by five to ten-fold at 
pressure-bearing sites (Schaefer and Redelmeier, 1996). The stratum corneum is 
populated with terminally differentiated keratinocytes (corneocytes) in a lipid matrix. 
Corneocytes are tight bundles of intracellular keratin surrounded by a cornified cell 
envelope; covalently cross-linked proteins and covalently bound lipid (Eckert, 1989, 
Steinert, 1993, Reichert et al., 1993). Corneocytes are flat, polyhedral-shaped 
anuclear cells which are approximately 40 µm in diameter and 0.5 µm in thickness 
(Marks and Barton, 1983). The intercellular region in the stratum corneum is 
composed of lipids that originate primarily from the exocytosis of lamellar bodies 
during the terminal differentiation of keratinocytes (Elias and Menon, 1991, 
Downing et al., 1993, Grayson et al., 1985, Lademann, 1986, Menon et al., 1992a). 
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5 
 
The upper layer of the stratum corneum is known as the stratum disjunctum and 
normally consists of approximately 3-5 cell layers and is actively undergoing 
desquamation (sloughing). The lower layer of the stratum corneum is known as the 
stratum compactum and consists of approximately 3 cell layers: it is thicker and more 
densely packed than the stratum disjunctum and more closely reflects the underlying 
viable epidermis (Hou et al., 1991, Fartasch, 1995). The stratum compactum also has 
a higher density of corneodesmosomes than the stratum disjunctum (Mils et al., 
1992). The stratum disjunctum contains 15% by weight of associated water 
compared to the water associated with the stratum compactum at 30% by weight, 
both of which are less hydrated than the viable dermis (70% by weight) (Warner et 
al., 1988, von Zglinicki et al., 1993). Thus, a gradient of water exists through the 
skin, with deeper viable layers presenting with higher hydration levels. 
Desquamation of the stratum corneum must be continuous in order to maintain 
thickness and must be tightly regulated to prevent hyperkeratinosis or alternatively, 
ablation (Egelrud et al., 1996, Wilkinson, 2008). 
The stratum corneum is also responsible for the barrier properties of the skin 
(Scheuplein and Blank, 1971). The corneocytes and lipids are present in the stratum 
corneum as a distinct structure represented in a brick and mortar model (further 
described in Section 1.2.1). The corneocyte bricks are attached to adjacent cells 
through corneodesmosomes. The lipid mortar is a lamellar arrangement 
predominantly composed of ceramides, free fatty acids, triglycerides and cholesterol 
(Table 1.1). It has been acknowledged that there is a complex relationship between 
stratum corneum lipid composition and biophysical properties, which ultimately 
influences the behaviour of the overall lipid system (Netzlaff et al., 2006).  
  Chapter 1 
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Table 1.1. Stratum Corneum Lipids (Adapted from Wilkinson (2008)) 
 
Lipid Type Abundance 
Ceramides 40% 
Free Cholesterol 27% 
Cholesterol Esters  2-5% 
Cholesterol Sulphate  3% 
Free Fatty Acids (mainly 22-24°C saturates) 9% 
Other Lipids (e.g. triglycerides) 11% 
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Lipid systems have the ability to exist in three different main phases; namely, the 
solid crystalline, crystalline (gel) and liquid crystalline phases (Schaefer and 
Redelmeier, 1996). Lipids are rigid in the crystalline phase, relatively rigid in the gel 
phase and present with rapid lateral mobility in the liquid crystalline phase. The 
liquid crystalline phase is found in all biological cell membranes (Schaefer and 
Redelmeier, 1996). Lipid phase transitions in model membranes can be initiated 
through a change in pressure, hydration, solvent, salt concentration, pH, cations, 
temperature and proteins (Schaefer and Redelmeier, 1996). In terms of dermal 
absorption, Potts and Franceour (1991) studied the biophysics of water loss through 
the skin and concluded that skin permeability was dependent upon conformational 
disorder in the lipid hydrocarbon chains, with enhanced penetration associated with a 
change to the liquid crystal phase. 
The stratum corneum is subject to continuous renewal of cells as a result of apical 
migration of cells from the stratum basale every 2 weeks in the mature adult 
(Monash and Blank, 1958, Montagna, 1961, Egelrud et al., 1996). Present 
underneath the stratum corneum are 10-20 layers of stratified epidermis, consisting 
of the keratinising epithelial cells responsible for the synthesis of the stratum 
corneum. The keratinisation process begins at the stratum basale layer, which is 
made up of cuboidal to columnar shaped cells attached by desmosomes to each other 
and to the basement membrane through hemidesmosomes. At this cell layer, two 
populations of basal cells exist, in which one group function as stem cells and the 
second as an anchor to the basement membrane (Monteiro-Riviere, 1996). During the 
keratinisation process, nuclei and organelles are broken down, lipids are expelled 
into the inter-corneocyte spaces, water content is decreased from 70% to 15% and 
cells are filled with keratin (Marks, 2004). Keratinocyte cells begin to flatten and 
  Chapter 1 
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increase in diameter from 10-12 µm to 20-30 µm, with a concomitant (10-20 fold) 
increase in volume from the stratum basale layer to the stratum corneum (Teumer et 
al., 1994).  
During terminal differentiation, keratinocytes produce keratohyalin granules, 
cornified envelopes, lamellar bodies and desmosome plaques (Manabe and O'Guin, 
1992, Wertz et al., 1989, Schwarz et al., 1990, Odland and Holbrook, 1987). 
Keratohyalin granules are dense, irregular amorphous deposits that contain 
profilaggrin, loricrin, cysteine-rich progein and keratins (Harding and Scott, 1983, 
Adams and Watts, 1993, Tezuka and Takahashi, 1987, Takahashi et al., 1992). 
Profilaggrin facilitates the bundling of keratin which represents the majority of 
proteins in the corneocytes (Schaefer and Redelmeier, 1996). Loricrin and cystatin A 
are major compounds of the cornified envelope (Steven et al., 1990). Desmosome 
plaques connect keratinocytes in the viable epidermis and are predominately present 
in the stratum spinosum. Lamellar bodies are present in keratinocytes of the upper 
stratum spinosum and stratum granulosum. These bodies contain lipid precursors of 
the intercellular lipid domains of the stratum corneum (Menon et al., 1992b). In 
order for degradation of the corneodesmosomes to occur (as part of the sloughing 
process) serine, cysteine and aspartic proteases are excreted into the extracellular 
spaces in the stratum corneum (Milstone, 2004).   
In addition to keratinocytes, the viable epidermis also contains (to a lesser extent) 
melanocytes (which produce the melanin pigment), Langerhans cells (responsible for 
antigen presentation and immune response) and Merkel cells which have a role in 
sensory perception (Jimbow et al., 1993, Stingl et al., 1993, Kim and Holbrook, 
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1995). Also present in the viable epidermis are terminal nerve fibres which provide a 
sensory function (pain, touch, heat, etc.) (Hillinges et al., 1995). 
Keratinocytes in the stratum basale are anchored into a structure known as the 
basement membrane which is present in the dermal-epidermal junction (Paulsson, 
1992, Yancey, 1995). The basement membrane is synthesised by the cells of the 
stratum basale and is made up of large macromolecules organised into a complex 
thin extracellular matrix (Monteiro-Riviere, 1996). The adhesion between the basal 
keratinocytes in this region provides continuous cellular signals which regulate cell 
proliferation and differentiation (Adams and Watts, 1993, Fuchs, 1993). The 
basement membrane consists of four components: the cell membrane of the basal 
epithelial cell, the lamina lucida (possibly an artefact of electron microscopy; Chan 
and Inoue (1994)), the lamina densa (an electron-dense area beneath the lamina 
lucida) and the subbasal lamina (containing anchoring fibrils, microfibril-type 
elements, and single collagen fibres) (Briggaman and Wheeler, 1975). The basement 
membrane has a variety of functions such as a role in maintaining epidermal-dermal 
adhesion and in restricting diffusion of large molecules between the epidermis and 
dermis (Monteiro-Riviere, 1996). The dermal-epidermal junction is a region which 
contains papillae that increases the surface area between the epidermis and dermis 
(Schaefer and Redelmeier, 1996). This area consists of downgrowths of epidermis 
which form ‘rete’ ridges in the skin, under which the superficial capillary plexus is 
located (Chilcott, 2008). This increase in surface area is responsible for facilitating 
diffusion of nutrients, growth factors and xenobiotics between the epidermis and 
dermis (Schaefer and Redelmeier, 1996).  
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1.1.2 The Dermis And Hypodermis 
The dermis consists of a network of fibrous, filamentous and amorphous connective 
tissue that provides both tensile strength and elasticity of the skin as well as 
structural support for both the nerve and vascular networks (Schaefer and 
Redelmeier, 1996). The connective tissue in the dermis is primarily composed of 
collagenous fibres and elastic connective tissue. The collagenous fibres form a 
scaffold that is present throughout the dermis and the elastic tissue provides elasticity 
for shape retention of the skin (Schaefer and Redelmeier, 1996). The cell populations 
present in the dermal tissue include fibroblasts, endothelial cells and mast cells. In 
addition, if conditions such as inflammation or wound healing occur, macrophages, 
lymphocytes and leukocytes may infiltrate this layer (Schaefer and Redelmeier, 
1996). The dermal layer also contains appendages such as hair follicles, sebaceous 
glands and sweat glands. 
There also exists a vast vascular network in the dermis, which is involved in 
processes such as nutrition, heat exchange, repair, immune responses and thermal 
regulation (Schaefer and Redelmeier, 1996). The vascular network in the dermis can 
be divided into an upper, papillary plexus and a lower, reticular plexus (Figure 1.1).  
The system of capillaries reach the upper epidermis, in which the capillary loops line 
the papillae which is in contact with the epidermis (Schaefer and Redelmeier, 1996). 
Also present in the dermis is the lymphatic system, which functions to regulate 
pressure from interstitial fluid (Schaefer and Redelmeier, 1996).  
The hypodermis functions to anchor the dermis to the underlying muscle and bone. 
This layer is comprised of connective and adipose tissue and has functions which 
include systemic metabolism and thermoregulation (Svesson, 2009). 
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1.1.3 Appendages  
Several appendages exist in the integument, such as sweat glands, hair follicles and 
sebaceous glands. 
The sweat glands consist of either eccrine glands (two-thirds of all glands) or 
apocrine glands (one-third of all glands), which secrete an isotonic solution in 
response to elevated skin temperatures and are the most numerous of all the 
appendages (Schaefer and Redelmeier, 1996). The glands consist of a coiled duct 
connected to the skin surface through a secretory tube and spiral channel 
(acrosyringium) which permeates the epidermis (Schaefer and Redelmeier, 1996).  
Hair follicles are classified into either fine vellus hair, which extend less than 1 
millimeter into the dermis or coarse terminal hair which extends more than 3 
millimeters into the hypodermis (Schaefer and Redelmeier, 1996). Both arrector pilli 
muscles and sebaceous glands are associated with hair follicles. The hair bulb is 
present within a region of connective tissue, termed the follicular papilla, which 
brings the hair in close proximity to blood vessels (Schaefer and Redelmeier, 1996). 
The appendageal route has also been under investigation as a potential transdermal 
route for nanoparticle dermal penetration. It has been demonstrated that particles 
ranging in size from 1.5 to 750 µm can deposit in the follicular duct as well as 
penetrating into terminal scalp follicles and superficial penetration into vellus hair 
follicles (Rolland et al., 1993, Toll et al., 2004, Sumian et al., 1999, Mordon et al., 
2003).  
Sebaceous glands are found in all regions of the body, however, the density of the 
glands per follicle and activity of the glands vary according to site and age (Wester 
and Maibach, 1993, Blume et al., 1991, Saint-Léger, 1994). This type of gland is 
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associated with hair follicles approximately 0.5 mm below the skin surface where the 
afferent ducts join (Schaefer and Redelmeier, 1996). The sebaceous glands consist of 
one or several lobes connected with a duct to the hair follicle. Sebaceous glandular 
activity is not present in infants and is reduced in the elderly (Schaefer and 
Redelmeier, 1996). The highest sebaceous gland activity occurs in the facial region 
and is absent in the palms of the hands and soles of the feet (Schaefer and 
Redelmeier, 1996). The sebaceous gland duct is not lined with stratum corneum and 
instead is surrounded by a single epidermal cell layer under which the dermis is 
present (Wilkinson, 2008). The sebaceous gland is a highly lipophilic environment 
due to the presence of sebum, whilst the dermis is a largely hydrophilic area due to 
the collagen and elastin gel matrix. Therefore, if a compound was able to partition 
from one to another, diffusion would immediately occur into the dermal tissue 
(Wilkinson, 2008).  
1.2 Dermal Absorption Theory 
The stratum corneum provides a good (but imperfect) barrier to the absorption of 
xenobiotics. The barrier has been acknowledged as the rate limiting step in the 
permeation and penetration of chemicals, initially identified through studies on the 
penetration of water and subsequent tape stripping of the stratum corneum (Blank, 
1953, Monash and Blank, 1958). Interestingly, this role of the stratum corneum was 
first alluded to by Smith et al. (1919). The outermost layer of the epidermis has also 
been exploited as a route of entry for topically applied therapeutic drugs. 
Percutaneous penetration is a process based on passive diffusion as no known active 
transport mechanisms exist in the stratum corneum (Ng et al., 1992, Hadgraft, 2001). 
Water is acknowledged as having a role as a skin penetration enhancer, as hydrated 
skin is generally more permeable than its non-hydrated counterpart (Roberts and 
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Walker, 1993). Water is capable of forming substantial interactions with amide 
linkages and protein side groups through acceptor and donor hydrogen bonds, and 
has almost no affinity for stratum corneum lipids besides transient hydrogen bonds 
with polar head groups in ceramides and phospholipids (Schaefer and Redelmeier, 
1996). Due to protein-water binding, the stratum corneum has the capacity to absorb 
five to six times its original weight in strongly bound water (Scheuplein, 1966, 
Scheuplein and Morgan, 1967). When skin is occluded, the water lost naturally to the 
environment becomes trapped within the intercellular spaces of the stratum corneum 
causing an increase in stratum corneum hydration (Warner et al., 2003). When 
occlusion of the skin occurred with human volunteers, it was seen that a higher water 
content was equivalent to an increase in permeability and penetration (Zhai and 
Maibach, 2002). The penetration enhancing effect of occlusion is complex and 
dependent on a number of other variables which also influence penetration (Bucks 
and Maibach, 1999). 
1.2.1 Routes of Absorption 
The stratum corneum has been described as a ‘brick and mortar’ model (Figure 1.2) 
due to the arrangement of corneocytes and lipids in this layer (Michaels et al., 1975). 
Due to steric hindrance, molecules greater than 500 Da are thought to be potentially 
excluded from crossing the stratum corneum (Bos and Meinardi, 2000). If 
penetration was to occur, it would happen via three possible routes, namely the 
intercellular, transcellular and transfollicular routes (Figure 1.2).   
The intercellular route is a tortuous pathway through the lipid lamellae around 
corneocytes, in comparison to the relatively lateral transcellular route through the 
corneocyte cells and the lipid lamellae. However, it should be noted that permeation 
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through multiple layers of corneocytes and lipids is both thermodynamically and 
kinetically un-favourable (Flynn, 1990).  
The third potential route (transfollicular) involves the passage of chemicals through 
hair follicles and sweat glands, a route thought to circumvent the stratum corneum. 
The entrance to the hair follicle could serve to trap particles and possibly prevent the 
uniform distribution of formulations over the skin surface (Schaefer and Redelmeier, 
1996). However, this route is still lined with corneocytes as well as sebum and 
metabolising enzymes, thereby creating another barrier to absorption (Chilcott, 
2008).  
If a molecule were to take the intercellular route through the stratum corneum, then 
the stacking of the corneocytes would be important, as this directly influences the 
path length for diffusion (Christophers et al., 1974). Both vertical and lateral 
distances between the corneocytes have been reported as 75 nm (Elias and Friend, 
1975). The tortuous path around corneocytes is thought to be a structural aspect of 
the human stratum corneum which could partly account for the barrier properties of 
the skin (Potts and Francoeur, 1991).  
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Figure 1.2: Brick And Mortar Model Of Human Stratum Corneum. The transcellular route is a route through the corneocyte cells and lipid 
bilayer. The intercellular route is through the lipid bilayer alone. The transfollicular route is a pathway down through the hair follicles. The 
distances between corneocytes in the stratum corneum (horizontal and vertical) have been acknowledged as approximately 75 nm in diameter 
(Viegas, 2014). 
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1.2.2 Absorption Kinetics 
Percutaneous penetration is governed by the basic laws of thermodynamics (Higuchi, 
1960). For example, a thermodynamic gradient may exist between a substance within 
a vehicle and the stratum corneum, in which case a lipophilic molecule present in an 
aqueous vehicle would preferentially partition into a lipid rich environment of the 
stratum corneum. The thermodynamic activity of a molecule in a vehicle is more 
important than its absolute concentration (Lippold and Schneemann, 1984, Hori et 
al., 1990, Moser et al., 2001).  
In order to experimentally determine the parameters of dermal absorption, two main 
skin exposure scenarios are used (Figure 1.3). ‘Infinite dose’ is a condition in which 
a substance is applied to the skin surface at a concentration which does not 
appreciably deplete over time. The infinite dose regime results in a steady-state 
penetration where the amount of substance penetrating the skin becomes constant 
over time. The time taken to reach steady-state is known as the ‘lag time’ (Pugh and 
Chilcott, 2008). Penetration rate (flux) is determined from the graph at steady-state 
(Jss). Kinetic parameters such as steady-state flux (Jss), permeability coefficient (Kp), 
diffusion coefficient (D) and lag time (τ) can be determined using the infinite dose 
situation (Equation 1.1-1.5).  However, the infinite dose is unrealistic as it does not 
generally reflect a ‘normal’ dermal exposure. Thus, finite dose is a more appropriate 
situation, in which a substance and its vehicle applied to the skin surface deplete 
steadily over time due to absorption into deeper layers of the skin (Pugh and Chilcott, 
2008). Using finite dosing conditions, the pseudo steady-state can be used to 
determine the maximum rate of penetration (JMax) using the linear portion of the 
penetration curve (Figure 1.3).  
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Figure 1.3: Infinite (A) And Finite (B) Dose Regimes. The infinite dose (A) results 
in ‘steady-state’ penetration (Jss) in which the time taken to reach steady state is ‘lag 
time’. The finite dose (B) results in a pseudo steady state which can be used to 
determine maximum flux (JMax) using the linear part of the curve. 
 
C
u
m
u
la
ti
v
e 
A
m
o
u
n
t 
P
en
et
ra
te
d
Time
Gradient =
Steady-State Flux
(Jss)
C
u
m
u
la
ti
v
e 
A
m
o
u
n
t 
P
en
et
ra
te
d
Time
Gradient =
Maximum Flux
(JMax)
A
B
  Chapter 1 
18 
 
1.2.3 Laws Of Diffusion  
A common definition for diffusion is, “the process by which matter is transported 
from part of a system to another as a result of random molecular motions” (Crank, 
1975). 
One of the earliest modellers of diffusion was Fourier, who proposed that the heat 
energy current density or flux (J) was proportional to the change in temperature with 
distance travelled, and in which the relationship is linear with respect to the constant 
(k) (Fourier, 1878). Adolf Fick then extrapolated the relationship between 
conduction of heat (as found by Fourier) to diffusion of molecules in order to 
describe chemical diffusion. 
Fick’s first law can be applied to the diffusion of molecules across a membrane at 
steady state and can be represented by Equation 1.1: 
Equation 1.1 
𝐽𝑆𝑆 = 𝐾𝑝 ∆𝐶 
 
In which case, the steady state flux (Jss) for a specific molecule potentially 
penetrating the skin (amount per unit area, per hour e.g. µg cm
-2
 hr
-1
) is directly 
related to the permeability coefficient (Kp) and the difference in concentration (∆C) 
across the skin (Grandjean 1990). Using infinite dose conditions, it is assumed that 
∆C remains constant and that infinite sink conditions maintain the concentration at 
zero leading to ∆C representing the concentration of a substance in the 
vehicle/solvent applied to the skin surface.  
  Chapter 1 
19 
 
1.2.4 Partitioning And Diffusivity  
Skin absorption can essentially be divided into three distinct stages (Pugh and 
Chilcott, 2008). The first stage is partitioning of the penetrant from the vehicle into 
the stratum corneum, a process that depends upon the thermodynamic activity of the 
penetrant in the vehicle versus the stratum corneum. The second stage is the 
diffusion of the penetrant through the stratum corneum, a process driven by a 
thermodynamic gradient. The third stage involves the partitioning of the penetrant 
from the stratum corneum into the deeper tissue (Pugh and Chilcott, 2008).  
After topical application of a compound, an equilibrium will gradually form between 
the concentration of penetrant in the vehicle (Cv) and concentration in the stratum 
corneum (CSc). These two concentrations are related by the partition coefficient/ 
membrane partition coefficient (KSc) according to Equation 1.2 (Pugh and Chilcott, 
2008): 
Equation 1.2 
𝐾𝑆𝑐 =  
𝐶𝑆𝑐
𝐶𝑉
 
The amount of penetrant in the stratum corneum affects the thermodynamic gradient 
through the stratum corneum and is related to the permeability coefficient (Kp) as 
follows in Equation 1.3: 
Equation 1.3 
𝐾𝑝 =  
𝐾𝑆𝑐𝐷
𝑥
 
Where D-diffusion coefficient; x- thickness of the stratum corneum.  
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When substituting the previous equation into Fick’s first law of diffusion, the 
following equation is created to show the relationship between the main factors 
affecting skin absorption in Equation 1.4: 
Equation 1.4 
𝐽𝑆𝑆  =  
𝐾𝑆𝑐𝐶𝑉𝐷
𝑥
 
 
Where D (the diffusion coefficient) is a measure of the diffusivity (or mobility) of a 
compound in the stratum corneum and is dependent on the size, shape and bonding 
capacity of the compound with components of the stratum corneum. The relationship 
of the diffusion coefficient to lag time (τ) and stratum corneum thickness (x) is 
represented as follows in Equation 1.5 (Pugh and Chilcott, 2008): 
Equation 1.5 
τ =  
𝑥2
6𝐷
 
 
1.3 Factors Affecting Dermal Absorption 
 
There are many factors thought to affect the percutaneous absorption of chemicals 
through the skin, both biological factors and physicochemical properties of the 
penetrant will be discussed.  
 
1.3.1 Biological Factors 
1.3.1.1  Anatomical Site 
Skin surface morphology is well documented as differing between anatomical sites 
(Maibach et al., 1971). These regional differences in the skin include epidermal 
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thickness, density of hair follicles and sweat and sebaceous ducts (Chilcott, 2008). It 
is not known as to why differences in skin permeability are seen for different 
anatomical sites. Specifically, the palm and forearm displayed similar permeability 
(Marzulli, 1962). When compared to forearm skin, the abdomen and dorsum of the 
hand had twice the permeability (Maibach et al., 1971). Human back skin showed a 
higher penetration rate of 
14
C-hydrocortisone compared to that of the forearm 
(Feldmann and Maibach, 1967). In the domestic pig, anatomical variability was seen 
as a greater increase in the absorption of parathion in the dorsum compared to the 
abdomen (Qiao et al., 1994). When comparing methyl nicotinate application sites on 
the forehead, forearm and palm of human skin, it was found that penetration was 
greatest through the forehead, intermediate through the forearm and the least through 
the palm (Tur et al., 1983).  
Studies have demonstrated that the thickness and number of cell layers of the human 
stratum corneum are variable for each anatomical region (Holbrook and Odland, 
1974). It should be noted that at present, no conclusive evidence exists to link skin 
barrier thickness to dermal absorption, moreso a lack of correlation has been found 
between skin barrier thickness between anatomical sites and percutaneous 
penetration (Chilcott, 2008, Schaefer and Redelmeier, 1996). In addition to 
thickness, an increase in corneocyte cell layers and corneocyte surface area has been 
documented as increasing the diffusional pathlength of dermal absorption of a 
penetrant (Rougier et al., 1988). However, no concrete evidence exists to prove that 
corneocyte size and/or thickness of the stratum corneum contributes to regional 
differences in permeation.  
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A  correlation was thought to be found between methyl nicotinate absorption and 
appendageal density (Tur et al., 1983). However, appendageal density is known to 
increase the skin surface area available for absorption, with denser follicular areas 
presenting with increases in skin absorption.  
Intracellular lipid content has been documented as differing between anatomical 
locations (Lampe et al., 1983). However, it has not been conclusively established 
that alterations in lipid content of the stratum corneum are responsible for differences 
in anatomical variations in dermal absorption. 
Therefore, anatomical variation is likely to affect dermal absorption through a variety 
of mechanisms that include density of appendages, corneocyte surface area, 
intercellular lipid content and even blood flow (Schaefer and Redelmeier, 1996). 
1.3.1.2 Age  
Age is also thought to be another factor in affecting dermal absorption of 
compounds. In general, morphological organisation and thickness of the human 
stratum corneum does not change with age (Lavker, 1979, Christophers and 
Kligman, 1965). However, age and gender-related differences in fatty acid 
composition of the stratum corneum lipids were found to be factors in influencing 
skin permeability (Nazzaro-Porro et al., 1979). Lipid content and cohesion of 
corneocytes in the stratum corneum has been shown to decrease with age and  
microscopic changes such as flattening of the epidermal-dermal junction, retraction 
of epidermal downgrowths, thinness, reduction in the output of sweat glands and a 
more heterogenous basal cell population were seen (Lavker, 1979, Lavker et al., 
1986, Lavker et al., 1987, Hull and Warfel, 1983, Gilchrest, 1984, Kligman et al., 
1985a, Kligman and Balin, 1989, Rapaport, 1973, Leveque et al., 1984). However, 
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Bronaugh et al. (1986) determined that there was no correlation between water 
permeability and time of harvest, adult age of skin, sex or race of skin samples, 
indicating that age-related differences in skin morphology do not necessarily affect 
skin permeability. 
Ageing of skin involves a multitude of factors, including many biological factors 
(e.g. lipid composition and blood flow) that can produce compound-dependent 
effects and affect percutaneous penetration (Monteiro-Riviere, 1996). However, there 
does not appear to be any conclusive evidence that ageing affects skin permeability 
in adults.  
1.3.1.3 Species Variation 
Excised human skin is widely considered the ‘gold standard’ for in vitro 
percutaneous absorption measurements (OECD, 2004). Different animal species 
have been put forward as alternatives to human skin, however, it has widely been 
acknowledged that animal skin is more permeable than human skin (Vecchia and 
Bunge, 2006, Walker et al., 1986). The thickness of the stratum corneum has been 
considered as a factor that contributes to species variation (Bronaugh et al., 1982, 
Scheuplein and Bronaugh, 1983). An additional factor attributing to the difference in 
permeation between species is thought to be the variation in skin surface lipids (Sato 
et al., 1991). 
The skin of the monkey and pig have been found to be better models in terms of 
predictive permeability than that of rodent skin (Wester and Maibach, 1984, Meyer 
et al., 1978, Monteiro-Riviere and Riviere, 1996, Reifenrath and Spencer, 1985). 
(Elias and Friend, 1975). Corneocytes are stacked and not-offset in murine stratum 
corneum, potentially allowing for a more direct route of penetration through the 
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barrier layer of skin which may explain the unusually permeable skins of mice 
compared to other species (Bergstresser and Chapman, 1980). Domestic pig skin is 
both morphologically and functionally closest to human skin than other animal 
models (Meyer et al., 1978, Monteiro-Riviere and Riviere, 1996, Calabrese, 1984) 
and can be readily obtained. Porcine skin has been acknowledged as a good animal 
model for percutaneous penetration based on the similarities to human skin, viz., a 
sparse hair coat, well-differentiated epidermal tissue, a dermis containing a well-
differentiated papillary body, high elastic-tissue content as well as similarities in 
vasculature (Monteiro-Riviere and Riviere, 1996, Simon and Maibach, 2000, Forbes, 
1969, Montagna and Yun, 1964). Moreover, the epidermis of porcine skin is known 
to be similar to human epidermal tissue in terms of epidermal turnover kinetics and 
characterisation of keratinous proteins (Weinstein, 1966).  Squalene, a wax ester, is 
the major lipid in human skin, whilst most animal species have substantial amounts 
of diester waxes: this difference has been suggested as a major factor in species 
variation in skin permeability (Nicolaides et al., 1968).  
Follicular density also differs between species, with porcine dorsum and human 
abdominal skin presenting with approximately 11 ± 1 hair follicles per cm2 in 
comparison to the back of rat skin (289 ± 21), murine skin (658 ± 38) and hairless 
murine (75 ± 6 follicles per cm2) (Bronaugh et al., 1982). It has been debated if 
anatomical areas with a higher density of hair follicles allow for a greater penetration 
of chemicals than less hirsute areas. However, it should be noted that the hair 
follicles are mainly lined with stratum corneum and the increase in surface area could 
have attributed to the higher rates of penetration in dense follicular areas (Monteiro-
Riviere, 1996) rather than trans-follicular penetration. Scalp skin for example, has a 
20 fold increase in surface area of the stratum corneum and consequently increases 
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the area available for skin absorption (Chilcott, 2008). Moreover, it has been 
previously demonstrated that hair follicles are not a major route for xenobiotics with 
the exception of metal ions (Scheuplein, 1976). 
1.3.1.4 Skin Metabolism 
The extent to which a compound is metabolised after percutaneous penetration can 
influence the extent of the total dose absorbed, as well as the toxic effect from any 
accompanying metabolites. Kao et al. (1985) found that the in vitro penetration of 
topically applied testosterone and benzo[a]pyrene was greatly affected by metabolic 
viability in a number of species. The parent compounds and full spectrum of 
metabolites from testosterone and benzo[a]pyrene were found in the viable skin 
preparations whereas only the parent compounds were found in previously frozen 
skin samples (Kao et al., 1985). The metabolism of the compounds was seen to differ 
with species, most likely due to the different expression of enzymes present in the 
epidermis of each animal skin (Kao et al., 1985). Overall, these results suggest that 
diffusion of chemical compounds into the epidermis may be influenced by metabolic 
activity and provide an additional mechanism for species differences.  
1.3.1.5 Skin Preparation And Storage Conditions 
If additional dermal tissue is present in the skin sample this could affect the 
percutaneous penetration of a compound, based upon associated physicochemical 
properties. Hydrophilic compounds were found to exhibit only small differences in 
absorption through a membrane containing extra hydrophilic dermis (Bronaugh, 
1996). Hydrophobic compounds on the other hand, exhibited with a slower 
penetration than the in vivo scenario (Bronaugh, 1996). Skin thickness was not found 
to influence the in vitro penetration of caffeine and benzoic acid, however 
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testosterone showed a higher maximum absorption rate when using dermatomed skin 
membrane and a higher amount in the skin after 24 hours (van de Sandt et al., 2004). 
When the epidermis of the skin was removed, compounds with lower log P values 
were absorbed more rapidly than compounds with a higher log P (Hawkins and 
Reifenrath, 1986). 
Full thickness skin should be chosen when animal skin is very thin, such as in the 
mouse and rabbit or when studying dermal or hypodermal delivery routes 
(Pendlington, 2008). A dermatome has been acknowledged as the most efficient way 
to prepare membranes for in vitro percutaneous absorption testing due to the ability 
to use this instrument with both hairy and hairless skin whilst retaining barrier 
integrity (Bronaugh, 1996). Human epidermal membranes can also be prepared from 
full-thickness skin by submerging the skin into 60ºC water, after which the epidermis 
will separate from the underlying tissue (Bronaugh et al., 1981, Scheuplein, 1965). 
Epidermal membranes are thought to more relevant than full-thickness or split 
thickness skin for in vitro transdermal testing, as there is no dermal tissue in this 
preparation to provide an additional barrier to penetration. Epidermal membranes can 
be prepared from human skin and weanling porcine ear skin. However, haired skin 
sections cannot be used in epidermal membrane preparation as hair shafts will 
remain in the dermis which will result in holes as the epidermis is separated. Skin 
barrier measurements should be performed on epidermal membranes in order to 
determine if the process of separation led to damage of the epidermis.  
Storage conditions of the skin may potentially affect skin permeability (Reifenrath 
and Kemppainen, 1991). Several researchers have experimentally determined that 
skin could be stored frozen up to one year without a significant change in water 
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permeability (Bronaugh et al., 1986, Franz, 1975, Harrison et al., 1984). However, 
Hawkins and Reifenrath (1984) found that pig skin stored frozen for more than 1 
week become more permeable to N, N-diethyl-m-toluamide. Hawkins and Reifenrath 
(1986) further measured radiolabelled benzoic acid, caffeine, N, N-diethyl-m-
toluamide, fluocinolone acetonide and lindate in both fresh and previously frozen  
porcine skin and found no significant differences in permeability after freezing skin 
for eight hours. It has been recommended that skin integrity should be evaluated 
following frozen storage (OECD, 2004). 
1.3.2 Mechanical Properties Of The Skin 
The effect of physical or mechanical properties of the skin on dermal absorption has 
been largely overlooked, with very few studies directly comparing the impact of 
both. The keratin in the skin forms a filamentous network allowing for cohesion, 
flexibility and elastic recovery in the stratum corneum (Young and Heath, 2000, 
Monteiro-Riviere, 2006). The stratum corneum maintains a high level of mechanical 
resistance due to the corneocyte cell structure (Egelrud et al., 1996).  
The slope of Young’s modulus (stress-strain curve) has been used to determine a true 
elasticity value of individual corneocytes (Lévêque et al., 1988). Under physiological 
conditions, the stretching/deformation of the stratum corneum is not due to 
elongation of corneocytes but to a conformational change provided by multiple 
intersecting furrows (Lévêque et al., 1988). Transepidermal water loss is influenced 
by skin stretching, due to the decrease in surface area facilitated by stretching, 
leading to lower rates of TEWL  than un-stretched skin (Pinnagoda et al., 1990).  
It is thought that energy provided by flexing could provide the additional force 
required for particle translocation from the skin surface. An in vitro skin flexing 
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device was first reported by Tinkle et al. (2003) and further used experimentally in 
studies reported by Rouse et al. (2007) and Zhang and Monteiro-Riviere (2008). The 
flexing apparatus consisted of two rectangular platforms attached to a 3-inch hinge, 
in which one platform was attached to a rotational motor and the other to a drawer 
slider. As the motor performed a rotation, the skin along the centre of the hinge 
underwent both vertical and horizontal movement in which both tensile and 
compressive forces were applied (Rouse et al., 2007). Normal physiological 
movement (i.e. flexing or stretching of skin) is thought to influence the percutaneous 
penetration of a range of ultra-fine particles (see Section 1.5.2.3). When using the 
Rouse et al. flexing device, particles were seen to penetrate into the viable epidermis 
and dermis. However these studies did not measure skin barrier integrity, and applied 
the particles after flexing, so it cannot be determined if the particles penetrated 
through an intact or damaged skin barrier layer and/or whether this was a direct 
result of skin flexing.  
1.3.2.1 Skin Damage Models  
Chemical Damage (Sodium Lauryl Sulphate) 
Sodium lauryl sulphate (SLS) is a small (288 Da) amphiphilic and anionic surfactant 
present in many consumer products due to its emulsifying and detergent properties 
(Effendy and Maibach, 1996). Sodium lauryl sulphate has been found to penetrate 
skin and interact with both lipid and protein, causing a disruption in barrier function 
as well as an increase in TEWL (Scheuplein and Ross, 1970, Elias, 1983). Detergents 
are known to deplete certain lipids from the intercellular spaces of the skin barrier 
layer (Imokawa et al., 1989). However, in vitro studies have discovered that after 
low concentrations of SLS exposure, the stratum corneum maintained a regular 
lamellar lipid arrangement (Fartasch, 1995, Fartasch, 1997).  This is in accordance 
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with biochemical studies which found experimentally induced scaly skin had the 
same amount of ceramides as healthy control skin (Froebe et al., 1990). A leading 
theory behind the basis of SLS-induced damage lies in the hyperhydration of the 
stratum corneum layer leading to eventual disorganisation of the lipid bilayers 
(Lévêque et al., 1993). Previous studies have shown when SLS is used at high 
volume, but identical concentration, a more intense skin reaction was seen (Frosch 
and Kligman, 1979). Surface area dose is also important for SLS-induced reactions, 
with smaller test areas found to elicit a limited irritant response in comparison to 
larger areas (Frosch and Kligman, 1979).   
Physical Damage 
Mechanical damage of the skin can provoke irritant dermatitis through physical 
processes such as friction, causing hyperkeratosis, erythema, scaling and vesicle 
formation (Morris-Jones et al., 2002, McMullen and Gawkroeder, 2006). In vitro 
abrasion of the epidermis alone is known to cause a two-fold increase in penetration 
in both human and rat skin (Bronaugh and Stewart, 1985). 
Tape stripping has been used in the past for enhancement of percutaneous 
penetration and as a model for studying diseased and irritated skin (Moon et al., 
1990, Benfledt and Serup, 1999). Tape stripping is the sequential removal of 
superficial stratum corneum by repeat topical application of adhesive tape and 
involves the determination of the amount of compound penetrated in the different 
layers of the stratum corneum (Dupuis et al., 1984, Rougier et al., 1986). However, 
this particular model of skin damage produces a large variability due to the practical 
difficulty associated with removing single, uniform layers of keratinocytes (Marttin 
et al., 1996, van der Molen and Riviere, 2005). The number of cells removed may 
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not be proportional to the number of tape strips due to factors such as force of strip 
removal, skin hydration, anatomical site and inter-individual variations in technique 
(Marttin et al., 1996).  
The change in percutaneous absorption through damaged skin must be characterised, 
as topical preparations are occasionally applied to a compromised barrier layer. 
Bronaugh and Stewart (1985) investigated the effect of damage (abrasion) on 
percutaneous penetration through human and rat skin. It was found that of all 
chemicals investigated, the increase in absorption through damaged skin was related 
to the initial extent to which the compounds were absorbed by the skin, with poorly 
absorbed chemicals showing the greatest increase in penetration.  
1.3.3 Physicochemical Properties Of The Penetrant 
There are a wide range of physicochemical properties that may affect dermal 
absorption of chemicals, with the primary factors generally considered to be 
molecular weight, volatility, lipophilicity, charge and hydrogen bonding (Brain and 
Chilcott, 2008).  
1.3.3.1 Molecular Weight 
Transdermal penetration of molecules with a molecular weight greater than 500 
Daltons is highly unlikely due to physical constraints in the stratum corneum (Bos 
and Meinardi, 2000). This is based upon the fact that the molecular weight of contact 
allergens, pharmaceutical agents used in topical dermatotherapy and topical drugs in 
drug delivery systems, are consistently less than 500 Daltons. However, passive and 
active methods have been developed to enhance percutaneous penetration, such as 
hydration of the stratum corneum, ultrasound, iontophoresis and skin abrasion (Barry 
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and Williams, 1995, Mitragotri et al., 1995, Bhatia and Singh, 1998, Brown et al., 
2008). 
1.3.3.2 Volatility 
Volatile chemical compounds will affect dermal absorption and cumulative amount 
penetrated. This is due to the fact that the amount of chemical present on the skin 
surface will deplete in proportion to the volatility of the compound (Chilcott, 2012). 
This is an effect which may be exacerbated when using non-occluded exposure. 
Extremely volatile chemicals may not have sufficient contact time with the skin 
surface in order to partition into the skin (Gilpin et al., 2009). An example of a 
highly volatile chemical would be the nerve agent sarin (GB), in which higher 
temperatures reduced the amount of liquid chemical in contact with the skin and 
therefore reduced the dermal penetration hazard (Chilcott, 2012). This is in direct 
contrast to VX (a non-volatile chemical warfare agent) which may remain present at 
relatively high temperatures and will therefore continue to be a dermal penetration 
hazard (Chilcott, 2012).  
1.3.3.3 Lipophilicity  
The inter-corneocyte lipid matrix is primarily composed of ceramides, free fatty 
acids and cholesterol (Table 1.1), rendering it a predominantly lipophilic 
environment and thus a factor influencing the percutaneous absorption of molecules. 
To determine solubility, the partitioning of a substance is measured between two 
immiscible liquids (e.g. octanol and water) at equilibrium. Generally, an octanol-
water partition coefficient (log P) between 1 and 3 is thought to be optimal for skin 
absorption (Brain and Chilcott, 2008).  Although the stratum corneum is highly 
lipophilic, the underlying dermis is a largely hydrophilic area. Therefore, in order for 
a substance to successfully traverse the epidermis to the viable dermis and/or site of 
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action, it must not be highly lipophilic or hydrophilic, or there is a risk it will get 
trapped or excluded from either layer (Brain and Chilcott, 2008). Pro-drugs have 
been used as a strategy for targeting of compounds to the viable skin tissue 
(Anderson, 1993, Higuchi and Yu, 1987). Briefly, compounds are modified in order 
to enhance percutaneous absorption into the stratum corneum. The modification 
involves the synthesis of a lipophilic precursor drug which, on entry to the viable 
epidermis, is metabolised to the active drug by esterases. Esterification of drugs is 
employed as a modification due to the relatively high activity of esterases present in 
the viable epidermis, after which, the compounds are expected to clear the target site 
as based upon pharmacokinetics (Schaefer and Redelmeier, 1996, Kao and Carver, 
1990).  
1.3.3.4 Charge 
In addition to the hydrophobic lipid domains, the stratum corneum also provides 
protection against the absorption of ions due to proteins present at the epidermal 
surface conferring both types of charge. However, more negative groups are present 
in the stratum corneum therefore aiding the absorption of cations over anions (Brain 
and Chilcott, 2008). For ions and non-electrolyte penetrants with many polar groups 
that are capable of hydrogen bonding with hydrated keratin, shunt diffusion (i.e. hair 
follicles) may be the predominant pathway (Scheuplein, 1976). This is due to 
relatively slow penetration of these compounds through keratin, attributing almost all 
penetration to the transfollicular route (Scheuplein, 1976). 
1.3.3.5 Hydrogen Bonding 
Hydrogen-bonding groups exist in the stratum corneum, allowing for transient 
hydrogen bonds to form with incoming penetrants. The influence of hydrogen 
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bonding on the rate of absorption depends upon the strength and number of bonds 
involved. Contemporary models of dermal absorption include a consideration of both 
acceptor and donor hydrogen bonding groups, in order to improve the predictive 
accuracy of percutaneous penetration (Moss et al., 2014).  
 
1.4 Dermal Absorption: Measurement And Techniques 
Measuring the dermal absorption of a particular penetrant is important, as the amount 
of compound penetrated could be sufficient to produce a toxic effect and thus may 
present a greater risk to human health. Chemicals that are too hazardous to test on 
human volunteers can be assessed for dermal absorption using an in vitro diffusion 
cell system.  
 
1.4.1 In Vitro Diffusion Cell Studies 
1.4.1.1 Skin 
The membrane chosen for in vitro testing should simulate the skin barrier layer as 
closely as possible, as well as model the condition being simulated (Bronaugh, 
1996). The ‘skin barrier layer’ refers to the thickness of the skin which a compound 
must diffuse through in vivo before absorption by capillaries in the upper dermis 
(papillary plexus) and removed by the systemic circulation (Bronaugh, 1996). The 
distance to the papillary plexus varies with skin type, being approximately 100 µm 
for human skin (Bronaugh, 1995a). Considerations for skin type as well as skin 
preparation and storage methods have been previously discussed in detail in Section 
1.3.1.5. 
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1.4.1.2 Receptor Fluid 
The choice of receptor fluid is dependent on the compound under study. For a 
hydrophilic compound, a physiological buffer (e.g. normal saline or isotonic buffer) 
may suffice (Bronaugh, 1996). The selection of receptor fluids for more lipophilic 
compounds is more complicated as these molecules will diffuse into the stratum 
corneum readily but may not partition from the skin into the receptor fluid. Thus, it is 
important to ensure that the penetrant has sufficient solubility in the receptor fluid 
and that the receptor fluid of choice does not alter skin barrier function (as chemicals 
that solubilise hydrophobic compounds could potentially remove lipids from the 
skin) (Bronaugh, 1996). This consideration further emphasises the need to perform 
skin integrity analysis prior to performing dermal absorption studies. Partitioning of 
a penetrant from the skin into the receptor fluid and mixing of the receptor chamber 
fluid are known to influence percutaneous absorption, especially for highly lipophilic 
penetrants (Crutcher and Maibach, 1969). The use of 50% aqueous ethanol as a 
receptor fluid has been shown to provide a good correlation between in vitro and in 
vivo absorption data when using lipophilic penetrants (Scott and Ramsey, 1987). 
Alternatively, aqueous based fluid can be mixed with excipients such as polyethylene 
glycol 20 oleyl ether (Volpo 20) and serum albumin to improve penetrant solubility 
(Schaefer and Redelmeier, 1996). 
1.4.1.3 In Vitro Diffusion Cell Systems 
Two types of diffusion cell exist to measure in vitro percutaneous penetration, static 
and flow-through cells (Figure 1.4). Recent designs of static diffusion cells have 
been based upon publications by T.J. Franz in the mid-1970s (Franz, 1975, Franz, 
1978) and flow-through cells from R.L. Bronaugh (Bronaugh, 1995a, Bronaugh, 
1995b). However, it should be noted that versions of both static and flow-through 
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diffusion cells have been used in percutaneous absorption studies since at least the 
1940s (Pendlington, 2008). 
Static cells consist of several parts; the (upper) donor chamber, (lower) receptor 
chamber, clamp, sampling arm, heated jacket (optional) and skin tissue (Figure 1.4- 
A). The skin (or relevant tissue under study) is securely clamped between the donor 
and receptor chambers. The donor area of the skin is then dosed with the substance 
under study and the amount that has permeated through the skin can then be 
measured in the receptor chamber via the sampling arm.  
The receptor chamber fluid is mixed thoroughly with magnetic stir bars and either 
placed in a water bath or incorporates a heated jacket to maintain the temperature of 
the skin at 32°C ± 1ºC. 
In contrast, flow-through diffusion cells (Figure 1.4- B) require a peristaltic pump to 
continuously deliver fresh receptor chamber fluid to each cell. The accuracy of the 
flow rate through the receptor chamber is important, as it is known to significantly 
influence skin penetration (Crutcher and Maibach, 1969). Flow-through diffusion 
cells are more practical for longer collection periods than the static cell, due to the 
use of automated samplers. The static cell allows for accumulation and quantification 
of slow penetrating compounds in the receptor fluid, whereas the samples may be too 
dilute for analysis using the flow-through diffusion cells (Pendlington, 2008). The 
van de Sandt et al. study (2004) determined that there were no differences found in 
the penetration of all three model compounds (benzoic acid, caffeine and 
testosterone) between different diffusion cell types. Whilst both types of cell provide 
equivalent results, the constant replacement of receptor fluid makes the flow-through 
diffusion cell more suitable for metabolic analysis, as the nutrients in the fluid do not 
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Figure 1.4: Static (A) And Flow-Through (B) Diffusion Cell Systems. Used for in vitro dermal absorption studies and consist of a donor 
chamber (where penetrant is applied) and a receptor chamber (where absorbed penetrant is collected). The tissue (e.g. skin) is clamped between 
the donor and receptor chamber. The sampling arm is used to collect aliquots of the receptor fluid which contains thoroughly mixed (inserted stir 
bars) substance that has penetrated through the skin. In the static cell, a heated jacket ensures that the skin is maintained at a temperature of 32°C 
± 1°C through connection to a heated re-circulating pump. In the flow-through cell, receptor fluid is pumped through each cell by a peristaltic 
pump which controls flow rate and the sampling arm allows for automated fraction collection (Viegas, 2014). 
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deplete over time and the biochemical viability of the skin can be maintained for 
longer periods (Bronaugh, 1996, Clowes et al., 1994).  
The OECD 428 method provides guidelines to measure the diffusion of chemicals 
onto and through the skin using either static or flow-through diffusion cells 
fabricated from inert materials. In a finite dose scenario, the guidelines recommend a 
skin surface ‘dose’ of 1-5 mg cm-2 for all solids and semi-solids and up to 10 µl cm-2 
for liquids (OECD, 2004). During a dermal absorption study, the compound under 
study is left in contact with the skin surface for a predetermined duration (reflecting 
practical exposure) and under stringent environmental conditions. Removal of the 
compound from the skin surface takes place after the exposure duration with a 
relevant cleansing method. The OECD recommends an exposure duration of 24 
hours as a maximum, but concedes that longer periods may be justified. It 
recommends that the skin be maintained at constant 32 ± 1°C and receptor fluid 
should be well-mixed and sampled at pre-determined time points throughout the 
experiment. Aliquots of receptor fluid samples and skin sections can then be 
analysed for the test chemical and/or metabolites. In order to validate the 
performance and reliability of the test system, a result for an appropriate reference 
chemical should be undertaken and compared to published literature for the method 
used. The reference chemical should be close in lipophilicity to the test subject or a 
number of reference substances of different lipophilicities that are known should be 
provided (OECD, 2004).  
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1.4.1.4 Skin Integrity Measurements 
There are several established methods to measure integument integrity and these 
include transepidermal electrical resistance (TER), permeability of tritiated water 
(
3
H2O) and transepidermal water loss (TEWL). 
Transepidermal Electrical Resistance 
Skin electrical resistivity is known to be a quantitative indicator of the structural 
integrity of the skin barrier layer (Allenby et al., 1969). Two electrodes are used to 
apply a voltage across a skin sample, in which the skin’s electrical current is then 
measured using an ammeter. The electrical resistance of the skin is obtained from 
using the skin electrical current and Ohm’s Law. The electrical resistance of the skin 
is multiplied by the available surface area to obtain electrical resistivity. If the 
electrical resistivity of excised skin is less than 50 kΩ cm-2, the barrier layer is then 
considered damaged (Kasting and Bowman, 1990, Rosell et al., 1998). A cut-off 
value is determined for the type of skin preparation and species of skin in use, with a 
higher value associated with skin damage due to the electrolytes leaking from the top 
solution through the skin into the lower solution. This technique has been adopted by 
the OECD as a recommended test for skin barrier integrity (OECD, 2004). 
Tritiated Water Permeability 
Water permeability has been extensively assessed through the skin both in vitro and 
in vivo (Bettley and Grice, 1967, Blank, 1952, Blank, 1953, DeLong et al., 1954, 
Idson, 1973, Scheuplein and Morgan, 1967). The water permeability coefficient (Kp) 
for skin has long been used to determine skin viability (Harrison et al., 1984, 
Bronaugh et al., 1981, Galey et al., 1976, Bronaugh and Stewart, 1985). As water is 
hydrophilic, the stratum corneum would be the rate limiting step in absorption and a 
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defect in the barrier layer would reflect in a higher absorption of tritiated water 
(Bronaugh et al., 1986).   
A relatively rapid (20 minute) tritiated water test was designed in order to determine 
skin integrity (Bronaugh et al., 1986). This test involved applying tritiated water at 
volume of 312.5 µl cm
-2
 and an activity of 0.33 µCi per diffusion cell. The tritiated 
water was left on the skin for 20 minutes, after which the excess water was removed 
by blotting and the skin surface was rinsed once with distilled water. The receptor 
fluid was sampled for 60 minutes after removal of tritiated water. This procedure was 
advantageous in measuring skin integrity prior to assessment of chemical penetration 
due to the relatively small amount of radioactivity needed and the diffusion of all 
tritiated water within an 80 minute period. The evaluation of water in the assessment 
of skin integrity was also compared against model compounds of varying polarity 
(Bronaugh et al., 1986). It was found that regardless of polarity, increases in water 
absorption in the 20 minute test were always accompanied by increases in the 
permeability of the chemical under study. The average permeability coefficient (Kp; 
Equation 1.1) of water through ex-vivo human abdominal skin ranged from 1.0-1.5 x 
10
-3
 cm h
-1
, as reported by several researchers (Bronaugh et al., 1986, Harrison et al., 
1984, Scheuplein, 1965). The Kp cut-off value for water permeation through human 
skin was determined to be 2.5 x 10
-3
 cm h
-1
 as this equivalent to the upper limit for 
steady state water permeation (Bronaugh et al., 1986).  
Transepidermal Water Loss  
Transepidermal water loss has been defined as the “constitutive outward loss of 
water from deeper epidermal layers of the skin in the absence of sweat gland 
activity” (Pinson 1941). Transepidermal water loss functions as a surrogate 
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measurement of skin barrier integrity by relating skin integrity to water loss from 
deeper layers of the skin to the skin surface. Rates of TEWL are measured using 
different types of evaporimeters (instrument to measure water evaporation) such as 
open and closed chamber probes (Schaefer and Redelmeier, 1996, Taylor, 2008). 
Evaporimetry is a surrogate measure of TEWL, since it relies on measuring a water 
vapour gradient above the skin surface: It is assumed that changes in the water 
vapour gradient above the skin equates to a change in permeability of the skin. 
Importantly, the appearance of water vapour above the skin is primarily based upon 
the phase transition from liquid to vapour. Therefore, any variable that can affect that 
phase transition will affect the apparent permeability of the skin. Many additional 
factors can therefore influence the water vapour gradient, such as environmental 
conditions and experimental conditions, which has necessitated the development of 
guidelines to minimise such artefacts (Pinnagoda et al., 1990).  
Transepidermal water loss has been previously used as a measure of barrier integrity 
for identifying undamaged and damaged skin (Lamaud et al., 1984, Lotte et al., 
1987, Aalto-Korte and Turpeinen, 1993, Tsai et al., 2003). Historically, TEWL has 
also been used in vivo as a test for both baseline skin barrier function and to quantify 
any subsequent damage. An increase in transepidermal water loss may be measured 
before visible inflammation occurs after exposure to ionic, polar and water-soluble 
irritants (e.g. sodium hydroxide, soaps and detergents) (Malten and Thiele, 1973). In 
contrast, exposure to un-ionised polar irritants (e.g. dimethyl sulfoxide) and un-
ionised non-polar, water-soluble irritants (e.g. hexanediol diacrylate and butaediol), 
did not increase TEWL until visible inflammation had occurred (Malten and den 
Arend, 1978, Malten et al., 1979). Several potential sources of interference for in 
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vivo TEWL measurements may include blood perfusion, metabolism, temperature 
variation and sweat gland activity (Benowitz et al., 1992, Kao et al., 1984, Blank and 
Scheuplein, 1969, Pinnagoda et al., 1990).  Using an evaporimeter to measure 
transepidermal water loss flux has been contested as a measurement of in vitro 
barrier integrity as studies have shown that measurements of TEWL rates do not 
always relate to skin permeability (Chilcott et al., 2002).  
Both TEWL and tritiated water permeability have been recommended by the OECD 
and the European Centre for the Validation of Alternative Methods (ECVAM) in 
assessing skin barrier integrity due to the relatively quick assessment of the quality of 
skin (OECD 2004; Howes et al. 1996).  
1.4.1.5 Model Compounds  
The OECD guideline 428 advises that novel diffusion cells be fully characterised 
before use by measuring and comparing the absorption of model (or reference) 
chemicals to OECD-compliant models. The reference compound(s) can be applied at 
the same time as a penetrant under study or can be compared to historic percutaneous 
penetration data relating to the model compound. Three commonly used reference 
compounds are benzoic acid, caffeine and testosterone (Table 1.2) and have been 
used to characterise such parameters as a comparison of animal skin to human skin, 
skin damage and skin storage conditions. 
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Table 1.2: Physicochemical Properties Of Benzoic Acid, Caffeine And Testosterone. Synonyms of each compound as well as chemical 
abstracts service (CAS) number, molecular weight (MW), solubility (Log P) and chemical structure. 
 
 
 
 
 
Compound Synonyms CAS MW Log P Structure
Benzoic Acid Benzenecarboxylic acid 65-85-0 122.10 1.83
Caffeine
3, 7-dihydro-1, 3, 7-trimethyl-
1H-purine-2, 6-dione
58-22-0 194.19 -0.01
Testosterone 4-androsten-17ß-ol-3-one 58-08-2 288.42 3.32
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In order to validate the use of animal skin in place of human skin in vitro, studies 
should be carried out with standard compounds to provide an estimation of dermal 
absorption parameters with the animal skin system. Reifenrath et al. (1984) found a 
significant correlation between human skin grafted onto athymic nude mice and 
human skin (r = 0.74) as well as between weanling Yorkshire pig skin and human 
skin (r = 0.83). There were no significant correlations found between human skin 
compared to hairless dog, or pig skin grafted onto athymic mice. Porcine skin was 
validated in vitro by Hawkins and Reifenrath (1986), in which permeability to 11 
compounds correlated well with that of human skin (r = 0.79). The correlation 
between porcine and human skin was further improved when split-thickness 
(dermatomed) skin was used rather than full thickness. Bartek et al. (1972) found 
that skin permeability was of the order: rabbit > rat > pig ≥ man and that the skin of 
the miniature swine had the closest percutaneous penetration properties to man. 
An important aspect for interpreting skin absorption data of model compounds (or 
indeed any penetrant) is the statistical distribution of data and hence appropriate 
statistical test. The distribution of Kp values for a range of model compounds (e.g. 5-
fluorouracil, oestradiol, water) was found to be best described as log-normal rather 
than normal (Williams et al., 1992, Cornell and Barry, 1995, Fasano et al., 2002). 
Khan et al. (2005) found that when using silicone membranes, the permeability 
coefficients of two model compounds (caffeine and testosterone) fitted a normal 
distribution. This statistical disparity is most likely indicative of the fact that artificial 
membranes comprise a homogenous barrier to diffusion whereas stratum corneum is 
a hybrid of different anatomical and biochemical barriers.  
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It is difficult to compare studies of model compounds performed by different 
laboratories, due to differences in skin membranes, dose regimes, penetrant solution 
preparation and study design. A multi-centre study sought to characterise the skin 
absorption of three model compounds (benzoic acid, caffeine and testosterone) in 
human and rat skin across ten different laboratories (van de Sandt et al., 2004). The 
maximum absorption of benzoic acid was greatest compared to both caffeine and 
testosterone (see Tables 1.3 - 1.5). In the majority of laboratories, benzoic acid and 
caffeine showed a higher penetration rate than testosterone (van de Sandt et al., 
2004). 
When comparing previous studies involving the use of benzoic acid, caffeine and 
testosterone, several points are apparent (see Table 1.3, Table 1.4 and Table 1.5). 
Generally, benzoic acid and caffeine have similar cumulative penetration kinetics, 
whereas testosterone is a much slower penetrant. This is to be expected, as 
testosterone has a relatively high log P value and high molecular weight compared to 
both benzoic acid and caffeine, both factors which will affect dermal absorption. As 
expected, skin damage (caused by abrasion) resulted in a 2-fold increase in skin 
absorption of benzoic acid and caffeine (Bronaugh and Stewart, 1985). Comparison 
of in vivo and in vitro porcine skin studies demonstrated that permeability to benzoic 
acid and caffeine remained relatively similar (Hawkins and Reifenrath, 1986). These 
data indicate good in vivo/in vitro correlation (Hawkins and Reifenrath, 1986). 
Moreover, the in vitro studies were performed both with split thickness and full 
thickness skin and so confirm that the presence of (hydrophilic) dermal tissue does 
not substantially alter the percutaneous penetration of hydrophilic penetrants 
(Hawkins and Reifenrath, 1986). The van de Sandt et al. (2004) multi-centre study 
consistently produced the highest skin absorption rates compared to other 
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researchers. This could be due to the higher dose that was used, due to the majority 
of other studies investigating the use of these compounds at a dose of 4 µg cm
-2
, as 
well as in some cases, a shorter exposure time of 24 hours. It should be noted that the 
calculations in Tables 1.3 to 1.5 do not take into account the lag times of the 
penetrants when converting from the applied dose penetrated to a mass amount per 
cm
-2
 per hour and therefore will underestimate the actual flux. 
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 Table 1.3: Studies Investigating Dermal Absorption Of Benzoic Acid. Cumulative amount penetrated is represented as the applied dose of 
testosterone (%) penetrated. The amounts in brackets are converted values from applied dose penetrated (%) to mass amount (µg cm
-2
 h
-1
) for the 
reported exposure duration. 
 
Chemical Paper Study Skin Dermal Absorption Parameter 
Benzoic Acid Reifenrath et al. 
(1984) 
In vivo 
In vivo 
In vivo 
Weanling Pig 
Human- Graft onto nude mice 
Pig- Graft onto nude mice 
Applied Dose Penetrated: 12% (0.001 µg cm-2 h-1) 
Applied Dose Penetrated: 40% (0.07 µg cm-2 h-1) 
Applied Dose Penetrated: 42% (0.07 µg cm-2 h-1)  
 Bronaugh and 
Stewart (1985) 
In vitro Human 
Human- Abraded 
Rat 
Rat- Abraded 
Applied Dose Penetrated: 28% (0.05 µg cm-2 h-1) 
Applied Dose Penetrated: 58% (0.10 µg cm-2 h-1) 
Applied Dose Penetrated: 20% (0.03 µg cm-2 h-1) 
Applied Dose Penetrated: 40% (0.07 µg cm-2 h-1) 
 Hawkins and 
Reifenrath (1986) 
In vivo  
In vitro 
In vitro 
Porcine 
Porcine- Full Thickness  
Porcine- Split Thickness 
Applied Dose Penetrated: 28% (0.02 µg cm-2 h-1) 
Applied Dose Penetrated: 21% (0.02 µg cm-2 h-1 ) 
Applied Dose Penetrated: 20% (0.02 µg cm-2 h-1) 
 van de Sandt et al. 
(2004) 
In vitro Human- Split Thickness Applied Dose Penetrated: 69 ± 15% (2.9± 0.6 µg 
cm-2 h-1)  
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 Table 1.4: Studies Investigating Dermal Absorption Of Caffeine. Cumulative amount penetrated is represented as the applied dose of 
testosterone (%) penetrated. Dermal absorption parameters listed include; permeability coefficient (Kp), the diffusion coefficient (D), membrane 
partition coefficient (Km), lag time and steady state flux (Jss) in mass amount per cm
-2
 per hour. The amounts in brackets are converted values 
from applied dose penetrated (%) to mass amount (µg cm
-2
 h
-1
) for the reported exposure duration. 
 
Chemical Paper Study Skin Dermal Absorption Parameter 
Caffeine Bartek et al. 
(1972) 
In vivo Porcine  Applied Dose Penetrated: 32% (0.01 µg cm-2 h-1 µg) 
 Reifenrath et al. 
(1984) 
In vivo 
In vivo 
In vivo 
Weaning Pig 
Human Graft 
Porcine Graft 
Applied Dose Penetrated: 20%   (0.002 µg cm-2 h-1) 
Applied Dose Penetrated: 42% (0.07 µg cm-2 h-1) 
Applied Dose Penetrated: 30% (0.05 µg cm-2 h-1) 
 Bronaugh and 
Stewart (1985) 
In vitro Human 
Human- Abraded 
Rat 
Rat- Abraded 
Applied Dose Penetrated: 41% (0.07 µg cm-2 h-1) 
Applied Dose Penetrated: 63% (0.1 µg cm-2 h-1) 
Applied Dose Penetrated: 56% (0.09 µg cm-2 h-1) 
Applied Dose Penetrated: 90% (0.2 µg cm-2 h-1) 
 Hawkins and 
Reifenrath (1986) 
In vivo 
In vitro 
In vitro 
Porcine 
Porcine - Full Thickness 
Porcine - Split Thickness 
Applied Dose Penetrated: 23% (0.02 µg cm-2 h-1) 
Applied Dose Penetrated: 20% (0.02 µg cm-2 h-1)  
Applied Dose Penetrated: 21% (0.02 µg cm-2 h-1) 
 Boucad et al. 
(2001) 
In vitro Human  
 
 
Human- Ultrasound 
 
Rat  
 
Rat- Ultrasound 
J
Max
- 1.1 ng cm
-2
 h
-1
 
Lag Time- 0.6 h 
J
Max
- 4 ng cm
-2
 h
-1
 
Lag Time- 0.5 h 
J
Max
- 0.2 ng cm
-2 
h
-1
 
J
Max
- 15 ng cm
-2 
h
-1
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 Van de Sandt et 
al.(2004) 
In vitro Human  Applied Dose Penetrated: 27 ± 11% (1.1 ± 0.5 µg cm-2 
h-1) 
 Khan et al. (2005) In vitro Porcine (Ear) Kp- 1.4 x 10
-3
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 Table 1.5: Studies Investigating Dermal Absorption Of Testosterone. Cumulative amount penetrated is represented as the applied dose of 
testosterone (%) penetrated. Dermal absorption parameters listed include; permeability coefficient (Kp), the diffusion coefficient (D), membrane 
partition coefficient (Km), lag time and steady state flux (Jss) in mass amount per cm
-2
 per hour. The amounts in brackets are converted values 
from applied dose penetrated (%) to mass amount (µg cm
-2
 h
-1
) for the reported exposure duration. 
 
Chemical Paper Study Skin Dermal Absorption Parameter 
Testosterone Scheuplein et al. 
(1967) 
In vitro 
In vivo 
Human- Intact 
 
K
p
- 4 x 10
-6
 cm h
-1
 
D- 2 x 10
-11
 cm
-2
 h
-1
 
K
m
- 23 
Lag Time- 38h 
J
ss
 (in vitro)- 40 moles cm
-2
 h
-1 
 
J
ss
 (in vivo)- 150 moles cm
-2
 h
-1
  
 Bartek et al. (1972) In vivo Porcine (Ear) Applied Dose Penetrated: 29% (0.01 µg cm
-2 h-1) 
 Kao et al. (1985) In vitro Human- Fresh 
Human- Frozen 
Applied Dose Penetrated: 50% (0.05 µg cm-2 h-1) 
Applied Dose Penetrated: 62% (0.06 µg cm-2 h-1) 
 Hawkins and 
Reifenrath (1984) 
In vitro Porcine  Applied Dose Penetrated: 3% (0.002 µg cm-2 h-1) 
 Reifenrath et al. 
(1984) 
In vivo 
In vivo 
In vivo 
Weaning Pig 
Human Skin Graft- Nude Mice 
Porcine Skin Graft- Nude Mice 
Applied Dose Penetrated: 5% (0.0005 µg cm-2 h-1) 
Applied Dose Penetrated: 40% (0.07 µg cm-2 h-1) 
Applied Dose Penetrated: 41% (0.07 µg cm-2 h-1) 
 Hawkins and 
Reifenrath (1986) 
In vivo 
In vitro 
In vitro 
Porcine Skin 
Porcine Skin- Split Thickness 
Porcine Skin- Full thickness 
Applied Dose Penetrated: 13% (0.01 µg cm-2 h-1)  
Applied Dose Penetrated: 3% (0.002 µg cm-2 h-1)  
Applied Dose Penetrated: 6% (0.005 µg cm-2 h-1) 
  
 
5
0
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 Tang et al (2002) In vitro Porcine (Dorsum)- Split 
Thickness 
K
p
 (experimental 22-25h)- 2 x 10
-3
 
cm h
-1
 
K
p
 (predicted 41-48h) 2 x 10
-3
 
 van de Sandt et al. 
(2004) 
In vitro Human- Split Thickness Applied Dose Penetrated: 23 ± 14% (0.9 ± 0.6 µg 
cm-2 h-1) 
 Khan et al (2005) In vitro Porcine (Ear)- Full Thickness Kp- 1 x 10
-2
 cm h
-1
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1.4.1.6 Limitations Of In Vitro Experimentation 
Many distinct advantages are associated with in vitro experimentation such as precise 
control over experimental parameters, the ability to test potentially toxic materials 
using human skin, direct measurements of the penetration and distribution of the 
penetrant within the skin and corresponding contribution to the 3Rs of reduction, 
refinement and replacement of animals in scientific research (Pendlington, 2008). 
Most notably however, the limitations that exist in this model are the lack of 
pharmacokinetic data available after percutaneous penetration (e.g. systemic 
distribution), an inability to perform a test to investigate metabolism within the skin 
without going to great lengths to ensure viability and a missing factor of 
pharmacodynamics (e.g. vasoconstriction and vasodilation) (Pendlington, 2008) and 
the lack of overt toxic responses such as erythema, blistering or other immune 
responses. 
1.4.2 In Vivo Dermal Absorption  
The dermal absorption of penetrants can be measured using human volunteers using 
a variety of methods. This is arguably the ‘gold standard’ for developing human risk 
assessment or optimising drug delivery systems or skin protectants, but can only be 
performed if the chemicals or drugs are of sufficiently low toxicity to justify their use 
in volunteers. Historically, radioisotope tracers have been used in the past with 
human volunteers to assess percutaneous absorption (Feldmann and Maibach, 1967, 
Feldmann and Maibach, 1965). It is now more common to use non-radiolabelled 
compounds to assess dermal absorption and to quantify amounts of the penetrant or 
metabolite(s) in blood and urine using analytical methods such as HPLC, GC-MS or 
LC-MS (Pendlington et al., 2001, Sampol et al., 2000, Jakasa et al., 2004). Local 
absorption and assessment of the depth of penetration can be assessed using 
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minimally invasive methods such as tape stripping and microdialysis. Non-invasive 
measurements of percutaneous penetration based on quantifying a local relevant 
biological response can also be assessed through visual erythema scoring, tissue 
viability imaging and laser Doppler imaging (erythema), infrared thermography (skin 
temperature), pH of the skin surface, transepidermal water loss (viability of the 
barrier layer), and skin reflectance spectroscopy (Patil et al., 1996).  
Further in-depth discussion about the use of vasodilators on human volunteers and 
two non-invasive monitoring methods (visual erythema scoring and laser Doppler 
imaging) relevant to this Thesis will be discussed. 
1.4.2.1 Model Compounds (Methyl Nicotinate) 
Nicotinates were examined in the latter part of the 20
th
 century as markers for skin 
permeation for studying both physicochemical properties and formulation effects 
(Albery and Hadgraft, 1979a, Albery and Hadgraft, 1979b, Albery and Hadgraft, 
1979c, Baker et al., 1969, Cronin and Stoughton, 1962, Hadgraft et al., 1973, 
Hadgraft et al., 1972, Stoughton et al., 1960). Following topical application to skin, 
nicotinic acid derivatives are known to rapidly elicit vasodilation of the peripheral 
blood vessels in the dermal papillae and produce notable erythema (Fulton et al., 
1959, Stoughton et al., 1960). When using an identical exposure time and 
concentration of methyl nicotinate, the time of onset of erythema is reproducible 
(Guy and Maibach, 1982). In terms of methyl nicotinate, Laser Doppler velocimetry 
has been reported as a rapid and sensitive technique for identifying and quantifying 
skin blood flow (Wester and Maibach, 1984). 
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1.4.2.2 Skin Response 
Visual Erythema Scoring 
 
Acute irritation and corrosion have been evaluated using a modified version of the 
Draize test, first outlined by John Draize and colleagues (Draize et al., 1944). The 
grading scale used in Draize-type tests ranges from a score of 0-4 for a description of 
both erythema and oedema formation, this was previously used to evaluate skin 
reactions using animals and can also be used for evaluating human skin responses 
(Table 2.4). Integrated scales, with the addition of papular, vesicular and bullous 
responses, ranging from 4-16 points have also been proposed (Patil et al., 1996). It 
should be noted that reliance of animal studies on the Draize test is being phased out 
in favour of more humane endpoints and alternative models (Balls et al., 1995). 
Laser Doppler Imaging 
Laser Doppler velocimetry (LDV) was shown to indicate changes in microvascular 
perfusion as early as 1975 (Stern, 1975). Laser Doppler velocimetry is a non-
invasive technique that detects changes in the microvasculature of the skin and was 
validated and developed for clinical evaluation of superficial blood flow in the skin 
(Holloway and Watkins, 1977, Watkins and Holloway, 1978, Stern et al., 1977). This 
technique was subsequently employed to detect blood perfusion changes after 
injection trauma and mild burns from transcutaneous oxygen monitoring (Holloway, 
1980, Enkema et al., 1981). Laser Doppler imaging built upon the principles of LDV 
as this technique uses the Doppler shift principle to determine the velocity of red 
blood cells in the papillary plexus using a 632 nm helium-neon (He-Ne) laser source 
which is directed towards skin tissue, penetrating to a depth of 1-1.5 mm. Laser light 
back-scattered from stationary particles remains at the same frequency as the light 
that entered the skin, whereas laser light from moving particles ( i.e. red blood cells) 
  Chapter 1 
54 
 
undergoes a shift in frequency according to the Doppler effect (Holloway and 
Watkins, 1977). Guy et al. (1983) found that LDV and photopulse plethysmography 
correlated well during in vivo monitoring of methyl nicotinate exposure in human 
volunteers, providing a useful non-invasive technique to explore drug disposition in 
the skin after topical application.  
Laser Scanning Confocal Microscopy  
When fluorescent samples are imaged using a conventional light microscope, the 
fluorescence in regions outside the area of interest interferes with the resolution of 
the areas in focus. This is especially true for specimens greater than 2 µm in 
thickness (Paddock, 1999). The optical principle of laser scanning confocal 
microscopy is to eliminate out of focus light in the specimen through spatial filtering 
(Paddock, 1999). This is physically achieved by incorporating the use of strategically 
placed pinholes into the apparatus. The point of light is focused by an objective lens 
into the specimen with any transmitted light that passes through focused using a 
second objective lens at a second pinhole (with identical focus to the first pinhole). 
Therefore, the pinholes were ‘confocal’ (Paddock, 1999). Any light passing through 
the second pinhole struck a low-noise photomultiplier which amplified the signal 
which was related to the brightness of the light. The second pinhole prevented light 
from above and below the plane of focus from striking the photomultiplier (Paddock, 
1999). Confocal microscopy has been used to visualise nanoparticle-cell interaction, 
with many studies documenting uptake of nanoparticles into cells (Calvo et al., 1994, 
Dailey et al., 2003, Gorelik et al., 2002, Kemp et al., 2008). Confocal microscopy 
has also been commonly used to visualise fluorescent nanoparticles and the skin 
(Rouse et al., 2007, Ryman-Rasmussen et al., 2006, Tinkle et al., 2003). 
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An alternative to single-photon confocal microscopy is multi-photon microscopy. 
Multi-photon microscopy allows for the deeper imaging of biological samples 
without the accompanying loss in resolution, light scattering or increase in 
photobleaching in comparison to wide-field and confocal microscopy (Williams et 
al., 2001, Denk et al., 1990). Multiphoton microscopy is a technique which uses 
longer wavelength photons, which are scattered less by biological tissue, and 
therefore is a better technique than confocal microscopy in visualising fluorescence 
through thick tissues (Halbhuber and Konig, 2003). Multiphoton has been used with 
quantum dot nanoparticles to visualise detailed cell structures (Ferrara et al., 2006).  
1.5 Dermal Toxicity 
 
The use of in vitro techniques can be beneficial in the testing of topical products such 
as barrier creams. However, such ‘static’ models fail to reproduce the normal 
movement of skin which could potentially alter the thickness and hence protective 
effect of barrier creams measured in vitro. This issue is discussed further when 
analysing potential nanoparticle penetration through the skin (see Section 1.5.2.3).  
One potential application of barrier creams is in the prevention and treatment of skin 
disorders such as incontinence associated dermatitis (IAD).  
1.5.1 Incontinence Associated Dermatitis  
1.5.1.1 Disease 
Incontinence associated dermatitis presents as inflammation of the skin surface, 
erythema and, in severe cases, oedema and blister formation (Voegeli, 2012). There 
are four primary objectives in managing moisture-associated skin damage; (1) 
adoption of a structured skin-care regimen, (2) use of products that prevent moisture 
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on ‘at-risk’ skin, (3) control of the cause behind excessive moisture and (4) treatment 
of any secondary infection (Gray et al., 2011). As many as 3-25% of the population 
in care homes within the United Kingdom have suffered from incontinence-
associated dermatitis (Newman et al., 2007). However, this number could be vastly 
underestimated, as prevalence of IAD has been acknowledged as being under-
reported due to a lack of validated assessment tools in addition to the stigma of the 
condition (Borchert et al., 2010).  
Incontinence-associated dermatitis has been defined as, “inflammation and erosion of 
the skin caused by prolonged exposure to various sources of moisture, including 
faeces, urine, perspiration and wound exudate” (Gray et al., 2007). This type of 
dermatitis falls under the category of moisture-associated skin damage (MASD). It 
has been theorised that there are several factors leading to the causation of 
incontinence-associated dermatitis. Possible changes in the pH of the skin’s acid 
mantle due to ammonia from urine as well as excessive moisture is thought to lead to 
disruption of the intercellular lipids and corneocytes in the skin barrier layer leading 
to skin irritation and breakdown (Warner et al., 2003, Langemo et al., 2011). 
Previous histological results have corroborated the disruption of the intercellular 
lipids and corneocyte structure, essentially leading to physical damage of the stratum 
corneum with associated loss of barrier function (Warner et al., 2003). Over-
hydration of the skin barrier layer is also known to elicit damage and as a 
consequence, irritants found in urine and faecal matter may penetrate the skin. 
Physical irritation such as the skin cleansing can further contribute to the breakdown 
of the epidermis (Gray, 2010). Therefore, topical skin protectants would provide an 
additional barrier to decrease exposure to both wash and irritant substances and in 
theory, result in a decrease in IAD. 
  Chapter 1 
57 
 
1.5.1.2 Prevention (Barrier Creams) 
Skin barrier creams have been proposed in the past to prevent and/or reduce dermal 
absorption from hazardous agents known to cause contact dermatitis (Schaefer and 
Redelmeier, 1996). However, researchers have been divided as if topical skin 
protectants have provided protection or exacerbated irritation (Wigger-Alberti et al., 
1998, Frosch et al., 1993, Schluter-Wigger and Elsner, 1996). Schliemann  et al. 
(2013) found that the protective efficacy of the creams was dependant on the amount 
of product applied per unit skin surface area and recommended the use of protective 
creams at doses less than 2 mg cm
-2
.  Basic preparations have consisted of a lipid or 
water emulsion, in addition to anti-microbials such as zinc oxide and titanium oxide 
(Voegeli, 2012). Water repellent silicone-based preparations such as dimethicone, in 
addition to mild antiseptic agents such as cetrimide and benzalkonium have also been 
employed (Voegeli, 2012). In addition to the above, pure white petrolatum (i.e. 
Vaseline) has also been used as a skin protectant due to inherent water-repellent 
properties as well as allowing for barrier recovery (Ghadially et al., 1992). 
The experimental formulation RD-1433 is a topical skin protectant initially 
developed to protect members of the armed forces against exposure to toxic 
chemicals. In vivo data has shown that this cream can reduce the size of skin lesions 
following exposure to skin damaging agent as well as decreasing mortality rate and 
protecting red blood cell activity when animals were exposed to organophosphorus 
nerve agents (Liu et al., 1999). Moreover, the perfluorinated composition of RD-
1433 may inhibit bacterial growth. The composition of RD-1433 also provides 
lubrication thereby eliminating possible skin friction and further associated damage 
from IAD. 
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1.5.2 Nanoparticles 
Nanoparticles are considered a relatively new dermal absorption risk as more 
consumer products have incorporated these particles without the relevant risk 
assessments. Nanoparticles are thought to be a unique dermal absorption hazard, as 
on average these particles are too large in size to penetrate through the stratum 
corneum. However, it is thought that with additional energy provided through skin 
flexing, these particles could have enough energy to then translocate into deeper 
(viable) layers of skin (Rouse et al., 2007).   
The potential for dermal absorption of nanoparticles has been investigated using both 
in vitro and in vivo methods (Rouse et al., 2007, Ryman-Rasmussen et al., 2006, 
Gratieri et al., 2010, Zhang and Monteiro-Riviere, 2008). The in vitro assessment of 
nanoparticle dermal penetration using standard diffusion cells (static/flow-through) 
may not be entirely appropriate as evidence exists to suggest skin movement could 
alter the absorption of nanoparticles (see Section 1.5.2.3). Hence, the main purpose 
of work outlined in this Thesis was to develop a more appropriate dermal exposure 
model for assessing percutaneous absorption of nanoparticles. 
1.5.2.1 Definition And Routes Of Exposure 
Nanoparticles can be defined as single particles with at least one dimension 
measuring less than 100 nm and are a subset of nanomaterials (Royal Society and 
Royal Academy of Engineering, 2004). These particles have unique size-dependent 
properties due to a larger surface area per unit mass, culminating in a more reactive 
species compared to the same material at a larger size (Zuin et al., 2007). The 
increase in surface area is an important factor which determines the bulk properties 
of each material, with the ratio of surface to total atoms or molecules increasing 
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exponentially with decreasing particle size. The increase in surface reactivity of 
nanoparticles could mean that these particles exhibit a greater biological activity per 
mass than larger particles should they enter a living organism and remain solid rather 
than dissolved into ions.  
Due to high surface energy resulting in inter-particle attraction through London, van 
der Waals and electrostatic forces, nanoparticles are often found in aggregates 
(physically connected) or agglomerates (loosely connected) (Werth et al., 2003). The 
physicochemical properties of nanoparticles such as size, shape, chemical 
composition, lattice structure, surface chemistry, surface charge and aggregation 
state make it particularly difficult to predict how these particles will react when 
studied in biological systems (Zuin et al., 2007). 
Nanomaterials have been used in a variety of industries encompassing sporting 
goods, tyres, electronic components, food packaging, sunscreens, cosmetics and 
antimicrobial and antifungal preparations (Table 1.6). Humans are also exposed to 
nanosized particles unintentionally through natural combustion processes such as 
forest fires and volcanoes (Table 1.6). An indirect source of exposure has been 
through ultrafine particulate matter present in air pollution from sources such as 
automobile engines and manufacturing industries (Table 1.6). 
Ingestion, inhalation and skin penetration are all potential exposure routes for both 
engineered and natural nanomaterials (Oberdörster et al., 2005). Inhalation is 
considered the most likely route of exposure from nanoparticles,  however concerns 
have been raised by the possibility of dermal penetration and further systemic 
exposure (Borm et al., 2006).  
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Table 1.6. Nanoparticle Origins And Sources (table from Oberdörster et al. (2005) 
 
Natural Anthropogenic 
        Un-intentional                             Intentional 
Forest fires Combustion engines Metals, semi-conductors, 
metal oxides, carbon, 
polymers 
Volcanoes Power plants Nano-wires, -spheres, 
needles, -tubes, -shells, 
-rings 
Viruses Incinerators Un-treated, coated 
particles in cosmetics, 
medical, fabrics, 
electronics, optics, 
displays, etc. 
Ferritin (12.5 nm) Jet engines  
Microparticles in active 
cells (< 100 nm) 
Metal, polymer fumes  
Biogenic magnetite Frying, broiling, grilling  
 Electric motors  
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Quantum Dot Nanoparticles 
Quantum dots (QDots) are nanocrystals comprising of a metallic core (usually 
cadmium and selenium) surrounded by an inorganic shell coating (commonly zinc 
sulphate). Quantum dot nanoparticles are fluorescent semi-conductor materials used 
for therapeutic, diagnostic and semi-conductor applications (Ryman-Rasmussen et 
al., 2006). One of the properties exhibited by quantum dots is photoluminescence. 
Two advantages that quantum dot nanoparticles hold over traditional fluorophores 
are a greater resistance to light-dependent oxidation (photobleaching) and a greater 
brightness due to high quantum yield and large molar extinction coefficient values 
(Ho and Leong, 2010). The high density of electrons present within quantum dots 
also make these nanoparticles ideal for visualisation by transmission electron 
microscopy (TEM) (Nisman et al., 2004).   
Quantum dots are atom clusters consisting of a distinct core, shell and coating. The 
core of the quantum dot consists of a few hundreds to thousands of atoms of semi-
conductor material, in some cases, cadmium mixed with selenium. This core is then 
stabilised by a surrounding semi-conductor shell (i.e. zinc sulphide), to enhance both 
optical and physical properties of the material. The shell has been shown to minimise 
leaching of cadmium from the core (Cho et al., 2007). Lastly, an amphiphilic 
polymer coating (i.e. polyethylene glycol) can be applied to provide a water-soluble 
surface that can be modified. A majority of quantum dots have the amphiphilic inner 
coating covalently bonded to a functionalised polyethylene glycol outer coating to 
decrease the possibilities of non-specific bonding. It has been demonstrated that 
quantum dot toxicity is dependent upon surface charge and surface coating (Hoshino 
et al., 2004). In order to introduce quantum dots into a biological system, water-
soluble dots are preferable. Therefore, dots have been synthesised with water-soluble 
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ligands, silanisation and encapsulation within block-copolymer micelles to improve 
hydrophilicity (Chan and Nile, 1998, Mattoussi et al., 2000, Gerion et al., 2001).  
1.5.2.2 Nanoparticle Characterisation 
The synthesis of nanomaterials can occur through either a bottom-up or top-down 
approach. The bottom-up approach, as described by Whitesides et al. (1991) involves 
one of the following processes: building structures using covalent bonds through 
chemical synthesis; covalent polymerization; ionic, hydrogen-bond or van der Waals 
interactions used to instigate self-assembly of crystal and colloid structures and 
lastly, molecular self-assembly using a combination of synthetic processes.  
When suspended in a liquid medium, nanoparticles may carry a surface electrical 
charge, dependent upon the physicochemical properties of the particle and the 
surrounding media (Eastman, 2005). The size and charge of a nanoparticle are two 
major factors that affect dispersion through adsorption of ions, contaminants and 
biomolecules (Powers et al., 2006). Additional energy may need to be provided in 
order to further disperse nanoparticle aggregates. Sonication involves the use of 
ultrasonic energy to physically break apart loose bonds between aggregates in 
solution (Zuin et al., 2007). Step-wise centrifugation has also been employed to 
further narrow the distribution range of nanoparticles.  
It has been recognised that no individual technique can provide the entire 
characterisation of a nanoparticulate sample (UK NanoSafety Partnership Group, 
2012). Multiple techniques are required for different sample forms (e.g. aerosol, 
suspension, dry powder, etc.) and the optimum set of required techniques is 
dependent upon the nanoparticle type, formulation under study and purpose of study 
(UK NanoSafety Partnership Group, 2012).  
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Dynamic Light Scattering 
 
Dynamic light scattering (DLS) or photon correlation spectroscopy (PCS) is a 
conventional characterisation technique used for measuring nanoparticle size in 
suspension. DLS measures the speed at which particles are diffusing within a 
suspension (due to Brownian motion) then detects the rate in which the intensity of 
the scattered light fluctuates. The hydrodynamic diameter of a nanoparticle is 
calculated from the translational diffusion coefficient using the Stokes-Einstein 
equation (Equation 1.6): 
Equation 1.6 
𝑑(𝐻) =  
𝑘𝑇
3𝜋𝜂𝐷
 
Where d(H)- hydrodynamic diameter;  k – Boltzmann’s constant; T- absolute temperature ;η – 
viscosity; D- translational diffusion coefficient 
 
 
This type of particle sizing is affected by ions in suspension as well as total ionic 
charge, as ions that are covalently attached to nanoparticles will be included in the 
hydrodynamic diameter. An alternative to DLS is nanoparticle tracking and analysis 
(NTA) which allows for each nanoparticle in suspension to be tracked in real-time 
and sized on a particle-by particle basis by a dedicated particle tracking image 
analysis program. Dynamic light scattering estimates particle size by using intensity 
weighted (z-average) distributions whereas NTA provides a particle size distribution 
due to a direct number/frequency distribution measurement. Both NTA and DLS 
allow for the measuring of the zeta potential (ζ) of a particle in suspension. Zeta 
potential is a physical property that is exhibited by any particle in suspension: greater 
than +30 mV and less than -30 mV indicates a stable suspension (Everett, 1994, 
Lyklema, 2000). 
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Transmission Electron Microscopy 
The characterisation technique favoured for both shape and aggregation state/size is 
transmission electron microscopy because this is a direct rather than inferred 
measurement. Transmission electron microscopy also provides a visual image of the 
nanoparticulate matter at a higher resolution. Transmission electron microscopy can 
also be coupled with energy dispersive x-ray spectroscopy (EDX) for identifying the 
sample composition. However, due to preparation methods for samples undergoing 
transmission electron microscopy (carbon grid room temperature desiccation) 
nanoparticle shape and size can differ from what is seen in a suspension. 
1.5.2.3 Dermal Absorption Of Nanoparticles 
The concerns for human health include a potential for cytotoxicity, accumulation in 
skin and other organs resulting in toxicity, metabolism of nanoparticles to smaller 
particles with increased toxicity, and toxicity of photo-activated nanoparticles (Tsuji 
et al., 2006). The dimensions of nanoparticles are important for potential 
percutaneous penetration as the pilosebaceous pores are reportedly 10-70 µm in 
diameter (Lauer et al., 1996),  sweat gland pores are 60-80 µm in diameter (Roberts, 
2004) and lastly, the lipid matrix surrounding the dead corneocytes fills a gap of only 
75 nm (Elias and Friend, 1975). It has been suggested that receptor-mediated 
pathways into the cell would not work for a nanoparticle greater than 100 nm (Royal 
Society and Royal Academy of Engineering, 2004). The size constraints for entry 
into the nucleus and epithelial barriers are 40 nm and less than 35 nm, respectively 
(Oberdörster et al., 2005). However, these size guidelines vary with surface 
modifications and nanoparticulate material. 
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As with all xenobiotics, the main barrier to dermal absorption of nanoparticles is the 
stratum corneum. In addition to the lipid lamellae, the varying polarities of the skin 
layers contribute to reducing penetration into the deeper viable skin layers (Labouta 
et al., 2011). Surface hydrophobicity was found to favour the passage of 
nanoparticles into the stratum corneum (Labouta et al., 2011). A skin exposure time 
of 6 hours (or greater) was determined as the minimum exposure time needed to see 
significant penetration for studying factors such as physicochemical properties, 
formulation effects and environmental conditions (Labouta et al., 2011). 
Studies investigating the dermal absorption of nanoparticles have used a variety of 
skin types, nanoparticles and exposure conditions, with some studies rejecting skin 
penetration (Pflücker et al., 2001, Schulz et al., 2002, Alvarez-Román et al., 2004, 
Gamer et al., 2006, Mavon et al., 2007, van der Merwe et al., 2009, Senzui et al., 
2010, Szikszai et al., 2010) and others which found evidence for the percutaneous 
penetration of nanoparticles (Alvarez-Román et al., 2004, Kertész et al., 2005, 
Lademann et al., 1999, Menzel et al., 2004, Ryman-Rasmussen et al., 2006, Tan et 
al., 1996, Larese et al., 2009, Wu et al., 2009a, Baroli et al., 2007).  
Dermal Absorption Studies Of Micro- And Nanoparticles  
The hypothesis that external force can provide the necessary energy for percutaneous 
absorption of ultrafine particles has been researched by several scientists. It is 
thought that mechanical stimulation occurring through repetitive skin movement may 
alter the structural organisation of the skin barrier layer, leading to increased 
penetration of nanoparticles. This theory is preceded by evidence from individuals 
who walked barefoot in the African rift valleys, amongst which there was a high 
prevalence of podoconiosis. This elephantiasis of the feet and legs was believed to be 
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caused by mechanical stressors due to the exposure of unprotected feet to soils with 
high concentrations of zirconium and beryllium particles (Blundell et al., 1989, 
Corachan et al., 1988). Particles were identified in both the lymph nodes and the 
dermis of individuals affected. This finding suggested that normal physiological 
movement can influence percutaneous absorption of particles. Both Tan et al. (1996) 
and Lademann et al. (1999) reported in vivo titanium dioxide penetration into the 
upper layers of the stratum corneum and hair follicles using repeated rubbing of 
sunscreen onto the volar forearm (which would induce skin flexing, as well as an 
additional effect of pressure). 
Tinkle et al.(2003) incorporated skin flexion in vitro for consideration of particulate 
penetration through human stratum corneum. Through mechanical flexing of human 
skin, beryllium particles were reported to penetrate the stratum corneum into the 
viable epidermis and, occasionally, reached the dermis. It was hypothesised that the 
flexing motion (20 flexes per minute at a 45 degree angle) provided the energy 
necessary for the particles to penetrate the stratum corneum. Subsequently, this 
device was used to assess the dermal absorption of a fullerene-substituted 
phenylalanine (Baa) and found that flexed samples showed a greater epidermal and 
dermal penetration compared to static samples (Rouse et al., 2007). Importantly, 
TEM showed nanoparticles localised in intercellular spaces of the stratum 
granulosum, suggesting migration through the skin occurred via an intercellular 
pathway. These results led to the hypothesis that the force applied to the skin during 
flexing could have caused a change in the morphology and architectural lipid 
organisation in the stratum corneum leading to a transient increase to the intercellular 
spaces and causing nanoparticle penetration (Rouse et al. 2007). The ability for these 
nanoparticles to translocate through the lipid matrix of the stratum corneum raises 
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the potential for absorption into circulation and accumulation at different sites in the 
body leading to possible systemic toxicity. However, it should be emphasised that 
the flexing took place before exposure to the nanoparticles and no test of skin 
integrity was performed in these studies. It is not unreasonable to assume that the 
relatively energetic flexing (20 flexes per minute) caused an irreversible increase in 
permeability due to physical damage. 
Quantum dot nanoparticles are photostable and inherently fluorescent, with 
wavelengths of emission directly related to the size of the material. Quantum dots 
allow for reliable multi-colour imaging of biological samples, even in living tissues 
where auto-fluorescence is a problem for traditional fluorophores (Chan et al., 2002). 
A number of studies have been performed with quantum dots, with conflicting 
outcomes (Table 1.7). 
Quantum dot nanoparticles are not able to penetrate intact skin when topically 
applied at a physiological pH, with accumulation observed in the hair follicles and 
skin furrows (Prow et al., 2012, Gratieri et al., 2010, Wu et al., 2009b). When skin 
flexing and massaging was studied, quantum dots were still found localised and 
retained on the surface of the stratum corneum, although the pattern of surface  
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Table 1.7: Quantum Dot Dermal Absorption Studies. A review of in vitro and in vivo dermal absorption studies involving quantum dot 
nanoparticles using intact and damaged skin of different species. Absorption of quantum dot nanoparticles varied according to treatment. 
Quantum Dot Paper Study Skin Treatment Absorption 
QD 505-525nm Paliwal et al. (2006) In vitro Porcine Full-
Thickness 
Sonophoresis and 
SLS 
Yes- Dots found within lipids 
in stratum corneum at barrier 
of stratum granulosum 
QD 565 and 655 
nm 
Neutral, Cationic 
and Anionic 
pH 8.3 and 9.0 
Ryman-Rasmussen et 
al. (2006) 
In vitro Porcine Split-
Thickness 
Intact Yes- QD 565 all attachments 
in epidermis and dermis by 8h, 
QD 655 PEG and PEG-Amine 
in epidermis by 8h, QD 655 
PEG-Carboxyl in epidermis at 
24h. 
QD 565 and 655 
nm 
Neutral, Cationic 
and Anionic 
pH 8.3 and 9.0 
Zhang and Monteiro-
Riviere (2008) 
In vitro Rat Skin Intact 
Flexed 
 
Tape-Stripped (10) 
Abraded 
No 
No- Increase of dots on skin 
surface 
No 
Yes- penetration of QD 655 at 
8h and with QD565 at 24h 
QD 621nm 
Neutral 
Zhang et al. (2008) In vitro Porcine Split-
Thickness 
Intact No- In upper stratum corneum 
and hair follicles 
QD 621nm 
Cationic  
Gopee et al. (2009) In vivo Mouse Dorsum Intact 
Tape-Stripped (5-20) 
Acetone-Treated 
Abraded 
No 
No 
No 
Yes- viable epidermis, dermis 
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and accumulation in liver and 
lymph nodes 
QD 565nm  
Cationic 
Jeong et al. (2010) In vivo 
In vitro 
Human 
Volunteers (2) 
EpiDerm 
Intact No- upper layers of the 
stratum corneum 
No- upper layers of stratum 
corneum 
QD 613nm Gratieri et al. (2010) In vitro Human Skin Intact 
Massaged 
 
Tape Stripped (20) 
No 
No- only affected pattern of 
distribution on skin surface 
Yes- small amounts in deeper 
stratum corneum of fully tape-
stripped and 10 minutes flexed 
skin 
Hydrophilic Seto et al. (2010) In vitro Human Full and 
Split Thickness 
Porcine Full and 
Split Thickness 
Intact 
Sonophoresis and 
SLS 
No 
Yes- Increase in penetration in 
split-thickness skin 
QD Cd/Se Core, 
Zn/S Shell 
Neutral, Cationic 
and Anionic 
Lopez et al. (2011) In vitro Porcine Skin- 
Full thickness 
Intact 
Sonophoresis and 
SLS 
Yes- 0.01% of applied dose 
Yes- 5 to 13 fold increase 
using 
follicular route and cavitations 
QD 565nm  
Neutral, Cationic 
and Anionic 
Prow et al. (2012) In vitro Human Skin pH 7.0 
pH 8.3 and 9.0 
 
Tape-Stripped (30) 
No 
Yes- QD 565 and QD 655 
PEG 
Yes- All dots found in upper 
dermis at 24h 
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QD 800 nm  
Anionic 
Lee et al. (2013) In vitro Nude Mice  Intact 
 
Laser irradiation  
(4 mJ) 
No- In outermost stratum 
corneum 
No- Increased amounts in 
stratum corneum and hair 
follicles 
QD 620nm  
Anionic  
Mortensen et al. 
(2013) 
In vivo Nude Mice Intact 
 
Ultraviolet 
irradiation 
No- Penetration into furrows 
and hair follicles  
Yes- In-frequently found in 
stratum corneum of damaged 
skin 
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spreading and total amount retained had increased (Zhang and Monteiro-Riviere, 
2008, Gratieri et al., 2010). Quantum dots are often supplied in alkaline vehicles (e.g. 
pH 8-9). When quantum dot nanoparticles were applied to the skin surface at a pH of 
8.3 and 9.0, penetration of these particles was seen to the level of the stratum 
granulosum in human skin and into the dermis of porcine skin (Prow et al., 2012, 
Ryman-Rasmussen et al., 2006). These data indicate that skin absorption of 
nanoparticles may occur when the skin barrier is disrupted. When the barrier was 
disrupted through active means (e.g. sonophoresis, SLS, etc.) quantum dot 
nanoparticles of different sizes and charges were seen in the dermis (Paliwal et al., 
2006, Lopez et al., 2011, Seto et al., 2010, Lee et al., 2013).  
Ultraviolet (UV) irradiation can also lead to damage of the skin barrier layer. This 
environmental stressor is particularly relevant to certain types of sunscreens which 
contain nanoparticles, as these are intended for use during UV skin exposure. 
Following UV exposure (360 mJ cm
-2
), QDots were sometimes found within the 
damaged areas of the stratum corneum where there was disorganisation of the 
corneocyte and lipid bilayer, allowing for looser junctions and alterations in the 
shape and morphology of the cells (Mortensen et al., 2013).  
Interestingly, following using UV skin irradiation in vivo, barrier disruption lead to 
significant increases in liver levels of cadmium in treated mice following exposure to 
quantum dot nanoparticles (Mortensen et al., 2013).   
Abraded skin has also been shown to allow the penetration of QDots to the level of 
the dermis after 8-24 hours (Zhang and Monteiro-Riviere, 2008, Gopee et al., 2009). 
The penetration of the dots into the viable epidermis and dermis led to accumulation 
of cadmium in the liver and lymph nodes of mice (Gopee et al., 2009). In contrast, 
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skin that was tape-stripped presented with a large variation in penetration, with either 
a lack of penetration or penetration into the upper layer of the dermis (Gratieri et al., 
2010, Zhang and Monteiro-Riviere, 2008, Gopee et al., 2009, Prow et al., 2012). 
Tape-stripping is known to be a highly variable procedure and as such, the actual 
amount of stratum corneum removed may be inconsistent, thereby leading to 
variation in percutaneous absorption.  
When quantum dots were injected transdermally, the dots were found in the 
capillaries of the skin and the regional lymph nodes (Larson et al., 2003, Kim et al., 
2004). These particles were mapped as travelling from the injection sites through the 
lymphatic system and finally to regional lymph nodes (Gopee et al., 2007). Transport 
mechanisms to the lymph nodes were likely macrophages and dendritic (Langerhans) 
cells (Ohl et al., 2004, Sato et al., 1998). It is thought that the quantum dot 
nanoparticles could be expelled from the body before the breakdown of the 
outermost polymer coating occurred, allowing the body protection from the cadmium 
core (Larson et al., 2003). However, other studies have demonstrated a time-
dependent loss of cadmium from injection sites and subsequent deposition in the 
liver, regional draining lymph nodes, kidney, spleen and hepatic lymph nodes after 
injection of QDots (Gopee et al., 2007). Kulvietis et al. (2013) demonstrated that, 
after subcutaneous injection in mice, dots were found in the dermis, hypodermis and 
muscle tissue. The basement membrane prevented upwards movement of these dots 
into the epidermal layers.  
1.5.2.4 Systemic Distribution Of Nanoparticles 
The rise in products incorporating nanotechnology has not been concurrently 
followed by the corresponding risk assessment of these products to human health and 
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the environment. If it is possible for nanoparticles to enter and distribute through the 
body, an understanding of accumulation or excretion of these particles needs to be 
determined.  
Proteins are known to adsorb onto the surface of nanoparticles, creating a structure 
referred to as a ‘protein corona’. It is thought that different proteins, when attached to 
the surface of a nanoparticle, can facilitate uptake into cells by active transport 
(Lynch et al., 2007). It has been argued that it is the amount and type of proteins 
making up the corona that evoke a biological response and not the physicochemical 
properties of the nanoparticle itself  (Lynch et al., 2007). Blood protein coronas are 
especially durable and, when coming into contact with a cellular membrane, it is the 
protein that signals cellular uptake (Walcyzk et al., 2010).  The proteins in the outer 
layer of the corona are slowly exchanged and it is believed that as the nanoparticle-
corona complex is transported throughout the body, the proteins change (Walcyzk et 
al., 2010). Different proteins are thought to influence differential uptake by specific 
target organs (Walcyzk et al., 2010). As nanoparticle and associated protein corona 
move within the body, it is thought these particles will reach areas of the body not 
possible by just the nanoparticle itself (Walcyzk et al., 2010).  
The dermal penetration and body distribution of titanium dioxide (TiO2) 
nanoparticles has been reported following dermal exposure of mice, as well as 
induction of delayed pathological lesions in major organs two months after exposure 
(Wu et al., 2009).  The TiO2 particles (21 nm) were found in the brain with no 
accompanying pathological lesions. However, the skin and the liver displayed severe 
pathological changes along with excess superoxide dismutase (SOD) and 
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malondialdehyde (MDA) levels which are associated with oxidative stress (Wu et al., 
2009a) 
The size and charge of QDot nanoparticles was found to affect elimination of these 
particles from the body as zwitterionic and neutral coatings prevented adsorption of 
serum proteins and allowed for excretion due to a size of < 15 nm (Choi et al., 2007). 
When injected, inert gold nanoparticles were found localised in macrophages, 
Kupffer liver cells, spleen, small intestine and mesenteric lymph node macrophages, 
possibly through endocytosis (Sadauskas et al., 2007). The ideal size of excretion has 
been debated with the size of < 5.5 nm resulting in the rapid and efficient clearance 
and elimination from the body by macrophages as well as filtration by the renal 
glomeruli (Sadauskas et al., 2007). 
1.6 Summary 
The skin is the first line of defence against the ingress of xenobiotics and a plethora 
of in vitro and in vivo techniques have been developed to characterise, assess, 
measure and elucidate the mechanisms of dermal absorption. 
Nanoparticles, in particular, present a contemporary risk to humans. However, an in 
vitro skin exposure model which offers an improvement on the current, static skin 
system is needed to fully elucidate the dermal hazard of nanoparticles. A flexing skin 
system is required to provide additional energy for translocation of particles which, 
under normal circumstances, would be physically excluded by their size. Moreover, a 
flexing skin system would provide a more practically relevant model for testing 
topical skin protectants, as the current (static skin) models cannot reproduce the 
effects of normal skin movement which may affect the patency of topical application.  
  Chapter 1 
 
75 
 
Therefore, the aims of this Thesis were: 
 To produce a novel in vitro diffusion cell (CutaFlex™) capable of producing 
reproducible flexion 
 To assess the dermal absorption of reference compounds measured with 
CutaFlex
™
 compared to the standard OECD-compliant Franz-type cell. 
 To characterise the effects of flexing on skin barrier function after chemical 
and physical damage of the skin barrier layer. 
 To characterise the effect of in vitro skin flexing on performance of a skin 
barrier cream. 
 To assess the effect of skin flexing on the dermal absorption of quantum dot 
nanoparticles of different sizes, shapes and charges. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Chapter 2 
 
76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 2: General Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Chapter 2 
 
77 
 
2.1. In Vitro Dermal Absorption Studies 
2.1.1. Chemicals 
Tritiated water (
3
H2O) was purchased from American Radiolabelled Chemicals 
(ARC) U.K. Ltd. (St. Louis, U.S.A.) with a specific activity of 1 mCi ml
-1
 and was 
mixed with deionised water (dH2O: obtained from the municipal water supply via a 
MilliQ Direct Q5 purification system, Watford, U.K.) to achieve a stock solution 
with a nominal activity of 0.0023 µCi µl
-1
.  
Carbon-14 radiolabelled “model compounds” benzoic acid, caffeine and testosterone 
were purchased from ARC U.K. Ltd with specific activities of 165 mCi mmol
-1
, 55 
mCi mmol
-1
 and 55 mCi mmol
-1
, respectively (Figure 2.1). Unlabelled benzoic acid, 
caffeine and testosterone were purchased from Sigma Aldrich (Gillingham, U.K.) 
and were reported to be more than 99% pure. The saturated solubility of each 
chemical in aqueous ethanol (22 ml) at 32°C was determined
1
 to be 90, 84 and 10 mg 
ml
-1
 for benzoic acid, caffeine and testosterone, respectively. To maintain the 
specific activity of each chemical solution, the equilibrium between dissolved to 
undissolved chemical had to be identical for both the radiolabelled and cold 
chemical. Therefore, equilibrated, unfiltered saturated solutions were prepared by 
mixing appropriate amounts of 
14
C-radiolabelled and unlabelled model compounds to 
achieve stock solutions with a nominal activity of 0.0113 µCi µl
-1
. Prior to dosing 
each chemical onto the skin surface, the radioactive stock solution was cooled to 0°C 
(using ice) and heated to 40°C (using heat blocks) and cycled 5 times (thermo-
cycling) with rigorous stirring between each step.  The solutions were then dosed 
onto the skin surface at 32°C. All suspensions were then stored at 5°C until further 
usage.  
                                                 
1
Solubility was determined by UV absorption spectroscopy using an appropriate range of calibration 
standards. 
  Chapter 2 
 
78 
 
 
 
 
 
 
 
Figure 2.1: Radiolabelled Carbon-14 Benzoic Acid, Caffeine, Methyl Nicotinate 
And Testosterone. The position of the carbon-14 isotope is indicated in each 
compound by an asterisk (*).  
 
 
 
 
 
 
Methyl Nicotinate
Benzoic Acid Caffeine
Testosterone
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*
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Ring-labelled 
14
C- methyl nicotinate was purchased from ARC as a dry powder with 
a specific activity of 55 mCi mmol
-1
 (Figure 2.1). Non-radioactive methyl nicotinate 
(MN) was reported to be more than 99% pure and was purchased from Sigma-
Aldrich (St. Louis, U.S.A.). A working solution of 
14
C-methyl nicotinate was 
prepared using 0.624 mg of radiolabelled methyl nicotinate supplemented with 1.09 
mg of non-radioactive methyl nicotinate in distilled water to achieve a 5 mM solution 
with a nominal activity of 0.1 µCi µl
-1
.  
Ultima Gold™ liquid scintillation cocktail and Soluene®- 350 tissue solubiliser were 
purchased from PerkinElmer (Waltham, U.S.A.). Phosphate buffered saline tablets, 
sodium lauryl sulphate, 10% neutral buffered formalin (NBF), Harris’ haematoxylin 
solution and eosin Y alcoholic solution were ordered from Sigma-Aldrich (St. Louis, 
U.S.A.). Phosphate buffered saline solution was prepared by adding 1 tablet to 200 
ml of distilled water.  Absolute ethanol, propan-2-ol (isopropyl alcohol), xylene, 1M 
hydrochloric acid and paraffin wax pellets were purchased from Fisher Scientific 
(Loughborough, U.K.). Absolute ethanol was diluted 50:50 with distilled water to 
produce a 50% aqueous ethanol solution.  
QTracker
®
 quantum dot nanoparticles were purchased from Molecular Probes, 
Invitrogen Corp. (Carlsbad, U.S.A.). QTracker
®
 565 and 655 nm PEG-Amine and 
PEG-Carboxyl quantum dots were supplied as 8 µM in 250 µl borate buffer. 
QTracker
® 
565 and 655 nm PEG coated quantum dots were supplied as 2 µM in 200 
µl borate buffer. Both the PEG-Amine and PEG-Carboxyl quantum dots were diluted 
1:7 and the PEG quantum dots by 1:2 using phosphate buffered saline to achieve a 
working solution of 1 µM at a pH of 7. All quantum dots were originally supplied in 
borate buffer, but were diluted using phosphate-buffered saline as it was confirmed 
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to have little or no effect on size or stability of the nanoparticle suspension 
(Invitrogen Corp, private communication). Immediately prior to each study, 
nanoparticle suspensions were subjected to cuphorn sonication at 12.7 kJ using an S-
4000 sonicator purchased from Misonix (Farmingdale, U.S.A.). 
White pearl bactericidal hand cleaning and caring lotion was purchased from 
DYSYS Chemical Systems (Baltinglas, Ireland). The topical skin protectant (barrier 
cream) “RD-1433” was provided by BRACCO Diagnostics Ltd and was reported to 
be of clinical research grade and so in compliance with the MHRA requirements in 
Annex I of the Council Directive 93/42/EEC of 1993 concerning medical devices 
(European Commision, 1993). Vaseline
®
 petroleum jelly was obtained from a local 
pharmaceutical retailer.  The density of each product was measured before study
2
 and 
determined as 2.24 g cm
-3
 for RD-1433 and 0.95 g cm
-3
 for Vaseline
®
.   
2.1.2. Skin Preparation 
Full thickness porcine skin was obtained post-mortem from female pigs (Sus scrofa, 
large white strain, 3 months of age and weight approximately 25 kg) purchased from 
a reputable supplier. Pigs were euthanised using a captive bolt. Skin was close 
clipped prior to removal from the dorsal aspect of each animal, after which all 
sections were wrapped in aluminium foil and stored flat at -20°C for up to 3 months 
before use. Skin was defrosted for approximately 24 hours at 5°C and dermatomed to 
a thickness of 500 µm using a Humeca D42 dermatome purchased from Eurosurgical 
Ltd. (Guildford, U.K.) before each study. Skin thickness was confirmed using a 
digital micrometer purchased from Tooled-Up (Middlesex, U.K.). Dermatomed skin 
                                                 
2
 The density of each product was calculated from weighing a known volume (1 ml) of product. 
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was then cut into squares measuring approximately 3 x 3 cm in preparation for 
mounting into diffusion cells.  
2.1.3. Diffusion Cells 
Static (Franz-type) glass diffusion cells were purchased from PermeGear 
(Hellertown, U.S.A.) and were of the horizontal, glass-jacketed variety (Figure 2.2-
A) with an available surface area of 1.77 cm
2
 and receptor chamber volume of 
approximately 14 ml. The flexing skin system (CutaFlex
™
) was based upon a 
modification of the standard Franz cell and was manufactured by BM Injections 
(Winchester, UK).  The modified cells were constructed from inert (PTFE) plastic 
and incorporated a bifurcated receptor sampling arm (Figure 2.2- B).  The upper arm 
was modified to accommodate a removable air-tight cap. The lower arm 
accommodated a latex bladder which was connected to an external Watson-Marlow 
520Di peristaltic pump (Falmouth, U.K.), controlled by bespoke software provided  
by Watson-Marlow (v1.0) which allowed for timed control of the pump (to control 
inflation/deflation of the latex bladder).  
After mounting the skin sections and clamping the donor chamber in place, the 
receptor chamber in each (static and CutaFlex
™
) diffusion cell was filled with either 
50% (v/v) aqueous ethanol or phosphate buffered saline as appropriate. The 
assembled diffusion cells were then placed in a metal chamber (Figure 2.3) on a 
magnetic stirrer, which mixed the receptor chamber fluid via two (12 x 6 mm) 
Teflon™ coated iron stir bars placed in each receptor chamber.  The jacket of each 
diffusion cell was connected to a Grant Instruments GD120 (Cambridge, U.K.) re-
circulating water heater via the diffusion cell manifold (Figure 2.3) in order to ensure 
a skin temperature of approximately 32°C ± 1°C (as confirmed using infrared  
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Figure 2.2: Two In Vitro Diffusion Cells Used For Percutaneous Penetration Testing: Franz-Type (A) and CutaFlex™ (B). The Franz-type 
(Left) static diffusion cell is comprised of a donor chamber (application of penetrant under study); receptor chamber (collection of penetrant that 
passes through membrane); skin section (clamped between the two chambers); sampling arm for removing aliquots of receptor fluid and a heated 
jacket to keep the skin at a constant temperature. CutaFlex™ is a novel flexing diffusion cell based upon the OECD-compliant Franz-type cell and 
consists of a latex bladder attached to an air-tight bung which is connected to a peristaltic pump; an air-tight screw cap seals the sampling arm of 
which receptor fluid samples are taken; a donor chamber; skin section; receptor chamber and a heated jacket (Viegas, 2014).  
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Figure 2.3: Diffusion Cell Apparatus Comprising Peristaltic Pump, Diffusion Manifolds Containing Franz-Type And CutaFlex™ 
Diffusion Cells And Re-Circulating Heated Pump. The peristaltic pump operated through the use of computer software, to inflate the latex 
bladder in CutaFlex™ cells. Both Franz-type and CutaFlex™ cells sat in metal chambers in the diffusion manifolds on top of stir blocks, in order to 
ensure constant mixing of receptor fluid contents. The re-circulating heated pump was connected to the diffusion cells via the diffusion manifold 
and ensured constant temperature of the skin within the cells (Viegas, 2014).  
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imaging; FLIR Model P620 Camera, Cambridge, U.K.). Diffusion cells were 
subsequently left to equilibrate overnight (minimum period of 12 hours) before use. 
Skin deflection in the CutaFlex
™
 diffusion cell was driven by air displacement 
generated by the peristaltic pump under controlled parameters (Figure 2.4). 
Peristaltic pump tubing with a bore size of 2.54 mm (internal diameter) was 
purchased from Scientific Laboratory Supplies (Wilford, U.K.) to connect the 
peristaltic pump directly to the latex bladders in each cell. Gauze inserts were not 
used under the skin in the CutaFlex
™
 or Franz-type diffusion systems (as this would 
prevent concave flexing).  
Skin deflection height was measured using a custom-made laboratory apparatus that 
sat on top of the skin surface and contained a piston with a ruler displaying 
millimetre markings. Characterisation of skin flexion height was performed using six 
CutaFlex
™
 cells and repeated approximately three times per cell. For the 
displacement of air as facilitated by the peristaltic pump, twelve revolutions per 
minute was the chosen speed for both forward (upwards) movement of 14 seconds 
and reverse (downwards) movement of 13 seconds. These values led to 
approximately 2 flexes per minute. Each diffusion cell was filmed for flexion using a 
digital camera, with both the start and end position of the top of the piston manually 
recorded. It was found that the maximum average of height displacement was 
approximately 3 millimetres.  
Based on the skin deflection height of 6 mm, volume displacement within the 
receptor chamber was calculated using the formula below: 
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Figure 2.4: Schematic Representation Of CutaFlex™ Skin Flexion. Air is introduced through the latex bladder via a peristaltic pump 
controlled using bespoke programmable computer software. The increase in air leads to an expansion of the latex bladder which displaces 
receptor fluid within the air-tight diffusion cell. The displacement of receptor fluid results in stretching of the skin outwards from the diffusion 
cell (maximum vertical displacement of 3 mm). When air is consequently pulled out of the diffusion cell system, vertical displacement of the 
skin occurs in the opposite (concave) direction to a maximum displacement of 3 mm (Viegas, 2014).  
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Equation 2.1  
𝑉𝑑𝑜𝑚𝑒 =  
𝜋 (3𝑎2 + ℎ2)
6
 
Where a = 0.75 cm and h = 0.3 cm 
 
Therefore, the volume of receptor fluid being pumped into/out of the receptor 
chamber to attain a maximum displacement as induced by a vertical displacement 
height of 6 mm was 279 µl (~ 2% of receptor chamber volume). 
2.1.4. Barrier Integrity Testing 
2.1.4.1. Transepidermal Water Loss 
Where applicable, an indirect measurement of structural integrity was performed on 
skin sections in each diffusion cell using an AquaFlux AF 200 closed-chamber 
evaporimeter with software (AquaFlux version 7.03) purchased from Biox (London, 
U.K.). The evaporimeter was calibrated prior to each use according to 
manufacturer’s instructions.  Briefly, the evaporimeter probe was set to accumulate 
approximately 0.02 mg of ice and a baseline value was taken after a 30 minute 
stabilisation period using a closed cap. The cap was then replaced with a 
measurement cap with an adapter specific for a 1.5 cm diameter donor chamber 
(used in this study) using a correction factor of 2.1 (applied by the software to 
account for the increased measurement height from the skin surface). Measurements 
of TEWL rates were subsequently acquired at equilibrium, defined as a standard 
deviation of 0.075 g m
-2
 h
-1
 over a 5 second time period (as per manufacturer’s 
instructions).  
2.1.4.2. Tritiated Water Permeability Testing 
Where applicable, the structural integrity of skin samples was measured directly 
using a modification of the “twenty minute test” (Bronaugh et al., 1986). Briefly, an 
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aliquot (250 µl) of fluid was removed from each receptor chamber prior to the 
addition of 442.5 µl of 
3
H2O working solution (2.3 nCi µl
-1
) to the skin surface 
(occluded) of each donor chamber (equating to a dose of 250 mg cm
-2
). A second 
aliquot (250 µl) of each receptor fluid was taken 30 minutes after application of the 
3
H2O. In both cases, the receptor fluid was replenished with fresh PBS solution (250 
µl) in order to ensure the volume of each chamber was kept constant. Aliquots were 
placed into vials containing 5 ml of LSC fluid. Any residual 
3
H2O was carefully 
removed from the skin surface with a syringe, followed by a wet swab and a dry 
swab of the skin surface. Standard solutions were prepared on the day of each 
experiment by addition of 100 µl of 
3
H2O to (a) cotton wool swabs and (b) un-
exposed skin tissue dissolved in 10 ml of Soluene-350. Each standard solution was 
prepared in triplicate and was subjected to an identical sampling regime of 250 µl 
aliquots into vials containing 5 ml of LSC fluid. A standard receptor chamber 
solution was prepared in triplicate by the addition of 442.5 µl of 
3
H2O working 
solution to 557.5 µl of fresh receptor fluid (phosphate buffered saline solution) from 
which a range of triplicate samples (25, 50, 75 and 100 µl) were taken and placed 
into vials containing 5 ml of LSC scintillation to produce a standard (calibration) 
curve. All vials were then subject to liquid scintillation counting as described in 
Section 2.3.1.  
2.1.5. Standard Penetrant Studies 
2.1.5.1. Bladder Adherence Studies 
An aliquot (442.5 µl) of either 
3
H2O or Carbon-14 chemical working solution was 
added to either 13.6 ml or 16 ml of PBS or 50% aqueous ethanol, in a Franz-type or 
CutaFlex
™
 receptor chamber. Receptor chambers were then sealed using Parafilm
®
 
and aliquots (250 µl) of receptor fluid were withdrawn from each diffusion cell at 
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regular intervals for up to 8 hours (tritiated water) or 51 hours (Carbon-14 
chemicals). Each aliquot was placed into a vial containing 5 ml of liquid scintillation 
counting fluid. Each receptor chamber was then replenished with an equivalent 
volume (250 µl) of fresh fluid to maintain constant volume after each sample was 
removed. After each study, the latex bladders were removed from each CutaFlex
™
 
cell and placed into vials containing 20 ml of absolute ethanol and aliquots (250 µl) 
were taken after 1 week and placed into vials containing 5 ml of LSC fluid. Standard 
calibration solutions were prepared as described in Section 2.1.4.2. All aliquots were 
subject to liquid scintillation counting as described in Section 2.3.1. 
2.1.5.2. Tritiated Water Dermal Absorption Studies 
Each experiment was initiated by the addition of 442.5 µl (250 mg cm
-2
) 
3
H2O 
working solution to the skin surface (occluded) in each donor chamber. Franz-type 
and CutaFlex
™
 diffusion cells (flexed for 0, 30, 60, 90, 120, 240, 360 and 480 
minutes) were tested for tritiated water permeability, with 9 diffusion cells per group. 
Samples of receptor fluid (250 µl) were withdrawn from each diffusion cell at 
regular intervals up to 9 hours post-exposure and were placed into vials containing 5 
ml of liquid scintillation counting fluid. Each receptor chamber was topped up with 
an equivalent volume (250 µl) of fresh fluid to maintain a constant volume in the 
receptor chamber. Standard calibration solutions were prepared as previously 
described in Section 2.1.4.2. Aliquots (250 µl) of each sample (i.e. swabs, skin and 
receptor fluid) were placed into vials containing 5 ml of LSC and subject to liquid 
scintillation counting (Section 2.3.1). 
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2.1.5.3. Carbon-14 Benzoic Acid, Caffeine and Testosterone Studies 
Skin Partition Coefficients 
Skin partition coefficients of benzoic acid, caffeine and testosterone were determined 
in triplicate: Dermatomed skin sections were weighed and then placed into separate 
vials containing 557.5 µl of 50% aqueous ethanol.  An aliquot (442.5 µl) of each 
Carbon-14 working solution was added to a vial containing the skin section, which 
was then exposed for 3 days at 32°C ± 1°C with occasional stirring. Sections were 
then removed, blotted and briefly rinsed with 50% aqueous ethanol. Each section 
was then added to a vial containing 5 ml of Soluene-350. After two weeks, aliquots 
(250 µl) were removed from each skin sample and analysed through liquid 
scintillation counting as described in Section 2.3.1. 
Dermal Absorption Studies 
An aliquot (250 µl) of fluid was removed from each receptor chamber prior to the 
addition of 442.5 µl (0.113 µCi µl
-1
) of either 
14
C-benzoic acid, caffeine or 
testosterone to the skin surface (occluded) of each donor chamber. Samples of 
receptor fluid (250 µl) were withdrawn from each diffusion cell at regular intervals 
up to 51 hours post-exposure and were placed into vials containing 5 ml of liquid 
scintillation fluid. Each receptor chamber was replenished with an equivalent volume 
(250 µl) of 50% aqueous ethanol to maintain a constant volume in the receptor 
chamber. After 51 hours, any remaining 
14
C-chemical was removed from the skin 
surface using a wet swab followed by a dry swab (repeated twice) which were each 
placed into vials containing 20 ml of absolute ethanol. After two weeks (with 
occasional shaking), aliquots (250 µl) were removed and placed into vials containing 
5 ml of liquid scintillation counting fluid. Skin samples were removed from diffusion 
cells and placed into vials containing 10 ml of Soluene-350 for two weeks, after 
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which aliquots (250 µl) were taken from each sample and placed into vials 
containing 5 ml of LSC fluid.  
Standard solutions were prepared on the day of each experiment by addition of 221 
µl of relevant 
14
C-chemical to (a) 6 cotton wool swabs in 20 ml of absolute ethanol 
and (b) un-exposed skin tissue dissolved in 10 ml of Soluene-350. Each solution was 
prepared in triplicate and was subjected to an identical sampling regime of 250 µl 
aliquots into vials containing 5 ml of LSC fluid. A standard receptor chamber 
solution was prepared in triplicate by the addition of 442.5 µl of 
14
C-chemical 
working solution to 557.5 µl of fresh receptor fluid (50% aqueous ethanol) from 
which a range of triplicate samples (25, 50, 75 and 100 µl) were taken and placed 
into vials containing 5 ml of LSC scintillation to produce a standard (calibration) 
curve. All vials were then subject to liquid scintillation counting as described in 
Section 2.3.1. 
Representative sections (3) from each treatment group were taken for 
autoradiography by the Typhoon FLA 7000 Typhoon System (GE Healthcare; 
Amersham, U.K.). After analysis, skin samples were placed into 5 ml of Soluene-350 
for two weeks, after which aliquots (250 µl) were placed into vials containing 5ml of 
LSC fluid. All vials were then subject to scintillation counting.  
Surface Spreading Of Carbon-14 Chemicals Visualised Using Autoradiography 
Representative carbon-14 treated skin samples as well as skin blanks were stored in a 
Kodak exposure cassette at -70°C until autoradiography was performed. Samples 
were defrosted at room temperature on the day of analysis. The re-usable exposure 
film was first wiped clean for 15 minutes using white light and read on the Typhoon 
system in order to ensure no residual signal was present from the previous use. The 
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exposure cassette was then lined with cellophane onto which the skin samples were 
placed. A layer of cellophane was then placed over the surface of all skin samples, to 
protect the exposure film from direct contact and the exposure cassette was then 
exposed to the skin in the dark for 3 hours at room temperature. After 3 hours, the 
film was removed from the exposure cassette and placed into the Typhoon system. 
The system was calibrated for the photomultiplier tubes set at 800 units, a resolution 
of 25 µM, latitude of L5 and a mode for a large film (20 x 40 cm). After the images 
were taken, the skin was dissolved in Soluene-350 and analysed using scintillation 
counting. All autoradiographs were subsequently analysed using public domain 
software (Image J, National Institute of Health, Version 1.74) to quantify intensity 
per unit area values, after which all treatment groups were compared to a non-treated 
control. 
2.1.6. Skin Damage Studies 
The purpose of these experiments was to compare the effects of skin damage 
between un-flexed and flexed skin.  Skin damage was quantified by measurements of 
TEWL rates and 
3
H2O permeability (Section 2.1.4) performed before and after skin 
damage. Standard solutions were prepared as previously described in Section 2.1.4.2. 
2.1.6.1. Phase I: Baseline Studies 
The initial studies were performed to determine baseline values of tritiated water and 
transepidermal water loss (TEWL) before and after flexion of the skin in the absence 
of damage. Briefly, transepidermal water loss and tritiated water measurements were 
taken both before and after skin flexion for 0, 30, 60, 90 or 120 minutes (Figure 2.5- 
I). 
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2.1.6.2.  Phase II: Chemical Damage (Sodium Lauryl Sulphate) 
After initial measurements of transepidermal water loss and tritiated water 
permeation, a solution of 5% (v/v) SLS was applied to the skin at 442.5 µl (250 µl 
cm
-2
) for a duration of 1 hour
3
. The SLS solution was then removed and the skin was 
swabbed with a wet and dry cotton swab (repeated in triplicate) to remove any 
residual SLS. After SLS removal, the diffusion cells were then flexed (or remained 
un-flexed) for up to two hours after which final TEWL and tritiated water 
measurements were taken (Figure 2.5- II).   
2.1.6.3. Phase III: Physical Damage  
Initial measurements of both transepidermal water loss and tritiated water permeation 
were taken before each piece of skin was punctured twice in situ (centrally) using a 
25 gauge hypodermic needle and were then flexed (or remain static) for up to two 
hours after which a second set of TEWL and tritiated water measurements were 
taken (Figure 2.5- III) . 
 
  
                                                 
3
 One hour was deemed the minimum time to produce significant skin damage in a series of pilot 
studies (data not shown). 
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Figure 2.5: Skin Damage Study Design: Baseline And Flexing Study Outline (I), 
Chemical Damage Study Outline (II) And Physical Damage Study Outline (III). 
Tritiated water permeability and transepidermal water flux measurements were used 
to assess barrier integrity. Both Franz-type cells (F) and CutaFlex™ (CF) diffusion 
cells were tested in either static (0) or flexing (30-120 minutes) conditions. The first 
phase of study evaluated the effect of flexing on skin integrity. The second set of 
studies assessed chemical damage (using sodium lauryl sulphate) of the skin when 
using flexing. The last phase of study assessed the effect of physical damage 
(punctures) of the skin when using flexing. 
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2.1.7. Quantum Dot Nanoparticle Characterisation 
2.1.7.1. Transmission Electron Microscopy (TEM) 
Aliquots (20 µl) of each quantum dot nanoparticle working suspension were applied 
to a standard carbon-mesh TEM grid purchased from Agar Scientific (Standsted, 
U.K.) and left to dry at room temperature. Samples were then hand delivered to 
BegbrokeNano (Yarnton, U.K.) for analysis
4
. Nanoparticle morphology and size 
were determined using a JOEL analytical TEM with a LaB6 electron gun with an 
accelerating voltage of 200 kV. Energy-dispersive x-ray analysis (EDX) was 
simultaneously performed to confirm elemental presence of analysed nanoparticles.  
2.1.7.2. Dynamic Light Scattering 
An aliquot (50 µl) of each quantum dot working suspension was placed into small 
volume (40 µl) cuvettes and characterised for median peak size (number-based) as 
well as overall distribution size and polydispersity index at 25°C using a Zetasizer 
NS purchased from Malvern (Malvern, U.K.). Each measurement was determined 
from up to 17 runs and a final average recorded from five replicates. 
2.1.8. Dermal Absorption Of Nanoparticles 
An indirect measurement of structural integrity was performed on skin sections in 
each diffusion cell using an evaporimeter to determine transepidermal water loss flux 
(Section 2.1.4.1). An aliquot (300 µl) of quantum dot suspension (1 µM) was applied 
to the skin surface of each donor chamber (occluded) for 8 hours. Excess quantum 
dot nanoparticle solution was removed from the skin surface of each diffusion cell by 
a dry swab followed by a wet swab, which were both placed into vials containing 20 
ml of distilled water. An equilibration time of one hour was observed before the final 
set of transepidermal water loss measurements in each diffusion cell. After TEWL 
                                                 
4
 TEM analysis was performed by BegbrokeNano-Oxford Materials Characterisation Service. 
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measurements were completed, skin sections were taken for visualisation of residual 
skin surface fluorescence using UV-light as further described in Section 2.1.10. Skin 
sections were then dehydrated for eventual embedding in paraffin wax and further 
analysis through H&E staining and laser scanning confocal microscopy as further 
described in Section 2.1.11.2 and 2.1.12, respectively. Receptor fluid from each 
diffusion cell, 14 or 16.4 ml for Franz or CutaFlex
™
 cells, respectively, was decanted 
into vials for further analysis through fluorescence spectrophotometry (Section 
2.1.9). 
2.1.9. Fluorimeter Analysis Of Skin Surface Swabs And Receptor Fluid  
Aliquots (3 ml) of skin swab and receptor fluid samples from each diffusion cell 
were analysed in triplicate for fluorescence intensity using a Cary Eclipse 
fluorescence spectrophotometer purchased from Agilent (Santa Clara, U.S.A.). An 
excitation wavelength of 488 nm was chosen with an emission wavelength of either 
565 or 655 nm were used for the relevant dots. A standard solution was prepared 
using aliquots of 2, 4, 8 and 10 µl of each 1 µM quantum dot suspension placed into 
20 ml of distilled water. Each standard was analysed in triplicate to construct a 
calibration curve.  
2.1.10. UV-Light Box Images Of Skin Surface 
Skin sections were placed into a bespoke light box which utilized 4 arrays of 16 LED 
light bulbs. A Canon EOS 60D digital camera with UV-filter was calibrated with an 
ISO speed of 1600, shutter speed of 0.2 seconds and an aperture of 5.6. All quantum 
dot treatment groups were paired with non-treated controls. Each image was 
analysed using ImageJ (v1.74) to obtain an intensity value per unit area. Each skin 
section was then compared to an un-treated control.  
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2.1.11. Histology 
2.1.11.1. Paraffin Embedding 
All skin sections were fixed overnight in 10% neutral-buffered formalin (NBF). Skin 
was then transferred through the steps outlined in Table 2.1, for dehydration leading 
to paraffin embedding using a Citadel 2000 tissue processor (ThermoFisher; 
Waltham, U.S.A).  
Molten paraffin wax was poured into 10 ml embedding moulds containing skin 
sections and allowed to set overnight. The paraffin wax blocks were cut on a 
Shandon
™
 Finesse 325 manual microtome (ThermoFisher; Waltham, U.S.A.) into 5 
µm sections, through the dermal tissue upwards
5
. Sections were floated on a 45ºC 
water bath to smooth out any wrinkles and mounted onto lysine (positively) coated 
microscope slides (VWR International; Lutterworth, U.K.). The paraffin wax 
sections were then baked onto the slides overnight in a 40ºC oven. Slides were then 
loaded into a slide rack and re-hydrated using the steps outlined in Table 2.2. 
 
 
 
 
 
 
 
 
 
                                                 
5
 This tissue orientation was used to prevent QDot particle translocation from the skin surface through 
the skin. The microtome blade was cleaned after each section was cut from the paraffin block. 
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Table 2.1: Skin Processing Schedule For Paraffin Wax Embedding. Skin was 
progressively dehydrated through graded steps of ethanol (EtOH). Xylene steps were 
used to displace ethanol in order for wax embedding. Total processing time was 12 
hours, after which skin sections were manually embedded into paraffin wax blocks. 
Concentration Duration 
70% EtOH 1 h 
95% EtOH 1 h 
100% EtOH 1 h 
100% EtOH 1.5 h 
100% EtOH 1.5 h 
Xylene 2 h 
Xylene 1 h 
Xylene 1 h 
Wax 1 h 
Wax 1 h 
 
 
 
Table 2.2: Skin Re-Hydration Schedule For H&E Staining Or Confocal 
Microscopy Analysis. After sectioning of paraffin blocks, paraffin skin sections on 
slides were passed through xylene and ethanol (EtOH) steps leading to either H&E 
staining or confocal analysis. 
Concentration Duration 
Xylene 10 min 
100% EtOH  6 min 
95% EtOH 3 min 
70% EtOH 3 min 
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2.1.11.2. H&E Staining 
Harris’ haematoxylin solution was filtered before each use. A 0.25% v/v 
hydrochloric acid in 70% ethanol solution was used for differentiation of the 
haematoxylin stain. Tissue dehydration into H&E stain and subsequent rehydration 
steps were followed for 5 µm skin sections for each quantum dot (Table 2.3). 
All resulting H&E stained skin sections were imaged using a Leitz LABORLUX 11 
purchased from Leica (Solms, Germany) with a 10x (0.25 NA) lens and images were 
acquired using a Canon PowerShot S5 IS camera with remote shooting software set 
for an ISO of 800 and tungsten exposure.  
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Table 2.3: Haematoxylin and Eosin Staining Chart For Quantum Dot Exposed 
Skin Sections. Skin was re-dehydrated by passing through xylene and a graded 
series of ethanol steps. Re-hydration was followed by skin staining with Harris’ 
haematoxylin solution after which skin was stained using Eosin Y. Skin was then 
dehydrated and a coverslip was attached to each slide. 
Step Chemical Time 
1 Xylene 10 min 
2 100% Ethanol 6 min 
3 95% Ethanol 3 min 
4 70% Ethanol 3 min 
5 Harris’ Haematoxylin Solution 2.5 min 
6 Rinse in running tap water 1 min 
7 Differentiate in 0.25% HCl in 70% Ethanol 3 dips 
8 Rinse in running tap water 1 min 
9 95% Ethanol 0.5 min 
10 Counterstain in Eosin Y 1 min 
11 Rinse in running tap water 0.25 min 
12 70% Ethanol 3 min 
13 95% Ethanol 3 min 
14 100% Ethanol 6 min 
15 Xylene 10 min 
16 Coverslip  
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2.1.12. Laser Scanning Confocal Microscopy 
Quantum dots were imaged in exposed skin samples using a C1 confocal laser 
scanner connected to an Eclipse TE 2000 U inverted fluorescence microscope using 
a 10x (0.3 NA) Plan Fluor DIC L/N1 dry objective purchased from Nikon (Tokyo, 
Japan). An Argon-Ion laser was used to excite the quantum dots at a wavelength of 
488 nm and a filter-based emission channel of 500-643 nm was used for 
visualisation. Gain settings for both the red and green channel were set at 100 units. 
Transmitted light was used to obtain skin structure details. The transmitted light 
channel gain was set at 37 units. Images were captured using the Nikon EZ-C1 
software (Gold version 3.90).  Images were chosen at 1024 pixel resolution with each 
image consisting of an average of 4 laser scans. It should be noted that due to the 
limited filter settings of the confocal microscope, QDot 565 fluorescence was made 
to appear red (not green).  
2.1.13. In Vitro Barrier Cream Efficacy Studies 
2.1.13.1. Evaporation Rate Of 14C-Methyl Nicotinate And 3H-Water 
Methyl nicotinate working solution was diluted by one third and un-labelled methyl 
nicotinate was added to achieve a 5 mM working solution (0.033 µCi µl
-1
). An 
aliquot (10 µl) of 
3
H2O stock solution was diluted by one-third to achieve a new 
working solution (0.033 µCi µl
-1
). CutaFlex
™
 diffusion cell groups were used with 
aluminium foil in the place of skin and heated to 32°C.  Following an equilibration 
time (2h), the aluminium foil in each donor chamber was dosed with either 10 µl of 
14
C-methyl nicotinate or 10 µl of tritiated water. Aluminium foil was subsequently 
removed from the manifold at time 0 (control), 5, 10, 15, 20, 30, 45, 60, 90 and 120 
minutes after dosing and placed directly into vials containing 5 ml of LSC fluid. 
Each time-point was replicated in triplicate. A standard calibration solution was 
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performed in triplicate using aluminium foil dosed with 2, 4, 8 and 10 µl aliquots of 
working solution and placed into vials containing 5 ml of LSC fluid. All samples 
were then analysed using scintillation counting as further described in Section 2.3.1.
 
2.1.13.2. Optimal Thickness Studies 
Both transepidermal water loss flux and tritiated water measurements relating to skin 
barrier integrity were performed as previously described in Section 2.1.4. The test 
products RD-1433 or Vaseline
®
 were applied at 3 nominal thicknesses of 0.01, 0.05 
and 0.1 mm (1.8, 8.9 and 17.7 µl, respectively) and in addition to an untreated 
control were assessed (6 diffusion cells per group) for 
14
C-methyl nicotinate 
penetration (Figure 2.6- I). Test products were uniformly spread onto the treated or 
untreated skin surface using a pre-weighed glove tip after which the glove tip was 
weighed again, for an estimation of product delivery. Studies were initiated by 
placing an aliquot (10 µl) of 
14
C-labelled methyl nicotinate onto the treated or 
untreated skin surface in each donor chamber. Samples of receptor fluid (250 µl) 
were removed from each diffusion cell at regular intervals for up to 180 minutes and 
placed into vials containing 5 ml of LSC fluid. Each receptor chamber was 
replenished with an equivalent volume of fresh fluid to maintain a constant volume. 
Twenty minutes after exposure, excess methyl nicotinate was removed with a cotton 
bud which was immersed in 20 ml of isopropyl alcohol for 2 weeks with occasional 
stirring, after which an aliquot (250 µl) was placed into vials containing 5 ml of LSC 
fluid. After a further 120 minutes had elapsed, the test products were removed from 
the skin surface using a cotton swab soaked with 0.25% of white pearl handwash 
solution followed by a dry swab (both repeated twice), all of which were placed into 
vials containing 20 ml of isopropyl alcohol. An aliquot (250 µl) of each sample was  
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Figure 2.6: In Vitro Schedule For Both Optimal Thickness (I) And Duration Of Efficacy Studies (II). CutaFlex™ flexed (CF F) and 
CutaFlex™ static (CF 0) cells were both tested with RD-1433 and Vaseline at thicknesses of 0, 0.01, 0.05 and 0.1 mm to determine a protective 
effect against 
14
C-methyl nicotinate. Following on from this, a nominal thickness of 0.1 mm was chosen for application at 1, 2, 4 and 6 hours.
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then placed into a vial containing 5 ml of LSC fluid.  A further flexing (or static) 
time period of 60 minutes was then observed after which a second set of TEWL and 
tritiated water permeability measurements were taken.  
Standard solutions were prepared on the day of each experiment by an addition of 5 
µl 
14
C-methyl nicotinate to (a) four cotton wool swabs in 20 ml of isopropyl alcohol 
and (b) un-treated skin tissue dissolved in 10 ml of Soluene-350. Each of the 
standard solutions was prepared in triplicate and aliquots (250 µl) of each sample 
were placed into vials containing 5 ml of LSC fluid. A standard receptor chamber 
solution was also prepared in triplicate by the addition of 10 µl of 
14
C-methyl 
nicotinate to 990 µl of fresh receptor fluid (phosphate buffered saline) from which a 
range of triplicate aliquots (25, 50, 75 and 100 µl) were placed into vials containing 5 
ml of LSC fluid. All samples were subject to liquid scintillation counting (Section 
2.3.1). 
2.1.13.3. Duration Of Efficacy Studies 
Measurements of transepidermal water loss flux and tritiated water permeability 
were performed (Section 2.1.4) to measure barrier integrity. A test product thickness 
of 0.1 mm (17.7 µl) was chosen for a staggered application of both RD-1433 and 
Vaseline over a period of 0 (control), 1, 2, 4 or 6 hours (Figure 2.6- II). This dose of 
test product was determined from the corresponding human volunteer studies 
(Section 2.2.2). Test products were uniformly spread onto the skin surface using the 
method previously described in Section 2.1.13.2. An aliquot (10 µl) of working 
solution of 
14
C-methyl nicotinate was applied to the skin surface in each donor 
chamber. Receptor fluid aliquots (250 µl) were removed from each diffusion cell at 
regular intervals up to 120 minutes. Each receptor chamber was replenished with an 
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equivalent volume in order to maintain a constant volume of receptor fluid. Twenty 
minutes after dosing, excess 
14
C-methyl nicotinate was removed using a cotton bud 
which was then placed into a vial containing 20 ml of isopropyl alcohol in which 
aliquots (250 µl) were subsequently placed into vials containing 5 ml of LSC fluid. 
Sixty minutes after exposure, residual test products were removed from the skin 
surface using a cotton wool swab moistened with handwash solution followed by a 
dry swab (repeated twice) which were placed into vials containing 20 ml of isopropyl 
alcohol. Aliquots (250 µl) were then taken from each swab sample and placed into 
vials containing 5 ml of LSC fluid. A further skin flexing (or static) time period of 60 
minutes was then observed after which a second set of TEWL and tritiated water 
permeability measurements were taken. Standard solutions were prepared as 
previously discussed in Section 2.1.13.2  
2.2. Clinical Trial  
Ethical approval to determine clinical efficacy of RD-1433 was granted by the 
National Research Ethics Service Committee (North East- Northern & Yorkshire, 
Reference: 12/NE/0255) and the Medicines and Healthcare Products Regulatory 
Agency (Reference: CI/2012/0033). All 12 participants provided fully informed 
consent. This work involved the input of staff from the Research Centre for 
Transdermal and Topical Drug Delivery and Toxicology. This study was performed 
‘double blind’ in accordance with the principles of GCP.  
2.2.1.  In Vivo Measurements  
2.2.1.1. Visual Erythema Scoring 
All treatment sites were evaluated for visual erythema and oedema using a Draize-
type scoring system. The grading scale used in Draize-type tests ranges from a score 
of 0-4 for a description of both erythema and oedema formation (Table 2.4). 
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Table 2.4. Grading Scale Used In Draize-Type Tests (Draize et al. (1944). 
Grading of both erythema and oedema on a scale from 0-4.  
 Erythema Oedema 
0 No erythema No oedema 
1 Very slight erythema (barely 
perceptible) 
Very slight oedema (barely 
perceptible) 
2 Well-defined erythema Slight oedema (edges of area well 
defined by definite raising 
3 Moderate to severe erythema Moderate oedema (raised approx. 
1mm) 
4 Severe erythema (beet redness) to 
slight eschar formations (injuries in 
depth) 
Severe oedema (raised more than 1 
mm and extending beyond area of 
exposure) 
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2.2.1.2. Laser Doppler Imaging 
A laser Doppler imager and software (Moor version 2.2) was purchased from Moor 
Instruments (Devon, U.K.) to measure cutaneous blood flow at each treatment site. 
The scanner was placed 15 cm above each treatment site and measurements were 
taken in triplicate. The scan speed was set at 200 milliseconds per line with a scan 
area of 15.7 cm x 12.5 cm. The triplicate images were then smoothed and averaged 
using the Moor software. Using the averaged flux image, circular regions of interest 
were manually drawn around each exposure site and these values were averaged per 
treatment.  
2.2.1.3. Tissue Viability Imaging 
Skin erythema was measured using a Tissue Viability Imager 600 and software (TiVi 
600 version 5.0) purchased from WheelsBridge (Linköping, Sweden). The camera 
was placed on a bespoke stand above the treatment areas. Images were taken in 
duplicate at a maximum resolution of 2074 x 1556 pixels with a colour span of 400. 
Percentage of erythema was then averaged per treatment. 
2.2.1.4. Transepidermal Water Loss 
Transepidermal water loss flux was analysed at each treatment site using a Biox 
AquaFlux AF200 probe (previously described in Section 2.1.5.1) with an appropriate 
in vivo measuring cap. 
2.2.2. Optimal Thickness Study 
Human volunteers (both sexes, 31-81 years of age) had six circular areas of 2.3 cm
2
 
drawn on the volar forearm of both arms with a non-permanent skin marker. One site 
on each arm was designated as an untreated control. The volume of Vaseline and 
RD-1433 dispensed was calculated by dividing the required thickness of the cream 
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(in mm) by 10 (cm) and then multiplying by the dosing area (2.3 cm
2
).  Test products 
RD-1433 and Vaseline were applied at five different nominal thicknesses of 0.01, 
0.02, 0.05, 0.1 and 0.2 mm (corresponding to 4.2, 8.3, 20.8, 41.5 and 83.1 µl, 
respectively) and in addition to an untreated control were assigned a treatment area 
(Figure 2.7- I). Methyl nicotinate was prepared fresh daily, as a 5 mM solution in 
distilled water. Initial measurements of TEWL, LDI, tissue viability imaging and 
visual erythema were taken before application of Vaseline and RD-1433 as outlined 
in Section 2.2.1. After products were applied to the skin surface, non-contact 
measurements of LDI, infrared, TiVi and visual erythema were taken. An aliquot (10 
µl) of methyl nicotinate was applied to the centre of each skin treatment area, after 
which non-contact measurements were taken at regular intervals until 120 minutes. 
Excess methyl nicotinate was removed 20 minutes post-exposure using a cotton bud. 
This was deemed necessary to avoid participants having to remain perfectly still for 
the 2 hour exposure period to avoid the droplet moving. A pilot study (data not 
reported) demonstrated that 20 minutes was sufficient to provide a maximum 
erythematous response. Both RD-1433 and Vaseline were removed 120 minutes 
post-exposure using warm water and detergent. Following a 60 minute rest period, 
the final set of contact and non-contact biophysical measurements were taken. For 
the purpose of this Thesis, only biophysical measurements of visual erythema 
scoring, laser Doppler imaging, tissue viability imaging and transepidermal water 
loss flux will be reported.  
2.2.3. Duration Of Efficacy Study 
Initial biophysical measurements and preparation of methyl nicotinate solution were 
performed as previously outlined in Section 2.2.2. Following the results of the  
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Figure 2.7: Clinical Trial Schedule For Optimal Thickness (I) And Duration Of Efficacy (II) Studies. Volunteers were tested with RD-1433 
and Vaseline at thicknesses of 0, 0.01, 0.02, 0.05, 0.1 and 0.2 mm to determine a protective effect against 
14
C-methyl nicotinate (Optimal 
Thickness Study). Following on from this, a nominal thickness of 0.1 mm was chosen for application at 1, 2, 4, 5 and 6 hours (Reapplication 
Frequency Study). 
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optimal thickness study
6
, a thickness of 0.1 mm was chosen for staggered application 
of both RD-1433 and Vaseline application for a period of 1, 2, 3, 4 and 6 hours 
before exposure to methyl nicotinate (Figure 2.7- II). During the staggered 
application period, volunteers were allowed to engage in light physical activity. After 
product application, non-contact biophysical measurements identical to the optimal 
thickness study measurements were taken. An aliquot (10 µl) of methyl nicotinate 
was applied to the treatment sites on both arms, after which non-contact biophysical 
measurements were taken for regular intervals up to 60 minutes. Excess methyl 
nicotinate was removed 20 minutes post-exposure. After 60 minutes, test products 
were removed using warm water and a mild detergent (white pearl handwash). Sites 
were allowed to air dry for a further 60 minutes, after which all biophysical 
measurements were taken.  
2.3. Sample And Statistical Analysis 
2.3.1. Scintillation Counting 
The radioactivity in all samples (receptor chamber fluid, skin, surface swabs, 
calibration standards) was quantified using a Tri-Carb 2810TR liquid scintillation 
analyser purchased from PerkinElmer (Waltham, U.S.A.), using an analysis runtime 
of 5 minutes per sample and a pre-set quench curve specific to the brand of liquid 
scintillation fluid (Ultima Gold
™
). For experiments which used both tritium and 
carbon-14, the Quanta Smart Tri-Carb software was set with specific limits. In order 
to count for tritium, the program was set to count in the region between 0 - 18.6 keV. 
To count for emissions from Carbon-14, the program was set to count in the region 
between 18.6 - 156 keV.  
                                                 
6
 The results for the optimal thickness study were used to ascertain the topical dose of RD-1433 and 
Vaseline
®
 required to determine the duration of efficacy.  
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The individual disintegrations per minute (DPM) values were normalised by 
subtraction of baseline samples and then divided by the specific activity of the 
radioactive substance to achieve a mass per sample. Specific activity was calculated 
as the amount of radioactivity (in DPM) a radioactive substance possessed per unit 
mass (in grams). Specific Activity was determined using relevant dose standards 
(Sections 2.1.4.2, 2.1.5.3 and 2.1.13). Once all time point aliquots were converted to 
mass quantities, a dilution factor was applied in order to calculate the total amount of 
radioactivity in the entire receptor chamber which contained either 14 ml (Franz-
type) or 16.2 ml (CutaFlex
™
) of receptor fluid. A cumulative amount was then 
calculated based on the total amount per receptor chamber as well as the addition of 
all previous aliquots removed and finally divided by the surface area of application 
(1.77 cm
2
). 
2.3.2. Statistical Testing 
All data were tested for normality using the Kolmogorov-Smirnov test. All treatment 
groups were then analysed against the relevant control using a Kruskal-Wallis non-
parametric ANOVA with Dunn’s post test. In regards to inter-group variability, 
individual Mann Whitney non-parametric tests were performed with a two-tail P 
value and a Bonferroni correction. Treatments in the same group were tested for 
significance using a non-parametric Wilcoxon matched-pairs test with a Bonferroni 
correction. Correlation between values was determined using Spearman’s rank 
correlation coefficient. The level of significance was predetermined at p < 0.05. The 
clinical study was performed ‘double blind’ in that neither the participants nor 
scientific staff knew which skin site had been assigned which treatment. The clinical 
study was only ‘unblinded’ when the statistical analysis was complete.  
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 Chapter 3: The Effect Of Flexing On Skin Penetration Of Model 
Compounds 
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3.1 Introduction 
The purpose of the work reported in this chapter was to characterise a novel diffusion 
cell system in order to determine the effect of in vitro flexing on normal skin barrier 
integrity. To achieve this aim, work was divided into three main stages: 
1. To assess the effects of skin flexing on skin barrier function measured directly 
(using 
3
H2O) and indirectly (TEWL). 
2. Characterisation of the novel flexing diffusion cell (CutaFlex™) using standard 
penetrants: 
3
H-water, 
14
C-benzoic acid, caffeine and testosterone. 
3. Investigation of the effects of skin flexing on skin barrier function following 
controlled physical or chemical damage. Barrier function was quantified directly 
(by measuring 
3
H2O penetration) and using TEWL. 
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3.2 Materials And Methods 
Tritiated water working solutions and equilibrated, saturated and un-filtered 
14
C-
benzoic acid, caffeine and testosterone solutions were prepared according to Section 
2.1.1. Porcine skin and Franz and CutaFlex
™
 diffusion cell systems were prepared as 
outlined in Section 2.1.2 and 2.1.3, respectively. A standard skin absorption protocol 
was followed for 
3
H2O (Section 2.1.5.2) and Carbon-14 chemicals (Section 2.1.5.3).  
Skin damage studies were performed according to protocols outlined in Section 
2.1.6. All samples were analysed using radiometric methods (Section 2.3.1). 
Statistical testing was performed as outlined in Section 2.3.2. 
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3.3 Results 
 
3.3.1 Skin Flexion 
No significant differences (p > 0.05) were found in either tritiated water permeation 
or transepidermal water loss between the Franz static control and CutaFlex
™
 static, 
30, 60, 90 and 120 minutes flexed groups in either baseline or flexing conditions 
(Figure 3.1). No significant differences (p > 0.05) in tritiated water penetration were 
seen with static skin or skin flexed from 30-120 minutes in the CutaFlex
™
 diffusion 
cells.  
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Figure 3.1: Flexing Of Porcine Skin As Measured By Tritiated Water 
Permeation (A) And Transepidermal Water Loss (B) In Franz (F), CutaFlex™ 
Static (CF 0) And CutaFlex™ 30-120 Minutes Flexed (CF 30, 60, 90 And 120) 
Diffusion Cells. Tritiated water was applied (250 mg cm
-2
) to the skin surface for 30 
minutes before and after skin flexion. Transepidermal water loss flux was also 
measured before and after skin flexion. All data are represented as mean + standard 
deviation of n=9 diffusion cells.  
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3.3.2 Skin Damage Studies 
3.3.2.1  Chemical Damage (Sodium Lauryl Sulphate) 
Significant differences were found in the amount of tritiated water penetrated 
between baseline and post-treatment with SLS between the Franz static control (p < 
0.01), CutaFlex
™
 static (p < 0.01) and CutaFlex
™
 30 (p < 0.01), 60 (p < 0.01), 90 (p 
< 0.05) and 120 (p < 0.01) minutes flexed groups (Figure 3.2, A). A decrease in skin 
integrity was detected in 100% of the treatment groups. 
Significant differences (p < 0.01) were found in transepidermal water loss flux 
between baseline and post-SLS treatment within the Franz static control (p < 0.05), 
CutaFlex
™
 static (p < 0.05), and CutaFlex
™
 60 minutes flexed (p < 0.05) groups 
(Figure 3.2, B). A decrease in skin integrity was detected in 50% of the treatment 
groups. 
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Figure 3.2: Chemical Damage Of Porcine Skin As Measured By Tritiated Water 
Permeation (Top) And Transepidermal Water Loss (Bottom) In Franz (F), 
CutaFlex™ Static (CF 0) And CutaFlex™ 30-120 Minutes Flexed (CF 30, 60, 90 
And 120 Diffusion Cells. Tritiated water was applied (250 mg cm
-2
) to the skin 
surface for 30 minutes before and after SLS treatment. Transepidermal water loss 
flux was also measured before and after SLS treatment. A 5% (v/v) solution of 
sodium lauryl sulphate was applied (250 µl cm
-2
) to the skin surface for 1 hour. All 
data are represented as mean + standard deviation of n=9 diffusion cells. An asterisk 
(*) represents a significant (p < 0.05) increase in either tritiated water penetration or 
TEWL flux as compared to baseline values for each treatment group. 
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3.3.2.2 Physical Damage (Punctures) 
Significant increases (p < 0.05) in tritiated water penetration were found between 
baseline and post-puncture treatment in all flexed skin treatment groups (Figure 3.3, 
A). A decrease in skin integrity was seen in 67% of groups treated.  
Significant increases (p < 0.05) in transepidermal water loss were found between 
baseline and post-puncture values within the CutaFlex
™
 static and CutaFlex
™
 30, 60, 
90 and 120 minutes flexed groups (Figure 3.3, B). A decrease in skin integrity was 
seen in 83% of the groups tested.  
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Figure 3.3: Physical Damage Of Porcine Skin As Measured By Tritiated Water 
Permeation (Top) And Transepidermal Water Loss (Bottom) In Franz (F), 
CutaFlex™ Static (CF 0) And CutaFlex™ 30-120 Minutes Flexed (CF 30, 60, 90 
And 120) Diffusion Cells. Tritiated water was applied (250 mg cm
-2
) to the skin 
surface for 30 minutes before and after two punctures were made through the entirety 
of the skin section in each diffusion cell. Transepidermal water loss flux was also 
measured before and after puncturing the skin. All data are represented as mean + 
standard deviation of n=9 diffusion cells. An asterisk (*) represents a significant (p < 
0.05) increase in either tritiated water penetration or TEWL flux as compared to 
baseline values for each treatment group. 
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3.3.3 Tritiated Water Permeability And Transepidermal Water Loss 
Correlation 
Baseline values of the applied amount of tritiated water penetrated and 
transepidermal water loss from all flexing and chemical and physical damage studies 
were collated and plotted (Figure 3.4). A poor correlation (r = 0.52) was found in 
baseline values between tritiated water and TEWL flux. The cut-off values between 
intact and damaged skin were determined as mean plus two standard deviations; 
Corresponding to 2.3% of the applied dose penetrated (
3
H2O) and flux of 18.3 g m
-2
 
h
-1 
(TEWL rate). When taking these values into consideration, the applied amount of 
tritiated water penetrated through porcine skin at baseline fell below the threshold 
value in 96% of all values tested (154 of 160 values). Transepidermal water loss flux 
measurements fell below the threshold in 94% of all values tested (151 out of 160 
values). There was a 46-fold difference found between the minimum and maximum 
tritiated water values as compared to a 3-fold difference between the minimum and 
maximum values of TEWL rates.  
When measuring the linear regression of baseline values of tritiated water penetration 
and transepidermal water loss flux, the correlation of the values ranged from 0.1-0.4 
(Figure 3.5, A, B and C). When measuring the linear regression of flexed, SLS 
treated and puncture treated values of tritiated water penetration and transepidermal 
water loss flux, the correlation of the values ranged from  0.06-0.4 (Figure 3.5, D, E 
and F). Therefore, there was no correlation found between TEWL rate and tritiated 
water penetrated. 
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Figure 3.4: Applied Dose Of Tritiated Water Penetrated As Correlated With 
Transepidermal Water Loss Flux For Baseline Measurements In Skin Damage 
Studies. Tritiated water was applied to the skin surface for 30 minutes (442.5 mg; 1 
µCi) and transepidermal water loss measurements were taken before and after 
flexion, sodium lauryl sulphate treatment and puncturing of the skin. The cut-off 
values for tritiated water applied dose penetrated and transepidermal water loss flux 
were set as mean + two standard deviations. The dotted vertical and horizontal lines 
represent the cut-off values for TEWL flux and applied dose of tritiated water 
penetrated, respectively.  
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Figure 3.5: Applied Dose Of Tritiated Water Penetrated As Correlated With Transepidermal Water Loss For Baseline (Top) And 
Flexed, SLS-Damaged And Puncture Damaged Treatments (Bottom) As Measures Of Skin Barrier Integrity. Tritiated water was applied 
to the skin surface for 30 minutes (442.5 mg; 1 µCi) and transepidermal water loss measurements were taken before and after flexion (A and D), 
sodium lauryl sulphate treatment (B and E) and puncturing of the skin (C and F). 
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3.3.4 Standard Penetrant Studies 
3.3.4.3 3H-Water Dermal Absorption Studies 
Cumulative Amount Penetrated 
The cumulative amount of 
3
H2O penetrating un-flexed skin mounted in the 
CutaFlex
™
 diffusion cells was not significantly different (p > 0.05) to that 
penetrating skin in standard Franz diffusion cells (Figure 3.1). Similarly, flexing of 
skin (for durations of 30-480 minutes) within the CutaFlex
™
 cells had no measurable 
effect on the cumulative absorption of 
3
H2O. 
Maximum Flux 
In terms of the rate of absorption of tritiated water through skin, there was no 
significant effect of flexing for the majority of the CutaFlex
™
 treatment groups 
(Figure 3.7). However, a statistically significant difference (p < 0.05) was observed 
between un-flexed skin in the Franz cell and skin flexed for 120 minutes in the 540 
minute study. Overall, the average steady-state flux of 
3
H2O ranged from 47 – 86 µg 
cm
-2
h
-1
.  
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Figure 3.6: Cumulative Amount Of Tritiated Water Penetrated Through Static 
(Franz, CutaFlex™ Static) And Flexed (CutaFlex™ 30-480 Minutes Flexed) 
Porcine Skin Over 360 (A) And 540 Minutes (B). Tritiated water was applied (250 
µl cm
-2
) to the skin surface at time 0. Skin mounted in CutaFlex™ cells was un-flexed 
(static) or flexed with a maximum amplitude of 6 mm, twice a minute for durations 
of 30-480 minutes. All diffusion cells remained static until 30 minutes after tritiated 
water was applied. All points are mean + standard deviation of n=9 diffusion cells. 
Values for the cumulative amount penetrated at study end are represented on the 
graph (QT). 
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Figure 3.7: Flux Profile Of Tritiated Water Penetrated Through Static (Franz, 
CutaFlex™ Static) And Flexed (CutaFlex™ 30-480 Minutes Flexed) Porcine Skin 
Over 360 (A) And 540 Minutes (B). Tritiated water was applied (250 µl cm
-2
) to the 
skin surface at time 0. All diffusion cells remained static until 30 minutes after 
tritiated water was applied. Maximum flux (JMax; µg cm
-2
 min
-1
) and time (min) of 
maximum flux are displayed on the graph. All points are mean + standard deviation 
of n=9 diffusion cells. An asterisk (*) represents a significant (p < 0.05) decrease in 
maximum flux compare to Franz (control) group. 
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3.3.4.4 14C-Benzoic Acid Dermal Absorption Study 
Transepidermal Water Loss 
There were no significant differences (p > 0.05) found in transepidermal water loss 
flux between baseline and post-treatment values within or between treatment groups 
(Figure 3.8). 
Skin Surface Spreading 
There were no significant differences (p > 0.05) observed in the amount of 
14
C-
benzoic acid remaining on the skin surface between any of the treatment groups 
(Figure 3.9). 
Cumulative Penetration 
There were no significant differences (p > 0.05) in the cumulative amount of 
14
C-
benzoic acid penetrated through the skin of the Franz static control group compared 
to the CutaFlex
™
 treatment groups (Figure 3.10). The flux of 
14
C-benzoic acid was 
not significantly different between unflexed skin (in Franz and CutaFlex
™
 diffusion 
cells) or flexed skin (p > 0.05) and ranged from an average of 200-240 µg cm
-2
 h
-1
. 
Mass-Balance 
Skin in the Franz cell system showed significantly (p < 0.05) lower amounts of 
14
C-
benzoic acid recovered from the skin surface as compared to static and flexed skin in 
the CutaFlex
™
 system. Quantitatively, the amount of 
14
C-benzoic acid recovered 
from the surface of skin from CutaFlex
™
 cells was approximately 3-4 fold higher 
than that from Franz cells. Moreover, there were no significant differences found in 
the amount of 
14
C-benzoic acid recovered in the skin samples and in the receptor 
fluid of any of the treatment groups (Figure 3.11).  
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Figure 3.8: Transepidermal Water Loss Flux Before And After 
14
C-Benzoic 
Acid Exposure In Static (Franz And CutaFlex™ Static) And Flexed (CutaFlex™ 
360 Minutes Flexed) Diffusion Cells. Benzoic acid was applied (442.5 µl) to the 
skin surface in a saturated, equilibrated un-filtered solution for 51 hours. All bars are 
represented as mean + standard deviation of n= 6 diffusion cells. 
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Figure 3.9: Surface Spreading Of 
14
C-Benzoic Acid Treated Static (Franz And 
CutaFlex™ Static) And Flexed (CutaFlex™ 360 Min Flexed) Porcine Skin 
Sections After 51 Hours Of Exposure: Autoradiographs (A) And Intensity 
Graph (B). Skin was assessed for surface spreading of Carbon-14 using 
representative autoradiography images (A). The average intensity of staining was 
quantified by image analysis to produce a relative intensity score by comparison to 
un-exposed (control) skin. Benzoic acid was applied (250 µl cm
-2
) to the skin surface 
in a saturated, equilibrated un-filtered solution at a concentration of 90 mg ml
-1
. All 
points are mean + standard deviation of n=3 skin sections.    
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Figure 3.10: Cumulative Amount Of 
14
C-Benzoic Acid Penetrated Through 
Static (Franz and CutaFlex™ Static) And Flexed (CutaFlex™ 360 Minutes 
Flexed) Porcine Skin Over 51 Hours. Benzoic acid was applied (250 µl cm
-2
) to the 
skin surface in a saturated, equilibrated un-filtered solution at a concentration of 90 
mg ml
-1
 and a volume of 442.5 µl (5 µCi) for 51 hours. Skin mounted in CutaFlex™ 
cells was un-flexed (static) or flexed with a maximum amplitude of 6 mm, twice a 
minute for a duration of 360 minutes. All points are mean + standard deviation of 
n=6 diffusion cells. Values for the cumulative amount penetrated at study end (QT) 
are represented on the graph in units of mg cm
-2
. Steady-state flux (Jss) values are 
represented on the graph in units of mg cm
-2
 h
-1
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Figure 3.11: Dose Distribution Of 
14
C-Benzoic Acid From Static (Franz and 
CutaFlex™ Static) And Flexed (CutaFlex™ 360 Minutes Flexed) Porcine Skin 
Samples After 51 Hours. Each bar on the graph indicates percentage of the dose 
applied (40 mg) that was recovered from the skin surface (On Skin), in the skin 
samples or in the receptor fluid. All bars are mean + standard deviation of n= 6 
diffusion cells. 
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3.3.4.5 14C-Caffeine Dermal Absorption Study 
Transepidermal Water Loss 
There were no significant differences (p > 0.05) found between baseline and post-
treatment values of transepidermal water loss flux within or between any of the 
treatment groups (Figure 3.12). 
Surface Spreading 
There were no significant differences (p > 0.05) found in the amount of surface 
14
C-
caffeine remaining on the skin of any of the treatment groups (Figure 3.13). 
Cumulative Penetration 
There were no significant differences (p > 0.05) found in the cumulative amount of 
14
C-caffeine penetrated in the Franz static control as compared to the CutaFlex
™
 
treatment groups (Figure 3.14). The steady-state flux of 
14
C-caffeine ranged from 40-
49 µg cm
-2
 h
-1
. 
Mass-Balance 
There were no significant differences (p > 0.05) in the amount of 
14
C-caffeine 
recovered on the skin surface, in the skin samples and in the receptor fluid in any of 
the treatment groups (Figure 3.15).  
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Figure 3.12: Transepidermal Water Loss Flux Before And After 
14
C-Caffeine 
Exposure In Static (Franz And CutaFlex™ Static) And Flexed (CutaFlex™ 360 
Minutes Flexed) Diffusion Cells. Benzoic acid was applied (250 µl cm
-2
) to the skin 
surface in a saturated, equilibrated un-filtered solution at a concentration of 84 mg 
ml
-1
 for 51 hours. All bars are represented as mean + standard deviation of n= 6 
diffusion cells. 
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Figure 3.13: Surface Spreading Of 
14
C-Caffeine Treated Static (Franz And 
CutaFlex™ Static) And Flexed (CutaFlex™ 360 Min Flexed) Porcine Skin 
Sections After 51 Hours Of Exposure: Autoradiographs (A) And Intensity 
Graph (B). Skin was assessed for surface spreading of Carbon-14 using 
autoradiography images (A). The average intensity of staining was quantified by 
image analysis to produce a relative intensity score by comparison to un-exposed 
(control) skin. Caffeine was applied (250 µl cm
-2
) to the skin surface in a saturated, 
equilibrated un-filtered solution at a concentration of 84 mg ml
-1
 for 51 hours. All 
points are mean + standard deviation of n=3 skin sections.    
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Figure 3.14: Cumulative Amount Of 
14
C-Caffeine Penetrated Through Static 
(Franz and CutaFlex™ Static) And Flexed (CutaFlex™ 360 Minutes Flexed) 
Porcine Skin Over 51 Hours. Caffeine acid was applied (250 µl cm
-2
) to the skin 
surface in a saturated, equilibrated un-filtered solution at a concentration of 84 mg 
ml
-1 
for 51 hours. Skin mounted in CutaFlex™ cells was un-flexed (static) or flexed 
with a maximum amplitude of 6 mm, twice a minute for a duration of 360 minutes. 
All points are mean + standard deviation of n=6 diffusion cells. Values for the 
cumulative amount penetrated at study end (QT) are represented on the graph in units 
of µg cm
-2
. Steady-state flux (Jss) values are represented on the graph in units of µg 
cm
-2
 h
-1
.  
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Figure 3.15: Dose Distribution Of 
14
C-Caffeine Acid From Static (Franz and 
CutaFlex™ Static) And Flexed (CutaFlex™ 360 Minutes Flexed) Porcine Skin 
Samples After 51 Hours. Each bar on the graph indicates percentage of the dose (37 
mg) applied that was recovered from the skin surface (On Skin), in the skin samples 
or in the receptor fluid. All bars are mean + standard deviation of n= 6 diffusion 
cells. 
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3.3.4.6 14C-Testosterone Dermal Absorption Study 
Transepidermal Water loss 
There were no significant differences (p > 0.05) found between baseline and post-
treatment values of transepidermal water loss flux within and between any of the 
treatment groups tested (Figure 3.16). 
Surface Spreading 
There were no significant differences (p > 0.05) between treatment groups of the 
amount of 
14
C-testosterone remaining on the skin surface (Figure 3.17). 
Cumulative Amount Penetrated 
There were no significant differences (p > 0.05) in the cumulative amount of 
14
C-
testosterone penetrating the skin in Franz static diffusion cells as compared to the 
CutaFlex
™
 treatment groups (Figure 3.18). The steady-state flux of 
14
C-testosterone 
ranged from 11-16 µg cm
-2
 h
-1
. 
Mass Balance 
There were no significant differences (p > 0.05) between the Franz static control as 
compared to CutaFlex
™
 static and CutaFlex
™
 360 minutes flexed groups in regards 
to the amount of 
14
C-testosterone remaining on the skin surface, in the skin or in the 
receptor fluid (Figure 3.19).  
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Figure 3.16: Transepidermal Water Loss Flux Before And After 
14
C-
Testosterone Acid Exposure In Static (Franz And CutaFlex™ Static) And Flexed 
(CutaFlex™ 360 Minutes Flexed) Diffusion Cells. Testosterone was applied (250 µl 
cm
-2
) to the skin surface in a saturated, equilibrated un-filtered solution at a 
concentration of 20 mg ml
-1
 for 51 hours. All bars are represented as mean + 
standard deviation of n= 6 diffusion cells. 
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Figure 3.17: Surface Spreading Of 
14
C-Testosterone Treated Static (Franz And 
CutaFlex™ Static) And Flexed (CutaFlex™ 360 Min Flexed) Porcine Skin 
Sections After 51 Hours Of Exposure: Autoradiographs (A) And Intensity 
Graph (B). Skin was assessed for surface spreading of Carbon-14 using 
autoradiography images (A). The average intensity of staining was quantified by 
image analysis to produce a relative intensity score by comparison to un-exposed 
(control) skin. Testosterone was applied (250 µl cm
-2
) to the skin surface in a 
saturated, equilibrated un-filtered solution at a concentration of 20 mg ml
-1
 for 51 
hours. All points are mean + standard deviation of n=3 skin sections.    
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Figure 3.18: Cumulative Amount Of 
14
C-Testosterone Penetrated Through 
Static (Franz and CutaFlex™ Static) And Flexed (CutaFlex™ 360 Minutes 
Flexed) Porcine Skin Over 51 Hours. Testosterone was applied (250 µl cm
-2
) to the 
skin surface in a saturated, equilibrated un-filtered solution at a concentration of 20 
mg ml
-1
 for 51 hours. The cumulative amount (µg cm
-2
) of testosterone penetrated 
after 51 hours is represented above the graph. All points are mean + standard 
deviation of n= 6 diffusion cells. Values for the cumulative amount penetrated at 
study end (QT) are represented on the graph in units of µg cm
-2
. Steady-state flux (Jss) 
values are represented on the graph in units of µg cm
-2
 h
-1
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Figure 3.19: Dose Distribution Of 
14
C-Testosterone From Static (Franz and 
CutaFlex™ Static) And Flexed (CutaFlex™ 360 Minutes Flexed) Porcine Skin 
Samples After 51 Hours. Each bar on the graph indicates percentage of the dose 
applied (8.9 mg) that was recovered from the skin surface (On Skin), in the skin 
samples or in the receptor fluid. All bars are mean + standard deviation of up to 6 
diffusion cells. 
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3.3.4.7 Dermal Absorption Parameters For All Carbon-14 Chemicals 
Dermal absorption parameters of cumulative amount penetrated, steady-state flux, 
membrane partition coefficient (Km), permeability coefficient (Kp), diffusion 
coefficient (D) and lag time (τ) values for benzoic acid, caffeine and testosterone 
were calculated according to Equations 1.1- 1.5 (pgs. 18- 20) and are listed in Table 
3.1. No significant differences in parameters were found between any of the 
treatment groups for the same chemical. In terms of the rate of dermal absorption 
(Jss), benzoic acid was the fastest penetrated and testosterone the slowest. However, 
when presented in terms of Kp + D (which take into account the concentration of 
penetrant applied to the skin surface), benzoic acid was most able to diffuse through 
the skin; followed by testosterone and lastly caffeine.  
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Table 3.1: Dermal Absorption Parameters Measured For Benzoic Acid, Caffeine And Testosterone. Cumulative amount penetrated, steady-
state flux, permeability coefficients, diffusion coefficients and lag time were measured for both static skin sections (Franz and CutaFlex™-static) 
and flexed skin (CutaFlex™ 360 minutes flexed).  
  
Cumulative 
Amount 
Penetrated 
mg cm-2
Steady State 
Flux
µg cm-2 h-1
Membrane 
Partition 
Coefficient 
(Km)
Permeability 
Coefficient
(Kp) x 10
-3
cm h-1
Diffusion 
Coefficient
(D) x 10-3
cm-2 h-1
Lag Time
(τ)  
minutes
Benzoic Acid
Franz
CutaFlex Static
CutaFlex Flexed
17.3 ± 5.30
13.7 ± 2.40
13.8 ± 1.70
240 ± 136
200 ± 59
224 ± 56
0.065 ± 0.02
2.69 ± 1.50 
2.17 ± 0.65
2.49 ± 0.63 
2.07 ± 1.16 
1.67 ± 0.50
1.91 ± 0.48
20 ± 10 
16 ± 4
14 ± 3
Caffeine
Franz
CutaFlex Static
CutaFlex Flexed
2.10 ± 0.35
2.30 ± 0.39
2.50 ± 0.28
40 ± 6
47 ± 9
49 ± 7
0.060 ± 0.01
0.38 ± 0.07
0.47 ± 0.09
0.30 ± 0.07
0.23 ± 0.04
0.29 ± 0.06
0.30 ± 0.04
107 ± 19
88 ± 16
84 ± 13
Testosterone
Franz
CutaFlex Static
CutaFlex Flexed
0.85 ± 0.20
0.57 ± 0.26
0.73 ± 0.32
16 ± 4
11 ± 5
15 ± 6
0.069 ± 0.00
0.80 ± 0.19
0.57 ± 0.24
0.73 ± 0.30
0.58 ± 0.14
0.41 ± 0.18
0.53 ± 0.22
46 ± 16
72 ± 30
55 ± 24
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3.4 Discussion 
Novel Flexing Diffusion Cell 
According to Brain et al. (2002), a well-made diffusion cell should encompass  the 
following parameters: be chemically inactive, robust and easy to handle, allow for 
the use of different sized-membranes, provide thorough mixing of receptor fluid 
contents, ensure close contact between membrane and receptor phase, maintain a 
constant temperature, have precisely calibrated volumes and diffusional areas 
(accurately engineered surface area), maintain membrane integrity, provide easy 
sampling and replenishment of receptor fluid, provide a good seal between donor and 
receptor chamber and be available at a reasonable cost.  
CutaFlex
™
 diffusion cell bodies were constructed from polytetrafluoroethylene 
(PTFE) an inert plastic and the expanding bladder from latex. This novel diffusion 
cell is based upon the OECD-compliant Franz-type static diffusion cell and as such 
can accommodate various preparations of skin, several magnetic stir bars and 
provides close contact between skin and receptor phase. In addition, an insert can be 
developed to provide support for skin equivalents. CutaFlex
™
 was also constructed to 
incorporate a jacketed chamber, which was connected through the diffusion manifold 
to a heated re-circulating pump, allowing for a consistent skin temperature.  
Due to the injection moulding process, each CutaFlex
™
 cell is identical and therefore 
will have negligible variations in receptor chamber parameters and diffusional area. 
Although the CutaFlex
™
 cell incorporates the use of an additional diaphragm arm, 
the sampling arm is in the same location as the static Franz cell and provides easy 
access for sampling receptor fluid as well as replacing media. Due to the 
manufacturing process (injection moulding) the CutaFlex
™
 system has been designed 
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to eliminate high costs. It is expected that CutaFlex
™
 will cost less than the average 
glass static Franz cell. 
One potential disadvantage of the current CutaFlex
™
 design is the latex bladder, 
which may potentially absorb or adsorb penetrants and thus artificially reduce 
penetrant concentration in the receptor chamber fluid. Indeed, the cumulative amount 
of penetrant 
3
H2O, benzoic acid and testosterone in CutaFlex
™
 receptor chambers 
was consistently less than Franz cells, suggesting that loss of penetrant through 
bladder adsorption or absorption may have occurred.  
Bladder Adherence Studies 
Therefore, both tritiated water and carbon-14 chemical bladder adherence studies 
were performed to determine if chemicals that penetrated through the skin could 
adhere to the bladder present in the receptor chamber. It was found that the amount 
of adherence of tritiated water to the latex bladder was consistently approximately 
1.16 mg cm
-2
 (0.26 % of the applied dose per cm
-2
) after 540 minutes. Benzoic acid, 
caffeine and testosterone were found to adhere to the latex balloon in consistent 
amounts equating to 0.15 mg cm
-2
 (0.38 % of applied dose per cm
-2
), 0.64 mg cm
-2
 
(1.71 % of applied dose per cm
-2
) and 0.05 mg cm
-2
 (0.57 % of applied dose per cm
-
2
), respectively after 51 hours. These amounts were not found to explain the small 
differences in penetration between the Franz and CutaFlex
™
 cells and so another part 
of the CutaFlex
™
 system may responsible. For example, the PTFE coating of the 
receptor chamber.  
Both tritiated water and TEWL flux rates in this study did not significantly vary from 
baseline after flexion of skin sections for up to 120 minutes. However, tritiated water 
and transepidermal water loss measurements did not show a correlation (r = 0.06). 
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Tritiated water measurements after 120-480 minutes of flexion did not differ from 
the static skin controls. These data demonstrate that under the conditions employed 
in these studies, skin flexing (2 flexes per minute, 6 mm maximum amplitude) had 
no measurable effects on baseline TEWL and tritiated water permeability. 
Dermal Absorption Of Model Compounds 
The OECD 428 guideline states that “thorough characterisation must be performed 
for a novel diffusion cell” (OECD, 2004). This characterisation consists of 
“measuring and comparing the absorption of model chemicals to the OECD-
compliant models” (OECD, 2004).  Model compounds (e.g. benzoic acid, caffeine, 
testosterone, 
3
H2O etc.) have been previously used to investigate (i) skin barrier 
integrity after frozen storage, (ii) comparison of animal and human skin, (iv) 
quantification of metabolic enzymes in animal and human skin, (v) characterisation 
of novel diffusion cells and (vi) investigation of skin properties after chemical or 
physical damage (Franz, 1975, Hawkins and Reifenrath, 1984, Reifenrath et al., 
1984, Harrison et al., 1984, Kao et al., 1985, Bronaugh and Stewart, 1985, Hawkins 
and Reifenrath, 1986, Reifenrath and Kemppainen, 1991) (see Sections 1.3.1.3 and 
1.4.1.5). 
In this study, tritiated water permeation was measured for each treatment group to 
study the effects of flexing skin from 0-480 minutes. It was imperative to analyse the 
effect of flexing on skin barrier integrity as damage to the skin barrier layer would 
impact the percutaneous absorption of both standard chemicals and nanoparticles. In 
vitro flexing of porcine skin from 0-480 minutes did not cause a change in skin 
barrier integrity when the skin was flexed twice per minute with a maximum 
displacement height of 6 mm. Tritiated water was applied to the skin surface in a 
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dose of 250 mg cm
-2
, allowing for full contact of the skin during exposure for all 
durations of flexing. This is in agreement to previous in vitro studies, in which the 
surface dose was in contact with flexing skin, however the skin was flexed outside of 
a diffusion cell system (Tinkle et al., 2003, Rouse et al., 2007). The change in water 
permeability through the stratum corneum has been documented as a good indicator 
of changes in permeability of both non-polar and polar chemicals (Bronaugh et al., 
1986). Therefore, as no significant differences were found in the amount of tritiated 
water penetrating immobile sections as compared to skin sections flexed from 30-480 
minutes, the flexing conditions (2 flexes per minute, 6 mm maximum displacement) 
used in this present study did not cause any measurable skin damage in terms of 
barrier function. 
The three carbon-14 model compounds used in this study, namely benzoic acid, 
caffeine and testosterone differ in physicochemical properties (Table 1.2). These 
model compounds are studied to provide estimations of dermal absorption for 
chemicals with similar properties. Benzoic acid has a log P value of 1.83 and the 
lowest molecular weight of the three compounds studied. Caffeine has a more 
hydrophilic Log P (e.g. -0.01) and a slightly higher molecular weight (e.g. 194) as 
compared to benzoic acid. Testosterone has a lipophilic log P (e.g. 3.32) and the 
highest molecular weight (e.g. 288) compared to benzoic acid and caffeine. A log P 
value between 1 and 3 is thought to be optimal for dermal absorption (Brain and 
Chilcott, 2008). Penetration of benzoic acid through the skin was an order of 
magnitude higher than both caffeine and testosterone. This is not in agreement with 
the literature, in which researchers using both in vivo testing and in vitro full- and 
split-thickness porcine skin observed similarities in the penetration between caffeine 
and benzoic acid (Reifenrath et al., 1984, Hawkins and Reifenrath, 1986). 
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Similarities in the general trend of penetration of benzoic acid and caffeine were also 
seen with in the literature when using human skin (in vitro) (Bronaugh and Stewart, 
1985). The absolute amounts penetrated for both caffeine and benzoic acid in the 
present study were greater than those published in the literature; thought to be 
attributed to the relatively low dose (4 µg cm
-2
), change of vehicle and exposure 
selected in previous studies in comparison to the saturated, equilibrated solution 
chosen for the present study (approximately 23 mg cm
-2
) as well as a change in 
vehicle. 
In contrast to the penetration of benzoic acid and caffeine, testosterone was found to 
penetrate porcine skin approximately 12-fold and 3-fold less, respectively. This 
finding is in agreement with the literature, with testosterone found to be the least 
permeable of all three compounds tested (van de Sandt et al., 2004, Hawkins and 
Reifenrath, 1984, Hawkins and Reifenrath, 1986). This is to be expected due to the 
relatively high lipophilicity of testosterone in addition to a high molecular weight, 
allowing for permeation from vehicle into the stratum corneum but difficulty 
diffusing through the stratum corneum to the viable epidermis underneath. As seen 
with caffeine and benzoic acid in the present study, the absolute amounts penetrated 
from testosterone were higher in this study as compared to the literature, a finding 
thought to be due to the amount applied in this study (i.e. 5 mg cm
-2
) as compared to 
past studies (i.e. 4 µg cm
-2
). The dose recovery of 
14
C-chemical in the skin and in the 
receptor fluid were not different amongst the treatment groups, which also reiterated 
the findings that flexion did not cause damage to the skin. However, the amount of 
14
C-benzoic acid recovered on the skin surface for the Franz treatment group was 
significantly lower than the CutaFlex
™
 groups, a fact that could be attributed to 
experimental design.  
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In order to determine certain parameters of dermal absorption (e.g. Jss, Km, Kp, D, 
and lag time) an infinite dose regime was selected for these studies. Although the 
infinite dose regime is not thought to reflect an in vivo exposure scenario, in order to 
determine the dermal absorption parameters a concentration that does not 
appreciably deplete over time is needed. There were no significant differences found 
between treatment groups in terms of steady-state flux, permeability coefficient (Kp), 
diffusion coefficient (D) or lag time for each chemical. It is difficult to compare the 
present parameters to the literature as skin source, skin preparation, compound 
concentration, vehicle choice and dose regime will impact the findings. However, as 
previous studies have used different conditions and methods of reporting skin 
absorption, the only comparison that can be made is that the general pattern of 
absorption from this study are in broad agreement with the literature. There was no 
significant difference between CutaFlex
™
 and Franz cells. Collectively, these data 
infer that the CutaFlex
™
 system is comparable to existing OECD compliant diffusion 
cells for measuring dermal absorption. Moreover, as there were no statistically 
significant differences in the CutaFlex
™
 cells flexed for 360 minutes, it can be found 
that flexing of skin does not cause a decrease in integrity of the skin barrier layer. 
The membrane partition coefficient for all three chemicals in this study was found to 
be similar between benzoic acid and testosterone and lower for caffeine. No 
comparable measurements of membrane partition coefficients were identified from 
the available literature. However, it is conceivable that the physicochemical 
properties for each chemical (i.e. Log P and molecular weight) attributed to 
differences in membrane partition coefficients, with a more lipophilic molecule 
showing larger partitioning into the skin than a hydrophilic one (e.g. testosterone 
compared to caffeine). Aqueous ethanol (50%) has been used as a receptor fluid for 
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lipophilic chemicals, in order to more realistically model the percutaneous 
penetration of the in vivo scenario (Scott and Ramsey, 1987). Hawkins and 
Reifenrath (1986) documented that the dermis provided a significant barrier to in 
vitro  penetration of compounds with high Log P values, whereas this barrier was not 
as significant in vivo. In this present study, testosterone could have been affected by 
the hydrophilic dermal tissue present, with much lower amounts of this compound 
penetrating as compared to the other two more hydrophilic compounds tested.  
In these studies it was found that the diffusion coefficient for testosterone was greater 
than that of caffeine. Testosterone, in comparison to caffeine, is much more 
lipophilic, a characteristic which seemed to compensate for the larger molecular 
weight of this compound to caffeine. Caffeine is highly hydrophilic and this no doubt 
slowed diffusion through the lipophilic stratum corneum. In the present study, lag 
time was measured for all compounds and found to be greatest for caffeine and 
benzoic acid as compared to testosterone. Lag time is an important dermal absorption 
parameter for a compound of interest, however determining in vitro lag time has 
been acknowledged as being difficult (Schaefer and Redelmeier, 1996) . A small 
change in steady state flux can lead to large changes in the estimation of lag time, 
and lag time is likely to be dependent upon the apparatus and mixing efficiency 
(Schaefer and Redelmeier, 1996). Previous studies found in the literature did not use 
a similar experimental design to the present study (i.e. infinite dose, equilibrated, 
saturated solution, 51 hours), therefore a comparison could not be drawn between 
dermal absorption parameters reported between this study and the existing literature.  
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Skin Damage Studies 
Standard methods to measure the viability of skin before the commencement of in 
vitro studies include both transepidermal water loss (TEWL) and tritiated water 
penetration in static diffusion cells. Both techniques have been recommended by the 
OECD and ECVAM in assessing skin barrier integrity due to the relatively quick 
assessment of the quality of skin (OECD, 2004, Howes et al., 1996). 
TEWL vs Tritiated Water 
Clearly, it would be useful to correlate tritiated water and TEWL methods of barrier 
integrity measurement in order to increase the ease of determining skin barrier 
viability. The results of the present in vitro studies have shown that baseline values 
of tritiated water penetration and transepidermal water loss did not correlate (r = 0.1-
0.4). The correlation between TEWL and tritiated water penetration basal values in 
excised human skin  reported by Chilcott et al. (2002) (r = 0.11) and  Hui et al. 
(2012)  from baseline  (r = 0.34) to 4 hours (r = 0.37) are in agreement with those 
found in this study. This is in contrast to results published by Elmahjoubi et al. 
(2009) which reported a good correlation between TEWL and tritiated water for 
basal rates (r= 0.90). In this study, the in vitro spread of baseline values from TEWL 
data ranged from 7-23 g m
-2
 hr
-1
 in comparison to the applied dose of tritiated water 
penetrated which ranged from 0.1-4.4% of the applied dose. Thus, the range of 
tritiated water values were an order of magnitude greater than that of TEWL rates 
and more variable (e.g. coefficient of variance), which is an indication that tritiated 
water is a more sensitive measure of barrier function.   
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Flexion Studies 
Using in vitro flexion for 360 minutes with model compounds did not show a 
difference in penetration, steady-state flux, permeability coefficient, diffusion 
coefficient or lag time. Collectively, these data provide unequivocal evidence that 
flexing of the skin (2 flexes per minute + 6 mm amplitude) did not cause any 
measurable effects on skin barrier function. A previous in vitro skin flexing device 
has been documented in the literature. However, that system was not present within a 
diffusion cell and was used to investigate potential for nanoparticle penetration 
through the skin (Tinkle et al., 2003, Rouse et al., 2007, Zhang and Monteiro-
Riviere, 2008). Previous studies with this device did not report any measurement of 
skin barrier integrity. 
Physical And Chemical Damage Of The Stratum Corneum  
When observing tritiated water permeation from chemically damaged skin, it was 
noted that both static and flexed skin groups showed significant decreases in barrier 
integrity after SLS treatment. Transepidermal water loss flux results indicated that 
significant increases in flux had occurred in both static treatment groups as well as 
the 60 minute flexed skin group, leading to a variation in results. In this study, a poor 
correlation (r = 0.6) was found between tritiated water and transepidermal water loss 
values after sodium lauryl sulphate damage treatment. This is in agreement with 
findings published in the literature (Elmahjoubi et al., 2009, Chilcott et al., 2002). 
The time after which TEWL measurements can be taken without residual effects 
from occlusion (i.e. evaporation of excess water) has not yet been conclusively 
determined. Multiple papers have recommended a 30 minute wait time (Berardesca 
and Maibach, 1988, Freeman and Maibach, 1988 , Goh and Chia, 1988)  while others 
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have taken a more conservative approach and advised either 1 hour (Agner and 
Serup, 1993) or 3 hours (Baker and Kligman, 1967) waiting time. As TEWL is used 
as an indication of skin barrier integrity, such a long period of time for a pre-study 
measurement would not be ideal. This has also been reflected in an OECD 
recommendation, in that “any pre-study skin evaluation should not take any longer 
than a few hours and would be performed immediately before application of a test 
product” (OECD 2004). In the present study, TEWL measurements were taken one 
hour after occlusion for the model compound. Rates of TEWL were measured 
directly after flexion and 2 hours after SLS treatment and 3 hours after puncture 
damage due to the time at which flexing at ceased in the two damage studies. Whilst 
this complies with OECD guidance, it should be noted that the magnitude of damage 
measured in vitro with TEWL tends to decrease with time (possibly as a result of the 
water gradient within the skin being re-established) (Chilcott and Farrar, 2000). 
In the present study, it was observed that only flexed skin sections (30-120 minutes) 
mounted in the CutaFlex
™
 cells presented with significant decreases in barrier 
integrity through puncturing as measured by tritiated water. When using 
transepidermal water loss rates, all groups except the Franz static cell, presented with 
significant decreases in skin integrity after puncture. In this study, there was no 
correlation (r = 0.4) found between tritiated water permeation and transepidermal 
water loss after physical damage of the skin. These findings agree with what has 
been documented in the literature (Elmahjoubi et al., 2009, Chilcott et al., 2002). The 
finding that static skin did not present with a decrease in skin integrity could be 
credited to swelling (through capillary action) of the skin resulting in the closure of 
the punctures (Elmahjoubi et al., 2009). Another alternative explanation is that the 
punctures present in the immobile skin sections could have been re-sealed due to the 
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elastic properties of the skin (i.e. collagen and elastin). The sealing of the punctures 
within the flexed skin sections could have been delayed by the flexing motion of the 
skin. It is conceivable that the difference between tritiated water and TEWL may be 
partially attributable to small amounts of receptor fluid ejected through the puncture 
holes during flexing, resulting in liquid on the skin surface. This explanation is 
supported by the observation that un-flexed skin did not show an increase in tritiated 
water penetrated, as did half of the static skin groups measured for TEWL rates. 
Collectively, these data indicate that skin subject to flexing does not exacerbate the 
decrease in skin barrier integrity. 
 
In summary, this work demonstrated that: 
 The novel flexing diffusion cell provides comparable measurements of dermal 
absorption to the OECD-compliant Franz-type static cell 
 In vitro skin flexing from 0-480 minutes does not cause a decrease in skin barrier 
function  
 Skin flexing does not generally exacerbate skin damage caused by SLS/punctures 
 Tritiated water permeation is a more sensitive indicator of barrier integrity 
compared to transepidermal water loss 
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 Chapter 4: The Effect Of Flexing On Quantum Dot Nanoparticle 
Skin Absorption 
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4.1. Introduction 
Work presented in the preceding chapter confirmed that the novel flexing skin 
system (CutaFlex
™
) provides percutaneous penetration measurements for model 
compounds that are in agreement with a traditional diffusion cell system and other 
workers (Table 1.3, Table 1.4, Table 1.5 and Table 3.1). The purpose of work 
reported in this chapter was to use the novel diffusion cell model to investigate the 
hypothesis that skin flexing could facilitate the dermal absorption of nanoparticles. 
In order to achieve this aim, the work was divided into two main stages: 
1. Characterisation of 6 quantum dots (QDot 565 and QDot 655; each coated in 
either PEG-amine, PEG-carboxyl or PEG) in terms of shape, size and distribution in 
suspension. 
2. Develop appropriate methodology for histology, confocal laser microscopy and 
skin surface fluorescence analysis for the detection and location of QDots 565 and 
656 (Figure 4.1) in the presence or absence of flexing. This method development 
work is not reported further but is mentioned here to demonstrate ‘due diligence’. 
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Figure 4.1: Quantum Dot Dermal Absorption Study: Method Development. 
Parameters that were optimised included skin preparation, skin processing methods, 
skin sectioning parameters, study method and confocal settings.  
 
 
 
 
 
  
•Fresh Skin vs Paraffin Embedded Skin Skin Preparation 
•IMS vs Ethanol As Dehydration Solvent 
•Room Temperature vs Chilled Block  
•Paraffin Wax Type 
Skin Processing Methods 
•Transverse Section vs Longitudinal Section 
•Cutting Stratum Corneum first or Dermis first 
•2-3 hours in oven vs Overnight in oven 
Skin Sectioning Parameters 
•Fully Blotted Swabs (2 wet; 2 dry) vs 2 Swabs (1 
wet;1 dry) 
Study Method  
•Objective Lens 
•Pinhole Diameter 
Confocal Settings 
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4.2. Materials and Methods 
Nanoparticle characterisation was performed using transmission electron microscopy 
(Section 2.1.7.1) and dynamic light scattering (Section 2.1.7.2). Porcine skin and 
Franz and CutaFlex
™
 diffusion cells were prepared as outlined in (Section 2.1.2 and 
2.1.3), respectively, according to a nanoparticle skin absorption protocol (Section 
2.1.8). Skin samples were subsequently analysed by standard light microscopy 
(Section 2.1.11.2) and confocal laser microscopy (Section 2.1.12). 
Briefly, all quantum dot nanoparticle suspensions were sonicated and characterised 
prior to dermal absorption studies. Rates of TEWL were measured at baseline and 
after exposure to quantum dots. Quantum dot nanoparticles 565 and 655 nm with 
PEG-amine, PEG-carboxyl or PEG attachments as well as the phosphate buffered 
saline solution (control) were applied to the skin surface at a dose of 169 µl cm
-2
 for 
eight hours. Excess quantum dot suspension was removed from the skin surface 
using a wet then dry swab and, along with receptor fluid samples, were analysed 
using a fluorescence spectrophotometer (Section 2.1.9). Skin surface images were 
then taken under ultra-violet illumination (Section 2.1.10). Skin samples were then 
processed and wax embedded for H&E staining and imaging on a laser scanning 
confocal microscope.   
This chapter represents a pilot study and is therefore limited in the scope of 
interpretation due to the relatively small number of skin samples. 
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4.3. Results 
4.3.1. Quantum Dot Nanoparticle Characterisation 
Transmission electron microscopy was performed on all QDot nanoparticles for 
characterisation of both shape and size (Figure 4.2- A). All QDot 565 nm particles 
were spherical in shape, with diameters ranging from 4 to 6nm (Table 4.1). In 
contrast, QDot 655 nm nanoparticles were more triangular in shape (Figure 4.2- B) 
and more consistent along the long (13nm) and short (5 – 6 nm) axis (Table 4.1). 
Dynamic light scattering measurements were performed in order to determine 
hydrodynamic diameters of all quantum dot nanoparticles in phosphate buffered 
saline solution (Table 4.1). When using the number-based distribution (less affected 
by large particulates), the hydrodynamic diameter of QDot 565 ranged from 13 nm 
(PEG-carboxyl) to 23 nm (PEG). The hydrodynamic diameters of QDot 655 were 
similar in range (Table 4.1).   
The polydispersity index of all QDot nanoparticles was found to be approximately 
0.5; midway between a small and broad distribution (Table 4.1). 
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Figure 4.2: Transmission Electron Micrographs Of Quantum Dot 565 nm (Top Row) And 655 nm (Bottom Row) With PEG-Amine 
(First Column), PEG-Carboxyl (Middle Column) And PEG (Third Column) Attachments. All scale bars (bottom left) are representative of 
10 nm. Magnification: 300,000X.  
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Table 4.1: Size Characterisation Of Quantum Dots 565 And 655 With PEG-Amine, PEG-Carboxyl And PEG Attachments Using 
Transmission Electron Microscopy And Dynamic Light Scattering. Transmission electron microscopy was used to determine size (d.nm; 
diameter in nanometers) and QD 655 was expressed as long axis x short axis. Dynamic light scattering individual peak sizes are stated in terms 
of number-based methods (diameter in nanometers). The polydispersity index is expressed on a 0-1 scale, with 0 representing a fully 
monodispersed suspension and 1 representing a polydispersed suspension. 
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4.3.2. Transepidermal Water Loss Rates 
There were no overt changes in the rates of transepidermal water loss (TEWL) 
following exposure to nanoparticles (Figure 4.3).  All TEWL rates were within 
normal values identified in Chapter 3 (Section 3.3.3) and therefore, the skin barrier 
integrity was not changed by flexing or nanoparticle exposure. 
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Figure 4.3: In Vitro Transepidermal Water Loss Rates Measured From Excised 
Pig Skin Treated With QDot 565 (A and B), 655(C and D) And PBS (Control-
E).  Measurements were taken before (baseline) or after exposure (post-treatment) to 
solutions containing quantum dots 565 (upper) and 655 (middle) or from untreated 
(controls; bottom) in the presence (“Flexed”) or absence (“Static”) of skin flexing.   
All data are represented as mean + standard deviation of n=3.  
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4.3.3. Skin Surface Recovery of QDots 
The recovery of unabsorbed QDots (from skin surface swabs) was quantified by 
fluorescence spectroscopy by reference to a range of calibration standards (Section 
2.1.9). With the exception of amine coated particles, there was an apparently large 
recovery of QDot 655 from the skin surface as compared to QDot 565 (Figure 4.4). 
There was no apparent difference in skin surface recovery between flexed and un-
flexed skin (for each QDot). The greatest recovery of fluorescence was observed 
with PEG-coated particles
7
. 
 
 
 
 
 
 
 
 
 
 
 
                                                 
7
 Due to the limited number of replicates performed (n = 3), statistical testing was not performed. 
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Figure 4.4: Skin Surface Fluorescence Recovery From Quantum Dot 565 (A), 
Quantum Dot 655 (C) And Control (B and D) Treated Groups. Flexed and static 
samples are represented in the same graph. Quantum dot 565 and 655 nm were tested 
with three attachments: PEG-Amine, PEG-Carboxyl and PEG. The control tested 
was phosphate buffered saline solution. Quantum dot suspension was applied (300 
µl; 300 pmols) to the skin surface for 8 hours. Skin was flexed in CutaFlex™ cells for 
6 hours (2 flexes per minute; 6 mm maximum displacement).  The same skin donor 
was used per study (i.e. for QDot and Control groups). All groups (n= 3) are 
represented as mean ± standard deviation. 
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4.3.4. Skin Surface Distribution of QDots 
Fluorescence staining of the skin was observed (to varying extents) with all QDot 
particles (Figure 4.5 and Figure 4.6). 
4.3.4.1. Quantum Dot 565 vs 655 nm  
All QDot 655 treated skin demonstrated apparently higher fluorescence staining 
compared to QDot 565 treated skin (Figure 4.5 and Figure 4.6). Thus, QDot 655 
nanoparticles seemed to partition into the stratum corneum in greater amounts than 
QDot 565. However, QD 565 presented with higher fluorescence staining of the hair 
follicles, as compared to QD 655 treated sections, this effect was most apparent in 
PEG-Amine and PEG-carboxyl groups. Therefore, charged QD 565 nanoparticles 
seemed to preferentially partition into hair follicles, in greater amounts than QD 655 
treated skin sections.  
4.3.4.2. Flexed vs Static Skin Sections 
Greater fluorescence was seen in flexed skin treated with carboxylic coated 
nanoparticles (both QDot 565 and 655) as compared to the static carboxylic treated 
groups (Figure 4.5 and Figure 4.6). Static skin treated with QDot 565 PEG-Amine 
and PEG-Carboxyl attachments showed greater staining of the hair follicles than the 
corresponding flexed skin.  
4.3.4.3. PEG-Amine, PEG-Carboxyl And PEG Attachments  
The negatively charged QDot attachment (PEG-Carboxyl) showed the greatest 
fluorescence in staining of the skin surface (both QDot 565 and 655) (Figure 4.5 and 
Figure 4.6).  
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Figure 4.5: Skin Surface Distribution Of Quantum Dot 565 And 655 With PEG-Amine, PEG-Carboxyl And PEG Attachments And 
Control Skin Sections. Representative sections were selected for each treatment group. Phosphate buffered saline and QDot nanoparticles were 
applied (169 µl cm
-2
) to flexed or static porcine skin for 8 hours. Fluorescence was then visualised using ultra-violet illumination. Each group 
consisted of n= 3 diffusion cells.  
CutaFlex Flexed CutaFlex Static
565 PEG-Amine 
Control-PBS
655 PEG-Amine 
565 PEG-Carboxyl 
655 PEG-Carboxyl 
Control-PBS
565- PEG 
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Figure 4.6: Quantum Dot 565 (A) And 655 (B) Skin Surface Relative 
Fluorescence Using Ultra-Violet Illumination. Fluoresence of quantum dot treated 
skin is represented in terms of percentage of untreated (phosphate buffered saline) 
control. Phosphate buffered saline and Quantum dot 565 and 655 nm with PEG-
Amine, PEG-Carboxyl or PEG attachments were applied (169 µl cm
-2
) to the skin 
surface for eight hours. Porcine skin was either flexed (6 hours) or remained static 
for the duration of the study. All groups (n=3) are represented as mean + standard 
deviation.  
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4.3.5. Haematoxylin And Eosin Stained Quantum Dot Skin Sections 
Haematoxylin and Eosin were used to stain both quantum dot treated skin sections as 
well as control skin sections in order to visualise skin structure (Figure 4.7, Figure 
4.8 and Figure 4.9). Skin sections were visualised with an intact stratum corneum.  
Hair follicles were observed in the sections taken for each group. This finding 
corresponds to the pattern of QDot fluorescence staining (i.e. hair follicles) found 
with UV-illuminated images of the skin surface. 
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Figure 4.7: Phosphate Buffered Saline Control Skin Sections From Quantum 
Dot Treated Porcine Skin Studies Stained With Haematoxylin And Eosin. 
Representative sections for each group were selected. Porcine Skin Sections Stained 
With Haematoxylin And Eosin. All skin sections were cut to 5 µm and visualised 
under a 10 x (0.24 NA) microscope. Groups consisted of n=3 diffusion cells. 
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Figure 4.8: Quantum Dot 565 PEG-Amine, PEG-Carboxyl And PEG Treated 
Flexed And Static Porcine Skin Stained With Haematoxylin And Eosin. 
Representative sections for each group were selected. All skin sections were cut to 5 
µm and visualised under a 10 x (0.24 NA) microscope. Groups consisted of n=3 
diffusion cells. 
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Figure 4.9: Quantum Dot 655 PEG-Amine, PEG-Carboxyl And PEG Treated 
Flexed And Static Porcine Skin Stained With Haematoxylin And Eosin. 
Representative sections from each group were selected. All skin sections were cut to 
5 µm and visualised under a 10 x (0.24 NA) microscope. Groups consisted of n=3 
diffusion cells. 
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4.3.6. Laser Scanning Confocal Micrographs Of Quantum Dot And PBS 
Treated Skin Samples 
Limited auto-fluorescence of the skin was seen with phosphate buffered saline skin 
sections (Figure 4.10). Skin structure detail of both PBS and QDot treated sections 
was visualised with accompanying transmitted light photos of each corresponding 
skin section (Figure 4.13, Figure 4.14 and Figure 4.15). 
All quantum dot nanoparticles were observed in the outermost stratum corneum of 
both flexed and static skin sections and not deeper (i.e. QDots were not found in the 
viable epidermis or dermis) (Figure 4.11 and Figure 4.12). Quantum dot 655 nm 
treated skin sections (all attachments) presented with an apparent increase in 
fluorescence compared to the corresponding QDot 565 nm nanoparticles (Figure 4.11 
and Figure 4.12). There were no visible differences in fluorescence between flexed 
and static skin sections with either QD 565 nm or QD 655 nm treated sections 
(Figure 4.11 and Figure 4.12).  The PEG-Carboxyl attachment was seen in the outer 
layers of the stratum corneum moreso than the other two attachments with both QDot 
565 and 655 nm nanoparticles (Figure 4.11 and Figure 4.12). The QD 655 PEG 
attachment was seen to stain the outline of corneocytes in the stratum corneum 
(Figure 4.12). In general, QDots were found to pool in furrows (Figure 4.11- A and 
Figure 4.12- A, B and C).  
It should be noted that using the confocal microscope laser filter settings were 
limited and resulted in QDot 565 nm fluorescence demonstrating a red-orange 
colour, compared to UV-light illumination of the dots where QDot 565 fluorescence 
was visualised as green.  
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Figure 4.10: Phosphate Buffered Saline (Control) Treated Porcine Skin Sections 
Visualised Using Confocal Microscopy. Representative sections were selected for 
each group. All skin sections were cut to 5 µm and visualised using a laser scanning 
confocal microscope with a laser line of 488 nm and an emission wavelength filter of 
500-643 nm. Phosphate buffered saline was applied to the skin at 169 µl cm
-2
 for 8 
hours. Groups consisted of n=3 diffusion cells. Scale bars indicate 100 µm. 
 
 
Control- PBS
  Chapter 4 
174 
 
 
Figure 4.11: Quantum Dot 565 PEG-Amine (A), PEG-Carboxyl (B) And PEG 
(C) Treated Flexed And Static Porcine Skin Sections Visualised Using Confocal 
Microscopy. Representative sections for each group were selected. All skin sections 
were cut to 5 µm and visualised using a laser scanning confocal microscope with a 
laser line of 488 nm and an emission wavelength filter of 500-643 nm. Quantum dots 
were applied to the skin at 169 µl cm
-2
 for 8 hours. All groups consisted of n=3 
diffusion cells. Scale bars indicate 100 µm. 
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Figure 4.12: Quantum Dot 655 PEG-Amine (A), PEG-Carboxyl (B) And PEG 
(C) Treated Flexed And Static Porcine Skin Sections Visualised Using Confocal 
Microscopy. Representative sections for each group were selected. All skin sections 
were cut to 5 µm and visualised using a laser scanning confocal microscope with a 
laser line of 488 nm and an emission wavelength filter of 500-643 nm. Quantum dots 
were applied to the skin at 169 µl cm
-2
 for 8 hours. All groups consisted of n=3 
diffusion cells. Scale bars indicate 100 µm. Arrows indicate accumulation in furrows. 
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.  
Figure 4.13: Phosphate Buffered Saline (Control) Treated Porcine Skin– 
Transmitted Light Images. Representative sections were chosen for each group. All 
skin sections were cut to 5 µm and visualised for structural details using a laser 
scanning confocal microscope under the transmitted light channel. Phosphate 
buffered saline was applied to the skin at 169 µl cm
-2
 for 8 hours. All groups 
consisted of n=3 diffusion cells. Scale bars indicate 100 µm. 
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Figure 4.14: Quantum Dot 565 PEG-Amine (A), PEG-Carboxyl (B) And PEG 
(C) Treated Flexed And Static Porcine Skin Sections- Transmitted Light 
Images. Representative sections for each group were selected. All skin sections were 
cut to 5 µm and visualised for structural details using a laser scanning confocal 
microscope under the transmitted light channel. Quantum dots were applied to the 
skin at 169 µl cm
-2
 for 8 hours. All groups consisted of n=3 diffusion cells. Scale 
bars indicate 100 µm. 
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Figure 4.15: Quantum Dot 655 PEG-Amine (A), PEG-Carboxyl (B) And PEG 
(C) Treated Flexed And Static Porcine Skin Sections- Transmitted Light 
Images. Representative sections for each group were selected. All skin sections were 
cut to 5 µm and visualised for structural details using a laser scanning confocal 
microscope under the transmitted light channel. Quantum dots were applied to the 
skin at 169 µl cm
-2
 for 8 hours. All groups consisted of n=3 diffusion cells. Scale 
bars indicate 100 µm. 
 
 
 
 
655 PEG-Amine
655 PEG-Carboxyl
655 PEG
CutaFlex Flexed CutaFlex Static
A
B
C
  Chapter 4 
179 
 
4.3.7. Receptor Fluid Fluorescence Recovery Of Quantum Dots 
There was no evidence for percutaneous penetration of QDots, as fluorescence 
measured in samples of receptor chamber fluid collected from QDot exposed skin 
was identical to that of unexposed (control) receptor fluid (Figure 4.16).  
It was observed that the different skin donors used in each QDot study had 
differences in skin auto-fluorescence, with PEG treated skin presenting with the 
highest auto-fluorescence (Figure 4.16).  
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Figure 4.16: Receptor Fluid Fluorescence Recovery From Quantum Dot 565 
(A), Quantum Dot 655 (C) And Control (B and D) Treated Skin. Flexed and 
static samples are represented in the same graph. Quantum dot 565 and 655 nm were 
tested with three attachments: PEG-Amine, PEG-Carboxyl and PEG. The untreated 
control was phosphate buffered saline solution. Quantum dot suspension was applied 
(300 µl; 300 pmols) to the skin surface for 8 hours. Skin was flexed in CutaFlex™ 
cells for 6 hours (2 flexes per minute; 6 mm maximum displacement).  The same 
skin donor was used per study (i.e. for QDot and Control groups). All groups (n= 3) 
are represented as mean ± standard deviation. 
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4.4. Discussion 
Preliminary findings presented in this Chapter have found that quantum dot 
nanoparticles applied to flexed or static skin were found in the stratum corneum and 
no deeper. Quantum dot 565 and 655 nm were characterised and found to be 
spherical and pyramidal, respectively in shape and within the size limits defined for 
nanoparticles. Skin surface recovery of QDots demonstrated follicular staining and 
accumulation in furrows, with the negatively charged particles showing a greater 
partitioning into the stratum corneum. Quantum dot 655 was shown to have a higher 
affinity for the stratum corneum than QDot 565. Most importantly, there were no 
overt differences in QDot partitioning or distribution in the stratum corneum in static 
skin compared to flexed skin. 
Nanoparticle Characterisation 
Transmission electron microscopy is a technique favoured for imaging of quantum 
dot nanoparticles, due to electron properties exhibited by these dots in providing a 
higher than average contrast and therefore an accompanying increase in detection 
(Nisman et al., 2004). Transmission electron microscopy can provide both direct 
measurements of size, shape and partial aggregation state with both qualitative and 
semi-quantitative techniques, with a spatial resolution of 0.5-3 nm (Soto et al., 2005, 
Sun et al., 2006, Andrievsky et al., 1999). In the present study, nanoparticle size was 
measured using both TEM and DLS. Due to the processing methods for TEM 
(drying on copper grids), this method is not thought to provide a fully accurate 
representation of the size distribution of particles in suspension (Murdock et al., 
2008). It was seen from transmission electron micrographs that quantum dot 655 nm 
were triangular in shape, in contrast to the spherical quantum dot 565 particles. The 
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difference in hydrodynamic radius between spherical and oblong particles introduces 
a variation in mobility and diffusion in both gas and liquid phases (Zuin et al., 2007). 
Additionally, as the diffusion of a spherical particle through a liquid phase is a key 
parameter used by DLS to calculate the size (in diameter) of a particle, a difference 
in sphericity of a particle can create a less accurate measurement. Therefore, both 
data (i.e. TEM and DLS) need to be interpreted with caution. The hydrophilic 
coatings of each QDot increased the hydrodynamic diameter by several-fold, due to 
solvation effects in aqueous solution, a result previously documented in the literature 
(Ryman-Rasmussen et al., 2006) and demonstrated that the QDots remained 
nanoscale particles. Nanoparticles which have been suspended in different 
physiological salt concentrations with differences in vehicle pH values have known 
to increase to micrometre size due to formation of aggregates with salt molecules 
(Murdock et al., 2008). The quantum dot nanoparticle shapes and sizes as defined by 
TEM (and DLS), respectively were very similar in this study as to the values 
published in the literature (Ryman-Rasmussen et al., 2006).  
Alternative characterisation techniques for nanoparticulate size include 
ultracentrifugation sedimentation, atomic force microscopy and nanoparticle tracking 
analysis. Hoo et al. (2008) found that when comparing characterisation techniques 
for nanoparticulate suspensions, AFM provided a better tool for distinguishing 
bimodal distributions whereas DLS could not differentiate between two particles 
closer than 1:8 of size. Atomic force microscopy also allowed for identification of 
large bimodal size distributions regardless of particle shape, unlike DLS (Hoo et al., 
2008). Dynamic light scattering is known to be both fast and accurate measurement 
for spherical particle monosized particles in suspension, however relying on the 
intensity-based sized distribution from DLS may be misleading when analysing 
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polydisperse mixtures (Hoo et al., 2008). These researchers recommended using 
number-based distributions in addition to further light scattering techniques or hybrid 
techniques for particle mixtures with broad particle size distributions.  
In this study, all quantum dot suspensions were subject to low frequency sonication 
(12,700 J) for five minutes before application to the skin surface to ensure optimal 
dispersion. It has been documented that applying the correct sonication energy and 
time is important in the optimal dispersion of a nanoparticle suspension (Mandzy et 
al., 2005). Bihari et al. (2008) characterised a number of different nanoparticles (e.g. 
titanium dioxide, polystyrene latex beads, carbon nanotubes and silver) in terms of 
size using different sonication parameters and surfactants and recommended 
sonication before adding surfactants and lastly, suspension in a physiological 
medium. In the present study, sonication was used before application of the QDots to 
the skin surface, in order to ensure each suspension was optimally dispersed (i.e. to 
ensure aggregation of particles was at a minimum). 
Skin Integrity 
A lengthy discussion on the use of an evaporimeter to measure skin barrier integrity 
has been covered in Chapter 3 (Section 3.4). A skin integrity measurement should be 
performed before a dermal absorption study, especially in the case of using 
previously frozen skin, due to the potential for damage to occur to the barrier layer 
whilst in storage. In the present study, transepidermal water loss measurements 
provided an indication (alongside histological and confocal analysis of skin 
structure) of skin barrier integrity. This was deemed even more important for this 
study, where some of the skin samples were subject to flexing. Both QDot 565 and 
655 nm with carboxyl attachments presented with higher TEWL than other quantum 
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dot groups, however it was also observed that the control data in this study presented 
with higher TEWL rates than the corresponding control data in the other studies. The 
difference in TEWL rates between studies can be attributed to different skin donors, 
with inter-individual differences noted between skin samples. Importantly, all TEWL 
values in this study fell below the threshold determined in Chapter 3, and therefore 
QDot exposed skin was not damaged. 
Previous studies investigating quantum dot nanoparticle dermal absorption have not 
taken skin integrity measurements before or after treatment (Rouse et al., 2007, 
Ryman-Rasmussen et al., 2006, Zhang and Monteiro-Riviere, 2008, Gratieri et al., 
2010). These previous studies have used an in vitro flexing device or skin massage, 
in which case, there was potential for skin barrier damage due to the lack of 
temperature and fluid control outside of a diffusion cell system, the high rate of 
flexing (20 flexes per minute) and the additional physical handling/manipulation of 
the skin. It is therefore hard to interpret the results of these studies as skin viability 
cannot be confirmed before nanoparticle application. The in vitro flexing device, 
CutaFlex
™
, tested in this Thesis incorporated in vitro flexion within a diffusion cell 
system, ensuring a constant skin temperature of 32ºC, adequate receptor fluid 
hydration and controlled parameters (2 flexes per minute; 6 mm maximum 
displacement) of flexing. The present study also incorporated the use of barrier 
integrity measurements which ensured integrity of skin before nanoparticle 
application as well as confirmation of structural viability after skin flexion. 
Confocal micrographs of each skin section confirmed that quantum dot nanoparticles 
were not present in any area except for the outermost stratum corneum. The amount 
of fluorescence in the receptor fluid of each diffusion cell was also quantified, in 
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order to equate this value with an estimation of the amount of originally applied 
quantum dot suspension. The values of fluorescence in the receptor fluid chambers of 
skin sections treated with QDots were identical to data from untreated (control) skin. 
It is conceivable that inherent auto-fluorescence of the skin samples in each study 
contributed to the fluorescence seen in the receptor fluid, the extent of which was 
dependent on the donor.  
Experimental Considerations 
As previously discussed in Chapter 1 (Section 1.3.1.3), the choice of species of skin 
is important as animal skin is generally more permeable than human skin (Vecchia 
and Bunge, 2006, Walker et al., 1986). A large proportion of the in vitro quantum 
dot dermal absorption studies (as outlined in Table 1.7) have chosen to study 
possible penetration through rat, mouse or porcine skin. It has been demonstrated 
that porcine skin is closer in structure and permeability to human skin, as compared 
to rodent skin (Wester and Maibach, 1984). In this study, porcine dorsum skin was 
selected due to this skin system being both morphologically and functionally closest 
to human skin as compared to rodent models (Meyer et al., 1978). 
In exposing the skin to quantum dot nanoparticles, previous studies have applied 
QDot nanoparticles to the skin in very small amounts (i.e. 80-320 nmol) (Rouse et 
al., 2007, Ryman-Rasmussen et al., 2006, Zhang and Monteiro-Riviere, 2008). In 
addition, the dose applied should be in contact with the skin while flexing conditions 
are ongoing to simulate physiological movement and contact, which is in agreement 
with previously conducted studies (Rouse et al., 2007, Zhang and Monteiro-Riviere, 
2008, Gratieri et al., 2010). In this Chapter, quantum dot suspensions were in contact 
with the skin for the duration of the study, including when the skin was flexed. When 
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studying in vitro flexing, it would be optimal for the quantum dot suspension to 
create a consistent layer on top of the skin surface, which was observed in this study 
by utilising a dose of 169 µl cm
-2
. This layer would then compensate for the transient 
increase in surface area, allowing for contact of the suspension even when the skin 
was at maximum displacement height. In this respect (i.e. incorporation of flexion 
into a diffusion cell and consistency of applied layer) during skin exposure, the 
CutaFlex
™
 system is unique. 
The pH and lipophilicity of the quantum dot nanoparticle suspension may also affect 
skin penetration. The stratum corneum has a pH ranging from pH 4 - 6 and is very 
lipophilic compared to the underlying epidermis which is hydrophilic. As the 
quantum dot nanoparticle suspensions were prepared for optimum solubility in a 
water-based vehicle, this would likely discourage partitioning into the stratum 
corneum. Ryman Rasmussen et al. (2006) and Prow et al. (2012) demonstrated that 
quantum dot nanoparticles are able to penetrate intact skin when using suspensions 
with pH ranging from 8.3-9.0. The use of such a basic pH could have impacted the 
stratum corneum viability, therefore leading to an increase in penetration. For 
example, a previous study has demonstrated that increasing the pH of a solution will 
result in enhanced absorption (Blank and Gould, 1959). The influence of pH on the 
flux of compounds across the stratum corneum is a complicated issue and relies on 
the permeability coefficient of the compound, thermodynamic activity of the 
compound in the solvent and the vehicle stratum corneum partition coefficient 
(Schaefer and Redelmeier, 1996). As nanoparticles are not thought to follow 
traditional diffusion through the stratum corneum, the effect of pH on the stratum 
corneum would likely have resulted in damage (i.e. lipid lamellae disorganisation) in 
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order for these relatively large particles to pass through into the viable epidermis and 
dermis. 
Quantum Dot Surface Staining 
In the present studies, skin surface images of quantum dot fluorescence revealed an 
greater fluorescence of skin staining with QDot 655 nm (vs QDot 565nm), especially 
when using the carboxylic attachment. It has been previously documented that in 
vitro flexion of skin samples resulted in an increase in quantum dot fluorescence on 
the skin surface (Zhang and Monteiro-Riviere, 2008). Massaging of the skin also 
resulted in altered surface patterns as well as accumulation in furrows and follicles 
(Gratieri et al., 2010, Wu et al., 2009b). This finding is consistent with results found 
in the present study, in which skin treated with both charged and neutral QDot 655 
particles showed an increase in staining as compared to QDot 565 particles. In 
addition, skin treated with QD 565 charged particles presented with an increase in 
follicular staining. 
Zhang et al.(2008) postulated that the polar groups on quantum dots may bind to 
hydrated keratin, thereby slowing movement through the stratum corneum. These 
researchers also found minimal penetration from the QDots with carboxyl 
attachments, although they were the smallest out of all 6 particles. In this chapter, 
both UV-Light images of QDot treated skin surfaces and fluorescence 
spectrophotometer analysis of skin surface swabs in this study postulated that QDot 
655 PEG-Carboxyl may have shown a greater affinity for the stratum corneum than 
the other 5 dots under study. A greater partitioning was thought to have occurred 
with QDot 655 particles. As previously discussed, the stratum corneum contains both 
positively and negatively charged groups, however this layer carries a net negative 
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charge (Brain and Chilcott, 2008). An electronegative charged horizontal field 
between the stratum granulosum and stratum corneum is thought to repel anions and 
prevent cations from penetration further into the skin (Montagna, 1962). There is a 
considerable pH gradient across the stratum corneum. The stratum corneum has been 
documented to be more permeable to neutral molecules than the salts of weak acids 
or bases (Swarbrick et al., 1984, Flynn, 1985). In this study, there was a decrease in 
neutral (PEG) QDot molecules remaining on the skin surface as compared to the 
charged (PEG-Amine and Carboxyl) QDot particles. In terms of charged molecules, 
the skin is permselective to cations, based upon ionotophoretic evidence in which 
more current was carried by cations than anions (Burnette and Ongpipattanakul, 
1987). Therefore, it was not expected to see an increase of negatively charged 
quantum on the surface of the skin. Further research into the mechanism of 
attachment to the stratum corneum will have to be conducted, but could possibly 
have been due to hydrogen bonding of protein via the ionised carboxyl group. 
Previous research has shown quantum dot nanoparticles in skin furrows and in the 
hair follicle infundibulum and that skin surface swabs did manage to remove QDots 
in the former but not the latter (Wu et al., 2009b). Pilot studies prior to those 
described in this Chapter (data not reported here) found that six skin surface swabs 
removed the majority of quantum dot suspension from the skin surface, presumably 
from the skin furrows. In the present study, skin surface swabs were seen to remove 
the majority of neutral QDots (especially in the case of QDot 565), and to a lesser 
extent the positively charged quantum dots, whilst the negative QDots partitioned 
into the stratum corneum and thus were not able to be removed to the same extent as 
the previous QDots. 
  Chapter 4 
189 
 
Skin Flexing 
Previous studies have shown that flexing of skin in vitro has advanced fullerene-
substituted amino acids as well as beryllium and zirconium particles further into the 
skin, reaching the dermal layers (Tinkle et al., 2003, Rouse et al., 2007). The results 
of this study have shown that in vitro flexion does not influence penetration of 
quantum dot nanoparticles in the absence of skin damage, as confocal micrographs of 
both static and flexed skin sections showed these particles contained in the outermost 
stratum corneum and no further.  
Previous studies have shown that flexion does not result in an increase of skin 
penetration of model penetrants (see Chapter 3). The quantum dot dermal absorption 
studies were performed under similar conditions as the standard penetrant studies; 
namely, 169 µl cm
-2
 applied dose and 8 hour occluded exposure period. Studies from 
Chapter 3, representing the percutaneous penetration of compounds with a range of 
physicochemical properties, also found that in vitro skin flexion did not cause a 
difference in penetration compared to static (unflexed) skin. It was thought that 
flexion of the skin could cause transient increases of space in the lipid lamellar 
bilayers, as well as providing additional kinetic energy for particles to move through 
the lamellar bilayers. However, such transient increases, if present, may also have 
been expected to affect the permeation and penetration of model compounds in 
Chapter 3, leading to an increase in penetration from flexing. As this effect was not 
documented, the ‘transient space theory’ may be discounted. A more credible theory 
of flexion assisted translocation could lie within the additional kinetic energy 
imparted to the skin by flexing, which may also impart kinetic energy to particles in 
the skin, theoretically allowing for deeper skin penetration. In general, quantum dots 
are known to be too large for diffusion (in comparison to model compounds diffusion 
  Chapter 4 
190 
 
at the molecular level) and too large to fit through individual lipid lamella (capable 
by individual molecules). In addition, the steric hindrance between adjacent 
corneocytes would be immense, a situation which can be equated to dropping an 
elephant between double decker buses which have an elephant-sized (75 nm) gap 
filled with tennis balls (lipid lamellae). It is theoretically possible in the above theory 
for the elephant to pass through the tennis balls. However it would require 
considerable external assistance.  
The intercellular pathway has been previously mentioned in the literature as one of 
the predominant pathways for penetration of quantum dot nanoparticles via skin 
flexion. This is due to the lateral and horizontal gaps between corneocytes occupied 
by lipid lamellae, which are thought to be large enough  (i.e. 75 nm) for possible 
penetration of small particles (Elias and Friend, 1975, Rouse et al., 2007). The 
second most common pathway mentioned in the penetration of nanoparticles is the 
follicular pathway. It was observed from our previous confocal micrographs (data 
not shown) that contained hair follicles that quantum dot nanoparticles were present 
in the follicular infundibulum, a result consistent with the literature (Gratieri et al., 
2010). The follicular pathway also has an increased surface area available for 
absorption. However, the follicular route is likely limited by the presence of sebum 
(and metabolising enzymes). It is thought the follicular route would not create as 
much of a shunt to the viable epidermis and dermis as previously suspected, except 
in the cases of small metal ions (Scheuplein, 1976). If such a shunt existed, this 
would have been visualised with fluorescence from QDots present in the lower 
epidermis and dermis of even intact skin, a result not documented in the literature.  
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The limited superficial ingress of the quantum dot nanoparticles could be attributed 
to the mechanics of the stratum conjunctum. In contrast, the stratum disjunctum lacks 
the hemi-desmosomes which bind adjacent corneocytes, thus facilitating 
desquamation. Moreover, the packing of corneocytes in the most superficial layer is 
known to be lipid-mediated and therefore has a greater susceptibility to mechanical 
and chemical induced disruption (Fartasch, 1996). The stratum conjunctum however, 
is known to be the most tightly packed layer of the stratum corneum, leading to a 
bottle neck effect in transport of material across the skin (Schatzlein and Cevc, 
1998). Additionally, although the stratum corneum is acknowledged as the skin 
barrier layer, removal of this layer does not eradicate all barrier properties of the 
skin. Tape stripping of the stratum corneum has been documented to increase water 
and solute permeability by 10-20 fold, an increase that represented the maximum 
decrease in barrier function seen in some pathological conditions (Schaefer and 
Redelmeier, 1996). Conversely, the water permeability was found to be 100 fold less 
than that observed for a stratified layer of keratinocytes (Schaefer and Redelmeier, 
1996). Therefore, maintenance of a barrier could be due to a number of factors such 
as partial removal of the stratum corneum, homeostatic responses to barrier damage, 
secretion and coagulation of interstitial fluid and lastly, lipid excretion (from lamellar 
bodies) located in the stratum spinosum and granulosum (Schaefer and Redelmeier, 
1996). Chemicals (or nanoparticles) that have penetrated into both intact and 
damaged stratum corneum may have also been limited in penetration due to the tight 
junctions that exist in the stratum granulosum (Bradner, 2009).  
In the present study, the robust structure and properties of the stratum corneum (i.e. 
solubility, steric hindrance, pH) have been shown to impede the penetration of 
quantum dot nanoparticles when using intact skin. This supports the conclusion of 
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previous studies using structurally viable skin. Moreover, this limited study has 
shown that skin flexion does not appear to facilitate translocation of QDots through 
the stratum corneum. However, it should be emphasised that further work is required 
to confirm these initial findings based on a limited number of skin samples.  
In summary, this work has demonstrated that: 
 Quantum dot nanoparticles of different shapes, charges and sizes did not appear 
to penetrate through intact porcine skin. 
 Flexed skin does not show differences in nanoparticle penetration to static skin 
 Quantum dot charge influenced the partitioning of dots present into the 
superficial skin surface. 
 Clearly further work is required to substantiate these initial studies. 
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 Chapter 5: An In Vitro-In Vivo Evaluation Of CutaFlex™ For 
Assessing Topical Skin Protection Against Methyl Nicotinate 
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5.1 Introduction 
The purpose of the work reported in this chapter was to investigate the effect of 
flexing on the in vitro performance of a topical skin protectant (RD-1433) during 
exposure to methyl nicotinate (MN) and to compare the resulting data with an 
evaluation of the same product under identical conditions when performed in vivo 
using human volunteers. 
It should be noted that the human volunteer study was conducted as part of a larger 
trial to investigate the relative efficacy of RD-1433 and white petroleum jelly B.P. 
(Vaseline
®
) for preventing or treating incontinence associated dermatitis (IAD): the 
studies presented here relate to preliminary work designed to identify (i) the 
optimum thickness of RD-1433 required to impart significant skin protection and (ii) 
the duration over which an optimum thickness of RD-1433 remains effective. 
Determination of optimum thickness and duration of efficacy were performed in 
vitro (CutaFlex
™
 diffusion cells) with dermatomed pig skin and in vivo using human 
volar forearm skin. The performance of the test products was assessed either by 
direct measurement of 
14
C-MN skin absorption (in vitro) or by measuring the 
rubefacient (erythematous) response to unlabelled MN (in vivo).  
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5.2 Materials and Methods 
Skin and diffusion cells were prepared as previously outlined in Sections 2.1.2 and 
2.1.3, respectively. A 5 mM solution of 
14
C-methyl nicotinate (
14
C-MN) was 
prepared as described in 2.1.1. Evaporation studies of 
14
C-methyl nicotinate and 
tritiated water were performed as outlined in Section 2.1.13.1. Tritiated water and 
transepidermal water loss barrier integrity measurements were performed as outlined 
in Section 2.1.4. The barrier cream (RD-1433) was reported to be of clinical research 
grade and so was in compliance with MHRA requirements as listed in Section 2.1.1. 
Both RD-1433 and Vaseline were tested in vitro for minimum thickness and duration 
of efficacy according to Section 2.1.13.2 and Section 2.1.13.3, respectively. All in 
vitro studies were quantified using radiometric analysis as described in Section 2.3.1. 
The details of the clinical trial performed with RD-1433 are outlined in Section 2.2. 
In vivo biophysical measurements were performed as detailed in Section 2.2.1. In 
vivo testing of RD-1433 and Vaseline for optimal thickness and duration of efficacy 
was performed as outlined in Section 2.2.2and 2.2.3, respectively. Statistical testing 
was performed as detailed in Section 2.3.2. 
Briefly, both RD-1433 and Vaseline were tested for efficacy against methyl 
nicotinate. In vitro studies involved the use of the novel flexing diffusion cell to test 
for optimal thickness of both RD-1433 and Vaseline at 0.01, 0.05 and 0.1mm as well 
as for duration of efficacy for 1, 2, 4 and 6 hours against 
14
C-methyl nicotinate. In 
vivo biophysical measurements of LDI, TiVi, Visual Erythema and TEWL tested the 
efficacy of both RD-1433 and Vaseline in human volunteers at the same thicknesses, 
durations of efficacy and concentration of MN (unlabeled) as in vitro studies. In vitro 
techniques were then compared to in vivo measurements to give an indication of 
sensitivity and predictive accuracy. 
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5.3 Results 
5.3.1 In Vitro Optimal Thickness Study 
5.3.1.1 14C-Methyl Nicotinate And 3H-Water Surface Evaporation 
The evaporation of 
14
C-MN solution was initially linear (approximately 0.11 mgml
-1
) 
up to approximately 45 minutes, after which no further evaporation was measurable 
(Figure 5.1). At 20 minutes (corresponding with the actual duration of exposure in 
vitro and in vivo), less than 50% of the applied dose remained. In contrast, the 
evaporation of water was exponential, with approximately 2% of the applied dose 
remaining after 20 minutes, after which the amount remaining was negligible (less 
than 0.02% of the applied dose).  
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Figure 5.1: Carbon-14 Methyl Nicotinate And Tritiated Water Surface      
Evaporation. Carbon-14 methyl nicotinate was applied (10 mg; 5mM solution) to 
aluminium foil for 120 minutes. Tritiated water was applied (10 mg) to aluminium 
foil for 120 minutes. All data (n =3) are represented as mean + standard deviation.  
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5.3.1.2 Measured Thickness Applied- RD-1433 and Vaseline® 
The actual thickness of RD-1433 applied to the skin samples was consistently lower 
than the nominal thickness (Figure 5.2). This experimental error was greatest at 0.01 
mm (approximately 60% of intended thickness) and approximately 80% for 0.05 and 
0.1 mm applications. 
In contrast, the dose of Vaseline
®
 applied to the skin surface was closer to the 
nominal thickness, being approximately 80-90% of the intended dose. 
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Figure 5.2: In Vitro Applied Thickness Of RD-1433 And Vaseline For Optimal 
Thickness Studies. Glove tips were weighed before and after product application in 
order to get a total amount applied to the skin surface. Amount was determined after 
factoring in the density of RD-1433 (2.358 g cm
-3
) and Vaseline (0.952 g cm
-3
). All 
data are represented as mean + standard deviation of 6 diffusion cells. 
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5.3.1.3 Barrier Viability Measurements 
There were no significant differences (p > 0.05) found in the transepidermal water 
loss flux rates or tritiated water penetration between baseline and post-treatment 
within a group, or between any of the treatment groups (Figure 5.3 and Figure 5.4).  
There was no correlation between tritiated water penetrated and transepidermal water 
loss flux at baseline (r = 0.08) and post-treatment (r = 0.4) values in RD-1433 treated 
skin. Similarly there was no correlation for baseline (r = -0.20) and post-treatment (r 
= 0.19) values in Vaseline
®
 treated skin.  
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Figure 5.3: In Vitro Transepidermal Water Loss Flux Before And After 
14
C-
Methyl Nicotinate Application In RD-1433 (A) And Vaseline (B) Treated 
Thickness Groups. Rates of TEWL were measured before test product application 
and application of 10 µl (1µCi total) of 
14
C-methyl nicotinate (Baseline) and after 
test product and 
14
C-methyl nicotinate removal (Post-Treatment). All data are 
represented as mean + standard deviation of 6 diffusion cells. 
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Figure 5.4: In Vitro Tritiated Water Penetration Before And After 
14
C-Methyl 
Nicotinate Application In RD-1433 (A) And Vaseline (B) Treated Thickness 
Groups. Tritiated water was applied for 30 minutes before test product application 
and application of 10 µl (1µCi total) of 
14
C-methyl nicotinate (Baseline) and after 
test product and 
14
C-methyl nicotinate removal (Post-Treatment). All data are 
represented as mean + standard deviation of 6 diffusion cells. 
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5.3.1.4  RD-1433 Treated Groups- Optimal Thickness Study 
Cumulative Amount Penetrated 
The application of RD-1433 at a thickness of 0.05 and 0.1 mm to both static and 
flexed skin resulted in a significant decrease (p < 0.05) in methyl nicotinate 
penetration. Furthermore, the 0.1 mm application provided 2-fold greater protection 
than 0.05 mm (Figure 5.5). When applied at 0.01 mm to flexed skin sections, pre-
treatment with RD-1433 caused a significant decrease (p < 0.05) in 
14
C-MN 
penetration compared to the control as well as a 3-fold decrease in penetration 
compared to corresponding static skin treated with RD-1433 at 0.01 mm. Within 
flexed skin sections, RD-1433 applied at 0.05 and 0.1 mm provided 3- and 5-fold, 
protection, respectively, against MN compared to 0.01mm. Within static groups 
treated with RD-1433 at 0.05 and 0.1 mm, protection of 10- and 16-fold was 
provided, respectively compared to the 0.01 mm treated sections.  
Maximum Flux 
Both static and flexed skin treated with RD-1433 at the two higher thicknesses 
showed significant (p < 0.05) 10-fold and 20-fold decreases in maximum flux, 
respectively compared to the skin treated with 0.01 mm (Figure 5.6). Furthermore, 
RD-1433 when applied at 0.1 mm significantly reduced the flux of methyl nicotinate 
by two-fold compared to the groups treated with 0.05 mm. There were no significant 
differences in the time of onset of maximum flux between all treatment groups.  
Thus, RD-1433 provided significant protection against 
14
C-MN in a dose-dependent 
manner, decreasing with thicker layers of application, although the thinnest layer 
tested was inconsistent. Additionally, skin sections (whether immobile or flexed) 
were significantly more protected against the penetration of methyl nicotinate when 
using RD-1433 applied at a 0.1 mm thickness.  
  Chapter 5 
204 
 
 
Figure 5.5: Cumulative Amount of 
14
C-Methyl Nicotinate Penetrated Through 
Static (A) And Flexed (B) Porcine Skin Treated With RD-1433 Over 180 
Minutes. RD-1433 was tested for protective effect against 
14
C-methyl nicotinate (10 
µl, 1 µCi applied) at thicknesses of 0.01, 0.05 and 0.1 mm. Excess nicotinate was 
removed at 20 minutes and RD-1433 was removed at 120 minutes. Asterisks (* and 
***) indicate significant (p < 0.05 and 0.001, respectively) reductions in the 
cumulative amount (µg cm
-2
) of 
14
C-methyl nicotinate penetrated at 180 minutes 
compared to the relevant control. Cumulative amount penetrated (QT) is represented 
on the graph as µg cm
-2
. All data are represented as mean + standard deviation of 
n=6 diffusion cells. 
B
0
100
200
300
400
500
600
700
800
900
0 50 100 150 200
Time (min)
RD Flex Control    568  200
RD Flex 0.01mm  206  122 *
RD Flex 0.05mm     75  34   ***
RD Flex 0.1mm       40  18   ***
A
m
o
u
n
t 
P
e
n
e
tr
at
e
d
 (
µ
g 
cm
 -2
)
QT
0
100
200
300
400
500
600
700
800
900
0 50 100 150 200
Time (min)
A
m
o
u
n
t 
P
e
n
e
tr
at
e
d
 (
µ
g 
cm
 -2
)
RD Static Control       633  170
RD Static 0.01mm      599  140
RD Static 0.05mm        61  32 ***
RD Static 0.1mm          37  17 ***
A
QT
  Chapter 5 
205 
 
 
Figure 5.6: In Vitro Flux Profile Of 
14
C-Methyl Nicotinate Penetrated Through 
Static (A) And Flexed (B) Porcine Skin Treated With RD-1433 Over 180 
Minutes. RD-1433 was tested for protective effect against 
14
C-methyl nicotinate (10 
µl; 1 µCi) at thicknesses of 0.01, 0.05 and 0.1 mm. Excess nicotinate was removed at 
20 minutes and RD was removed at 120 minutes. Asterisks (***) indicate significant 
(p < 0.001) reductions in maximum flux (JMax; µg cm
-2
 min
-1
) compared to the 
relevant control. Time at which maximum flux occurred (TMax) was also compared. 
All data are represented as mean + standard deviation of n=6 diffusion cells. 
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5.3.1.5 Vaseline®Treated Groups- Optimal Thickness Study 
Cumulative Amount Penetrated 
Both immobile and flexed skin treated with Vaseline
® 
at a nominal thickness of 0.05 
mm demonstrated significant reductions (p < 0.05) in 
14
C-MN penetration, compared 
to untreated controls. Moreover, static skin treated with Vaseline
®
 at 0.1 mm also 
showed a significant reduction in methyl nicotinate penetration compared to the 
untreated control (Figure 5.7). In comparison to the RD-1433 treated groups, static 
and flexed skin treated with Vaseline
® 
showed less protection against methyl 
nicotinate penetration at the highest thickness (0.1 mm) compared to the intermediate 
(0.05 mm) thickness groups. Moreover, skin sections treated with Vaseline
®
 at 0.05 
mm showed 2- 3-fold reductions in methyl nicotinate penetration in flexed and static 
skin, respectively compared to 0.01 mm Vaseline
®
 treated sections. 
When contrasted with Vaseline
®
 treated skin, RD-1433 provided significantly more 
protection, amounting to 3- and 10-fold, when used at thicknesses of 0.05 and 0.1 
mm, respectively in both static and flexed skin.  
Maximum Flux 
Both static and flexed skin treated with Vaseline
®
 at 0.05 mm showed significant 
reductions (p < 0.05) in flux compared to the untreated control (Figure 5.8). In 
addition, static skin treated with Vaseline
®
 at 0.1 mm demonstrated significant 
reduction in flux compared to the untreated control. Application of Vaseline
® 
at 0.05 
and 0.1 mm significantly reduced the flux of methyl nicotinate by approximately 2-
fold for both static and flexed skin.  
In comparison to Vaseline
®
 treated groups, static and flexed skin sections treated 
with RD-1433 at 0.05 and 0.1 mm thickness provided significant reductions 
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amounting to approximately 3- to 13-fold, respectively in flux compared to the 
corresponding Vaseline
®
 treated groups at 0.05 and 0.1 mm. In addition, Vaseline
®
 
treated groups did not show a dose-dependence, with inconsistent results seen 
between 0.05 and 0.1 mm treated skin. 
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Figure 5.7: Cumulative Amount of 
14
C- Methyl Nicotinate Penetrated Through 
Static (A) And Flexed (B) Porcine Skin Treated With Vaseline® Over 180 
Minutes. Vaseline® was tested for protective effect against 
14
C-methyl nicotinate (10 
µl; 1 µCi applied) at thicknesses of 0.01, 0.05 and 0.1 mm. Excess nicotinate was 
removed at 20 minutes and Vaseline was removed at 120 minutes. Asterisks (* and 
**) indicate significant (p < 0.05 and 0.01, respectively) reductions in the cumulative 
amount (µg cm
-2
) of 
14
C-methyl nicotinate penetrated at 180 minutes compared to the 
relevant control. Cumulative amount (QT) is represented on the graph as µg cm
-2
. All 
data are represented as mean + standard deviation of n=6 diffusion cells. 
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Figure 5.8: In Vitro Flux Profile Of 
14
C-Methyl Nicotinate Penetrated Through 
Static (A) And Flexed (B) Porcine Skin Treated With Vaseline Over 180 
Minutes. Vaseline was tested for protective effect against 
14
C-methyl nicotinate (10 
µl; 1 µCi) at thicknesses of 0.01, 0.05 and 0.1 mm. Excess nicotinate was removed at 
20 minutes and Vaseline was removed at 120 minutes. Asterisks (* and **) indicate 
significant (p < 0.05 and 0.01, respectively) reductions in maximum penetration rate 
(JMax; µg cm
-2
 min
-1
) compared to the relevant control. Time at which maximum 
flux occurred (TMax) was also studied. All data are represented as mean + standard 
deviation of n=6 diffusion cells. 
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5.3.1.6 Dose Distribution Of 14C-Methyl Nicotinate: RD-1433 And Vaseline® 
Skin Surface Recovery Of Excess Methyl Nicotinate After 20 Minutes 
Both flexed and immobile skin sections treated with RD-1433 and Vaseline
®
 at 0.05 
and 0.1 mm showed significant recovery (p < 0.001 and 0.01, respectively) of methyl 
nicotinate from the skin surface after 20 minutes compared to the untreated control 
and 0.01 mm treated sections (Figure 5.9). Static and flexed skin treated with 0.01 
mm of either RD-1433 or Vaseline
® 
showed significantly decreased (p < 0.001) 
amounts of surface recovery of methyl nicotinate compared to the 0.05 and 0.1 mm 
treated groups.  
Skin Surface Wash Of RD-1433 And Vaseline After 120 Minutes 
Both flexed and immobile skin sections treated with RD-1433 at all three thicknesses 
(0.01, 0.05 and 0.1 mm) showed significant recovery (flexed p < 0.001, 0.01 and 
0.01; static p < 0.1, respectively) of methyl nicotinate after 120 minutes. In contrast, 
there was no significant recovery (p > 0.05) of methyl nicotinate with any of the 
Vaseline
®
 treated skin.  
Skin Recovery Of Methyl Nicotinate  
Both static and flexed skin groups treated with RD-1433 at 0.05 mm showed 
significantly less recovery (p < 0.05 and 0.01, respectively) of methyl nicotinate from 
skin sections compared to the untreated controls. This result (p < 0.05) was also seen 
with the 0.05 mm flexed Vaseline
®
 treated group. 
Control Recovery 
The total recovery of methyl nicotinate from control (untreated) groups was 
approximately 20% of the total applied dose, which was significantly less than the 
total recovery from RD-1433 and Vaseline
®
 treated groups. 
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Figure 5.9: Dose Distribution Of 
14
C-Methyl Nicotinate From Static And Flexed Porcine Skin Samples Treated With RD-1433 And Vaseline
®
 Over 180 Minutes. 
Test products were treated at thicknesses of 0.01, 0.05 and 0.1 mm. Each bar on the graph indicates percentage of the dose (10.024 mg) applied that was either contained in 
swabs at 15 minutes (On Skin- 15 min), with RD-1433 and Vaseline after removal at 120 minutes (On Skin- 120 min) in the skin samples or in the receptor fluid. Asterisks 
(***) indicate significant (p < 0.001) increases in the amount of 
14
C-methyl nicotinate found in the 20 minute swabs compared to the control. Circle and cross symbols ((фф 
and ффф) indicate significant (p < 0.01 and 0.001, respectively) increases in the amount of 14C-methyl nicotinate found in the 120 minutes swabs compared to the control. The 
Y symbol with 2 parallel lines represents significant decreases (p < 0.05 and 0.01, respectively) in 
14
C-methyl nicotinate found in the skin compared to the control. All data 
are represented as mean + standard deviation of 6 diffusion cells. 
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5.3.2 In Vivo Optimal Thickness Study 
5.3.2.1 Thickness Applied 
In contrast to the in vitro studies, the actual thickness of both RD-1433 and 
Vaseline
®
 were generally within 80-90% of the intended (nominal) thickness (Figure 
5.10). 
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Figure 5.10: In Vivo Applied Thickness Of RD-1433 And Vaseline
®
 For Optimal 
Thickness Studies. Glove tips were weighed before and after product application in 
order to get a total amount applied to the skin surface. This amount was determined 
after factoring in the density of RD-1433 (2.358 g cm
-3
) and Vaseline (0.952 g cm
-3
). 
All data are represented as mean + standard deviation of 12 volunteers. 
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5.3.2.2 In Vivo Barrier Integrity Measurement- TEWL 
There were no significant differences seen in the transepidermal water loss flux 
between the baseline and post-treatment values within or between treatment groups 
(Figure 5.11). Transepidermal water loss flux was consistently lower in all post-
treatment measurements. 
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Figure 5.11: In Vivo Transepidermal Water Loss Flux Before And After 
14
C-
Methyl Nicotinate Application In RD-1433 (A) And Vaseline (B) Treated 
Thickness Groups. TEWL was measured before test product application and 
application of 10 µl of methyl nicotinate (A) and after test product and methyl 
nicotinate removal (B).  All data are represented as mean + standard deviation of 12 
volunteers. 
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5.3.2.3 Visual Erythema Scoring 
Skin sites treated with RD-1433 at 0.05 and 0.1 mm showed a dose-dependent and 
significant (p < 0.05) decrease in erythema compared to the untreated control (Figure 
5.12, A). Vaseline
®
 treated sites, when tested at all thicknesses, did not significantly 
reduce erythema compared to the untreated control (Figure 5.12, B). 
Moreover, RD-1433 (when applied at all thicknesses) was found to significantly (p < 
0.05) reduce erythema compared to the Vaseline
® 
treated groups. When applied at 
0.01 mm, RD-1433 treated skin showed a 4-fold decrease in erythema compared to 
the untreated control and a 2-fold decrease compared to erythema with application at 
0.05 mm. 
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Figure 5.12: Visual Erythema Scoring For Human Volunteers Treated With 
RD-1433 (A) And Vaseline
®
 (B) Over 180 Minutes. RD-1433 and Vaseline were 
applied to separate application sites on the volar forearm at thicknesses of 0.01, 0.05 
and 0.1 mm before rubefacient application. An untreated control site was present on 
both arms. Methyl nicotinate was applied (10 µl; 5 mM) to the forearm at time 0. 
Excess methyl nicotinate was removed at 20 minutes and products were removed at 
120 minutes. All data (n=12) are represented as mean + standard error of the mean. 
Asterisks (** and ***) represent a significant (p < 0.05 and 0.01, respectively) 
decrease in visual erythema as compared to the untreated control. 
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5.3.2.4 Tissue Imaging Viability 
Skin sites treated with RD-1433 at both 0.05 and 0.1 mm thicknesses showed 
significantly (p < 0.05) reduced erythema compared to the untreated control. In 
addition, RD-1433 treated skin showed a dose-dependent decrease in erythema with 
increasing thicknesses applied. Skin sites treated with Vaseline
®
 did not differ 
significantly in respect to erythema compared to the untreated control (Figure 5.13). 
Skin treated with RD-1433 at all thicknesses showed significant reductions (p < 
0.05) in erythema compared to Vaseline treated sections, equating to an approximate 
reduction in erythema of 3- to 11-fold with increasing RD-1433 thickness, 
respectively (Figure 5.13). 
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Figure 5.13: Tissue Viability Imaging Of Human Volunteers Treated With RD-
1433 (A) And Vaseline® (B) Over 180 Minutes. RD-1433 and Vaseline were 
applied to separate application sites on the volar forearm at thicknesses of 0.01, 0.05 
and 0.1 mm before rubefacient application. An untreated control site was present on 
both arms. Methyl nicotinate was applied (10 µl; 5 mM) to the forearm at time 0. 
Excess methyl nicotinate was removed at 20 minutes and products were removed at 
120 minutes. All data (n=12) are represented as mean + standard error of the mean. 
Asterisks (***) represent a significant (p < 0.001) decrease in erythema as compared 
to the untreated control. 
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5.3.2.5 Laser Doppler Imaging- Blood Flow  
Skin sites treated with RD-1433 at a thickness of 0.05 and 0.1 mm demonstrated 
significant reductions in blood flow compared to the RD-1433 0.01 mm treated 
group and  the untreated control (Figure 5.14). All skin treated with RD-1433 
showed a dose-dependent decrease in blood flow with increasing thickness of 
product used. Skin sites treated with Vaseline
® 
did not show significantly different 
erythema compared to the untreated control. 
All skin sites treated with RD-1433 showed significant decreases (p < 0.05)  in blood 
flow compared to corresponding Vaseline
®
 treated sites, with decreases 
approximately 2- fold to 20-fold for increasing RD-1433 treated thicknesses. Skin 
sites treated with RD-1433 0.1 mm provided more than a 2-fold decrease in blood 
flow compared to RD-1433 0.05 mm treated sites. 
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Figure 5.14: Laser Doppler Imaging Of Human Volunteer Blood Flow Of RD-
1433 (A) And Vaseline® (B) Over 180 Minutes RD-1433 and Vaseline were 
applied to separate application sites on the volar forearm at thicknesses of 0.01, 0.05 
and 0.1 mm before rubefacient application. An untreated control site was present on 
both arms. Methyl nicotinate was applied (10 µl; 5 mM) to the forearm at time 0. 
Excess methyl nicotinate was removed at 20 minutes and products were removed at 
120 minutes. All data (n=12) are represented as mean + standard error of the mean. 
Asterisks (***) represent a significant (p < 0.001) decrease in blood flow as 
compared to the untreated control. 
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5.3.2.6 Laser Doppler Imaging- Maximum Blood Flow 
Skin sites treated with RD-1433 at a thickness of 0.05 and 0.1 mm presented with 
significantly (p < 0.05) reduced maximum blood flux compared to RD-1433 sites 
treated at 0.01 mm and the untreated control (Figure 5.15). A dose-dependent 
decrease was seen in maximum blood flow with increasing RD-1433 thicknesses 
used. Skin sites treated with Vaseline
®
 did not demonstrate maximum blood flow 
rates distinguishable from the untreated control. 
All skin sites treated with RD-1433 showed significant decreases in maximum blood 
flow compared to sites treated with Vaseline
®
. In addition, RD-1433 skin sites 
treated with 0.1 mm showed significantly reduced maximum blood flow in 
comparison to the lesser thicknesses of RD-1433. 
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Figure 5.15: Laser Doppler Imaging Of Human Volunteers- Maximum Blood 
Flow Of RD-1433 (A) And Vaseline® (B) Over 180 Minutes. RD-1433 and 
Vaseline were applied to separate application sites on the volar forearm at 
thicknesses of 0.01, 0.05 and 0.1 mm before rubefacient application. An untreated 
control site was present on both arms. Methyl nicotinate was applied (10 µl; 5 mM) 
to the forearm at time 0. Excess methyl nicotinate was removed at 20 minutes and 
products were removed at 120 minutes. All data (n=12) are represented as mean + 
standard error of the mean. Asterisks (** and ***) represent a significant (p < 0.05 
and 0.01, respectively) decrease in visual erythema as compared to the untreated 
control. 
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5.3.3 In Vitro Duration Of Efficacy Study 
5.3.3.1 Barrier Integrity Measurements  
When evaluating transepidermal water loss flux in both immobile and flexed skin 
treated with RD-1433 and Vaseline
®
, there were no significant differences between 
baseline and post-treatment values either within or between treatment groups (Figure 
5.16). An identical result was seen with tritiated water penetration (Figure 5.17). 
There was no correlation between tritiated water penetrated and TEWL flux at both 
baseline (r= 0.23) and post-treatment (r= 0.35) in skin treated with RD-1433. There 
was also no correlation between tritiated water penetrated and TEWL flux at both 
baseline (r= 0.20) and post-treatment (r= 0.17) in Vaseline
®
 treated groups. 
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Figure 5.16: Transepidermal Water Loss Flux In Static And Flexed Porcine 
Skin Exposed To 
14
C-Methyl Nicotinate And Treated With RD-1433 (A) And 
Vaseline (B) At Different Durations Of Efficacy. TEWL was measured before test 
product application and 10 µl (1µCi total) of 
14
C-methyl nicotinate (Baseline) and 
after test product and 
14
C-methyl nicotinate removal (Post-Treatment).  All data are 
represented as mean + standard deviation of 6 diffusion cells. 
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Figure 5.17: Tritiated Water Penetration In Static And Flexed Porcine Skin 
Treated With RD-1433 (A) And Vaseline (B) Used At Different Durations Of 
Efficacy. Tritiated water was applied for 30 minutes before test product application 
and 10 µl (1µCi total) of 
14
C-methyl nicotinate (Baseline) and after test product and 
14
C-methyl nicotinate removal (Post-Treatment). All data are represented as mean + 
standard deviation of 6 diffusion cells. 
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5.3.3.2 RD-1433 Treated Groups- Duration Of Efficacy Study 
Cumulative Amount Penetrated 
Both static and flexed skin treated with RD-1433 from 1-6 hours showed significant 
decreases (p < 0.001) in the cumulative amount of methyl nicotinate penetrated 
compared to the untreated control (Figure 5.18).  
Maximum Flux 
Static groups treated with RD-1433 at 1, 2, 4 and 6 hours had significantly (p < 
0.001) lower maximum flux compared to the static control (Figure 5.19).  
Both static and flexed skin treated with RD-1433 for 1-6 hours had significantly 
lower (p < 0.001) maximum flux values compared to the relevant controls. All skin 
treated with RD-1433 from 1-6 hours showed identical maximum flux rates, which 
equated to approximately a 29-fold decrease in methyl nicotinate flux compared to 
the control.  
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Figure 5.18: Cumulative Amount of 
14
C- Methyl Nicotinate Penetrated Through 
Static (A) And Flexed (B) Porcine Skin Treated With RD-1433 Over 120 
Minutes. RD-1433 (0.1 mm thickness) was tested for protective effect against 
14
C-
methyl nicotinate (10 µl, 1 µCi applied) for durations of 1, 2, 4 and 6 hours. Excess 
nicotinate was removed at 20 minutes and RD-1433 was removed at 60 minutes. The 
cumulative amount penetrated at study end (QT) is represented on the graph in µg 
cm
-2
 h
-1
. Asterisks (***) indicate significant (p < 0.001) reductions in the cumulative 
amount (µg cm
-2
) of 
14
C-methyl nicotinate penetrated at 120 minutes compared to the 
relevant control. All data are represented as mean + standard deviation of n=6 
diffusion cells. 
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Figure 5.19: Flux Profile Of 
14
C-Methyl Nicotinate Penetrated Through Static 
(A) And Flexed (B) Porcine Skin Treated With RD-1433 Over 120 Minutes. RD-
1433 (0.1 mm thickness) was tested for protective effect against 
14
C-methyl 
nicotinate (10 µl, 1 µCi applied) for durations of 1, 2, 4 and 6 hours. Excess 
nicotinate was removed at 20 minutes and RD-1433 was removed at 60 minutes. 
Asterisks (***) indicate significant (p < 0.001) reductions in maximum flux (JMax; 
µg cm
-2
 min
-1
) compared to the relevant control. All data are represented as mean + 
standard deviation of n=6 diffusion cells. 
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5.3.3.3 Vaseline® Treated Groups- Duration Of Efficacy Study 
Cumulative Amount Penetrated 
Flexed skin treated with Vaseline
® 
for 2 hours showed a significant decrease (p < 
0.05) in methyl nicotinate penetrated compared to the untreated control (Figure 
5.20). In addition, both static and flexed skin treated with Vaseline
® 
for 4 hours 
showed significant decreases (p < 0.05) in the penetration of methyl nicotinate 
compared to the untreated control. Although not significant (p > 0.05), Vaseline
® 
treated skin from 1-4 hours showed approximately a 5-fold decrease in methyl 
nicotinate penetrated compared to the untreated control. Skin treated with Vaseline
®
 
for 6 hours showed higher amounts of methyl nicotinate penetrated compared to the 
1-4 hour treated groups. 
Both static and flexed skin treated with RD-1433 showed significant decreases (p < 
0.05) in cumulative penetration of methyl nicotinate compared to the corresponding 
Vaseline
®
 treated groups. The decrease in penetration of methyl nicotinate from 1-6 
hours in skin treated with RD-1433 was approximately 10-fold less than that of 
Vaseline
® 
treated skin.   
Maximum Flux 
Both static and flexed skin treated with Vaseline
® 
at 4 hours showed significant 
decreases (p < 0.05) in maximum flux of methyl nicotinate compared to the untreated 
control (Figure 5.21). Although not significant, skin treated with Vaseline
®
 for 1-4 
hours showed approximately a 6-fold decrease in maximum flux of methyl nicotinate 
compared to the untreated control. Skin treated with Vaseline
® 
for 6 hours showed 
higher maximum flux rates compared to the 1-4 hour treated groups.  
  Chapter 5 
231 
 
Skin treated with RD-1433 from 1-6 hours showed significantly lower maximum 
flux than skin treated with Vaseline
® 
from 1-6 hours, equating to approximately 5-
fold decreases from the 1-4 hour groups and 10-fold decreases compared to the 
Vaseline
® 
6 hour treatment group.  
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Figure 5.20: Cumulative Amount of 
14
C- Methyl Nicotinate Penetrated Through 
Porcine Skin Treated with Vaseline
®
 In Static (A) and Flexed (B) Skin Over 120 
Minutes. Vaseline
®
 (0.1 mm thickness) was tested for protective effect against 
14
C-
methyl nicotinate (10 µl, 1 µCi applied) for durations of 1, 2, 4 and 6 hours. Excess 
nicotinate was removed at 20 minutes and Vaseline
®
 was removed at 60 minutes. 
The cumulative amount penetrated at study end (QT) is represented on the graph in 
µg cm
-2
 h
-1
. Asterisks (* and **) indicate significant (p < 0.05 and 0.01, respectively) 
reductions in the cumulative amount (µg cm
-2
) of 
14
C-methyl nicotinate penetrated at 
120 minutes compared to the relevant control. All data are represented as mean + 
standard deviation of n=6 diffusion cells. 
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Figure 5.21: Flux Profile Of 
14
C-Methyl Nicotinate Penetrated Through Static 
(A) And Flexed (B) Porcine Skin Treated With Vaseline
®
 Over 120 Minutes 
Vaseline
®
 (0.1 mm thickness) was tested for protective effect against 
14
C-methyl 
nicotinate (10 µl, 1 µCi applied) for durations of 1, 2, 4 and 6 hours. Excess 
nicotinate was removed at 20 minutes and Vaseline
®
 was removed at 60 minutes.  
Asterisks (* and **) indicate significant (p < 0.05 and 0.01, respectively) reductions 
in maximum flux (JMax; µg cm
-2
 h
-1
) compared to the relevant control. All data are 
represented as mean + standard deviation of n=6 diffusion cells.  
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5.3.3.4 Dose Recovery Of 14C-Methyl Nicotinate- Duration Of Efficacy Study 
Skin Surface Recovery Of Methyl Nicotinate At 20 Minutes 
Both static and flexed skin treated with RD-1433 showed significantly (p < 0.05) 
greater recovery of methyl nicotinate at 20 minutes on the skin surface than the 
untreated control groups (Figure 5.22).   
Immobile skin treated with Vaseline
® 
 for 1, 4 and 6 hours and flexed skin treated 
with Vaseline
® 
 for 2, 4 and 6 hours showed significantly (p < 0.05) greater recovery 
of methyl nicotinate at 20 minutes from the skin surface than the untreated controls. 
Skin Wash Of RD-1433 And Vaseline At 60 Minutes 
All skin treated with RD-1433 showed similar recovery of methyl nicotinate at 60 
minutes compared to the untreated control. Similar recovery rates were seen with 
skin treated with Vaseline
®
 for 1, 2 and 4 hours compared to the untreated control, 
however both 6 hour treated Vaseline
®
 groups showed significant decreases in the 
recovery of methyl nicotinate at 60 minutes compared to the untreated control. 
A significant decrease (p < 0.05) in the recovery of methyl nicotinate from the skin 
wash at 60 minutes was seen in both static and flexed skin treated with Vaseline
®
 for 
6 hours. 
Skin Recovery Of Methyl Nicotinate 
All static and flexed groups treated with RD-1433 showed similar recovery of methyl 
nicotinate in the skin compared to the untreated controls. Static and flexed groups 
treated with Vaseline
®
 from 1-4 hours showed similar skin recovery of methyl 
nicotinate, however groups treated with Vaseline
®
 for 6 hours demonstrated 
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significant (p < 0.05) decreases in the amount of methyl nicotinate recovered in the 
skin compared to the untreated controls.  
Control Groups 
Both static and flexed untreated skin showed total recoveries of methyl nicotinate 
totalling approximately 20% of the applied dose, this was significantly (p < 0.05) 
less methyl nicotinate recovered compared to the RD-1433 and Vaseline
®
 treated 
groups. 
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Figure 5.22: Dose Distribution Of 
14
C-Methyl Nicotinate From Flexed And Static Porcine Skin Treated With RD-1433 And Vaseline
®
 Over 120 Minutes. Test 
products were applied to the skin surface at a thickness of 0.1 mm for 1, 2, 4 or 6 hours. Carbon-14 methyl nicotinate was applied at 10 µl (1 µCi total) per diffusion cell at 
time 0. The percentage of the dose (10.024 mg) applied was found on the skin at 20 minutes (On Skin- 20 Min), with test products at 60 minutes (On Skin- 60 Min), in the 
skin samples and in the receptor fluid. Asterisks (*, ** and ***) indicate a significant (p < 0.05, 0.01 and 0.001, respectively) increase in the amount of 
14
C-methyl nicotinate 
found in the 20 minute samples compared to the relevant control. The circle with cross symbol indicates a significant (p < 0.05) decrease in the amount of 
14
C-MN recovered 
at 60 minutes compared to the relevant control. The Y symbol with 2 parallel lines represents a significant decrease (p < 0.05) in 
14
C-methyl nicotinate found in the skin 
compared to the control.  All data are represented as mean + standard deviation of 6 diffusion cells.  
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5.3.4 In Vivo Duration Of Efficacy Study 
5.3.4.1 Barrier Integrity Measurement- TEWL 
There were no significant differences found in TEWL rate for static and flexed skin 
sections treated with RD-1433 and Vaseline
® 
between baseline and post-treatment 
values within a treatment group and values between groups (Figure 5.23). All post-
treatment values demonstrated lower TEWL rates compared to baseline values.  
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Figure 5.23: In Vivo Transepidermal Water Loss Flux Before And After 
14
C-
Methyl Nicotinate Application In RD-1433 (A) And Vaseline
®
 (B) Duration Of 
Efficacy Groups. TEWL was measured before test product application and 
application of 10 µl of methyl nicotinate (Baseline) and after test product and methyl 
nicotinate removal (Post-Treatment).  All data are represented as mean + standard 
deviation of 12 volunteers. 
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5.3.4.2 Visual Erythema 
Skin sites treated with RD-1433 for 1, 2 and 4 hours showed significant decreases (p 
< 0.001, 0.01 and 0.001, respectively) in erythema compared to the untreated control 
(Figure 5.24- A). There were no significant decreases in erythema in the Vaseline
®
 
treated groups compared to the untreated control (Figure 5.24- B). 
Skin sites treated with RD-1433 from 1-6 hours showed significantly (p < 0.05) less 
visual erythema compared to Vaseline
® 
treated groups, this equated to an 
approximate 2- to 3-fold decrease in RD-1433 treated groups. 
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Figure 5.24: Visual Erythema Scoring For Human Volunteers Treated With 
RD-1433 (A) And Vaseline
®
 (B) For Different Durations. RD-1433 and Vaseline
®
 
were applied at 0.1 mm to separate application sites on the volar forearm at 1, 2, 4 
and 6 hours before rubefacient application. An untreated control site was present on 
both arms. Methyl nicotinate was applied (10 µl; 5 mM) to the forearm at time 0. 
Excess methyl nicotinate was removed at 20 minutes and products were removed at 
60 minutes. All data (n=12) are represented as mean + standard error of the mean. 
Asterisks (** and ***) represent a significant (p < 0.05 and 0.01, respectively) 
decrease in visual erythema as compared to the untreated control. 
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5.3.4.3 Tissue Viability Imaging 
Skin sites treated with RD-1433 for 1, 2 and 4 hours showed significant (p < 0.05) 
decreases in erythema compared to the untreated control (Figure 5.25, A). A 
noticeable decrease in erythema was seen between baseline and application of test 
product, this is possibly a surface optical effect due to the opacity of the product 
resulting in a decrease in light penetration through the skin. There were no 
significant decreases in the Vaseline
®
 treated groups compared to the untreated 
control (Figure 5.25, B). 
All skin sites treated with RD-1433 from 1-6 hours showed significant (p < 0.05) 
decreases in erythema compared to the correspondingly treated Vaseline
®
 groups. 
Quantitatively, RD-1433 treated skin showed erythema an order of magnitude lower 
than from Vaseline treated skin. Although not significant, RD-1433 treated at 1 and 2 
hours showed lower erythema responses than RD-1433 treated groups at 4 and 6 
hours.  
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Figure 5.25: Tissue Viability Imaging Of Human Volunteers Treated With RD-
1433 (Top) And Vaseline® (Bottom) For Duration Of Efficacy Studies. RD-1433 
and Vaseline
®
 were applied at 0.1 mm to separate application sites on the volar 
forearm at 1, 2, 4 and 6 hours before rubefacient application. An untreated control 
site was present on both arms. Methyl nicotinate was applied (10 µl; 5 mM) to the 
forearm at time 0. Excess methyl nicotinate was removed at 20 minutes and products 
were removed at 60 minutes. All data (n=12) are represented as mean + standard 
error of the mean. Asterisks (*, ** and ***) represent a significant (p < 0.05, 0.01 
and 0.001, respectively) decrease in erythema as compared to the untreated control. 
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5.3.4.4 Laser Doppler Imaging- Blood Flow  
Skin sites treated with RD-1433 for 1, 2, 4 and 6 hours showed significant (p < 0.05) 
decreases in blood flow compared to the untreated control (Figure 5.26- A). Skin 
treated with RD-1433 showed a time-dependent increase in penetration of methyl 
nicotinate corresponding to an increase in duration. In comparison, no significant 
differences were found in blood flow between Vaseline
®
 treated groups compared to 
the untreated control (Figure 5.26- B). 
All skin sites treated with RD-1433 were shown to have significantly lower (p < 
0.05) blood flow compared to all corresponding Vaseline
®
 treated groups. 
Quantitatively, RD-1433 treated skin showed blood flow an order of magnitude 
lower than blood flow from Vaseline
®
 treated groups.  
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Figure 5.26: Laser Doppler Imaging Of Human Volunteer Blood Flow Of RD-
1433 (A) And Vaseline® (B) For Duration Of Efficacy Studies. RD-1433 and 
Vaseline
®
 were applied at 0.1 mm to separate application sites on the volar forearm 
at 1, 2, 4 and 6 hours before rubefacient application. An untreated control site was 
present on both arms. Methyl nicotinate was applied (10 µl; 5 mM) to the forearm at 
time 0. Excess methyl nicotinate was removed at 20 minutes and products were 
removed at 60 minutes. All values (n=12) are represented as mean + standard error 
of the mean. Asterisks (*, ** and ***) represent a significant (p < 0.05, 0.01 and 
0.001, respectively) decrease in blood flow as compared to the untreated control. 
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5.3.4.5 Laser Doppler Imaging- Maximum Blood Flux 
Skin sites treated with RD-1433 for 1, 2, 4 and 6 hours showed significant (p < 0.05) 
decreases in maximum blood flow compared to the untreated control (Figure 5.27- 
A). All skin treated with RD-1433 showed time-dependent increases in methyl 
nicotinate penetration corresponding to an increase in duration. There were no 
significant differences (p > 0.05) between the Vaseline
®
 treated groups compared to 
the untreated control (Figure 5.27- B). 
Skin sites treated with RD-1433 showed significant (p < 0.05) decreases in 
maximum blood flow flux compared to the corresponding Vaseline
®
 treated groups. 
The decreases in maximum blood flow flux ranged from 4- to 7-fold in RD-1433 
treated groups compared to the corresponding Vaseline
®
 treated groups. 
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Figure 5.27: Laser Doppler Imaging Of Human Volunteers- Maximum Blood 
Flow Of RD-1433 (A) And Vaseline® (B) For Duration Of Efficacy Studies. Both 
RD-1433 and Vaseline
®
 were applied at 0.1 mm to separate application sites on the 
volar forearm at 1, 2, 4 and 6 hours before rubefacient application. An untreated 
control site was present on both arms. Methyl nicotinate was applied (10 µl; 5 mM) 
to the forearm at time 0. Excess methyl nicotinate was removed at 20 minutes and 
products were removed at 60 minutes. All data (n=12) are represented as mean + 
standard error of the mean. Asterisks (*, ** and ***) represent a significant (p < 
0.05, 0.01 and 0.001, respectively) decrease in maximum blood flow as compared to 
the untreated control. 
 
0
100
200
300
400
500
600
-50 0 50 100 150
B
lo
o
d
 F
lo
w
 (
ar
b
)
Time (min)
RD Control        1380   240
RD 1h                  164  43  ***
RD 2h                     176  72 ***
RD 4h                     301  73 **
RD 6h                     427  73 *
AUC
Vas Control        1519  201
Vas 1h                 1384  215
Vas 2h                 1461  225 
Vas 4h                 1520  165 
Vas 6h                 1598  159
0
100
200
300
400
500
600
-50 0 50 100 150
B
lo
o
d
 F
lo
w
 (
ar
b
)
Time (min)
AUC
A
B
  Chapter 5 
247 
 
5.3.5 Summation Of In Vitro And In Vivo Results 
In general, both in vitro and in vivo results demonstrated that RD-1433 treated skin 
provided the most protection against 
14
C-MN penetration (and resulting flux) as well 
as erythema and blood flow reductions. When observing optimal thickness, it was 
shown that in vitro radiometric results for skin treated with RD-1433 matched results 
obtained with all the biophysical measurements (i.e. visual erythema, TiVi and LDI). 
When investigating the duration of efficacy, it was seen that in vitro radiometric 
measurements for skin treated with RD-1433 from 1 to 4 hours duration matched 
with all biophysical measurements with the 6 hour duration only observed to match 
with LDI measurements. Additionally, it was discovered that in vitro measurements 
may have been more sensitive, in detecting small changes in the amounts of 
14
C-MN 
in test product treated skin.  
Correspondingly, the sensitivity calculated (maximum amount penetrated/twice 
background) using an in vitro radiometric assay was 10 fold, this is in comparison to 
in vivo biophysical measurements (maximum response/twice background) of 1.4 fold 
and 3.5 fold for tissue viability imaging and laser Doppler imaging, respectively. 
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Figure 5.28: Statistical Summary Of Optimal Thickness Studies (A) And Duration Of Efficacy Studies (B) For In Vitro And In Vivo 
Data. Methyl nicotinate was applied at same concentration (5 mM) to both in vitro porcine skin (dorsum) and in vivo human volunteers (volar 
forearm). Methyl nicotinate application in vitro was quantified using radiometric assays to calculate cumulative penetration and maximum flux. 
Rates of TEWL were taken at baseline and post-treatment for both in vitro and in vivo studies. Biophysical measurements were used to quantify 
an erythematous response (visual erythema, tissue viability imaging) and blood flow (laser Doppler imaging) following application of RD-1433 
and Vaseline
®
 and subsequent in vivo application of methyl nicotinate. Green areas indicate significant decreases (p < 0.05) in methyl nicotinate 
penetration (in vitro) or significant decreases in erythema and blood flow response (in vivo) as compared to the untreated controls. Thatched 
green areas indicate matching statistical results from in vitro experimentation to in vivo clinical trial data.  
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5.4 Discussion 
Overall, the work presented in this Chapter has demonstrated that a topical skin 
protectant (RD-1433) can significantly reduce the dermal absorption of methyl 
nicotinate in a dose-dependent manner. There was a high degree of correlation 
between the in vitro pig skin absorption kinetics of 
14
C-MN and the corresponding 
physiological response to MN measured using in vivo biophysical techniques with 
human volunteers. The in vitro-in vivo correlation in barrier cream performance was 
somewhat improved when the skin was flexed in vitro, although flexing did not 
affect the baseline absorption kinetics of MN (in the absence of treatments) as 
demonstrated in Chapter 3 with model compounds benzoic acid, caffeine and 
testosterone. 
Pig vs Human Skin 
Marzulli et al. (1969), when using chemical warfare agents of varying 
physicochemical properties, found that the dorsum of weanling pigs approximated 
that of the human forearm in regards to permeability characteristics. Although it is 
acknowledged that human skin is the gold standard for in vitro testing of dermal 
absorption, porcine skin has been shown as a good model for human skin 
permeability (Walker et al., 1986). In the present studies, porcine skin was used in 
vitro due to ethics surrounding the use of human skin as well as cost, reduced inter-
individual variation (i.e. same gene pool, age and gender) and most importantly, the 
amount of skin available for the multitude of studies needed.  
It was ascertained in both the optimal thickness and duration of efficacy studies with 
both test products, that maximum penetration and time taken to reach maximum, 
were very similar when using porcine dorsum skin and human volar forearm. Methyl 
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nicotinate has been documented in producing an erythema intensity that increases to 
a maximum reaction before fading away until a point as to where it is no longer 
visually detectable (Fountain et al., 1969, Guy and Maibach, 1982). Both human and 
porcine skin showed maximum penetration occurring at approximately 30 minutes. 
Theoretically, the maximum flux of methyl nicotinate in vitro should have peaked at 
a time closer to time zero due to the 2- to 3- fold increase in permeability with 
porcine skin compared to human skin. Due to the mechanism of methyl nicotinate, 
blood flow is affected at the level of the papillary plexus (leading to erythema, etc.). 
In vitro porcine skin was dermatomed to 500 µm, a thickness that would include 
dermal tissue, and this is may explain the delay in maximum flux. However, it is 
thought that the relatively rapid penetration of methyl nicotinate may account for 
similarities in penetration of MN between pig and human skin. In comparison to 
model compounds, the penetration of methyl nicotinate was relatively faster. The 
extremely rapid penetration of MN in both porcine and human skin would reduce the 
known relative difference between species as compounds penetrating rapidly over a 
short duration are difficult to measure due to inherent skin variability.  
Application Of Test Products 
The actual thickness of RD-1433 and Vaseline
®
 applied to the skin both in vitro and 
in vivo was determined to be very close to the nominal thickness required. However, 
in vivo application of both test products was found to be consistently closer to 
nominal thickness as compared to in vitro application. This result was to be expected 
as the relative ease in applying the test products in vivo (i.e. larger surface area, solid 
support) contrasted with the relatively difficult application of the test products to a 
skin section present within a diffusion cell. As the skin sections did not have rigid 
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inserts for support, a high degree of caution was taken in the spreading of test 
products, in order to ensure that skin damage did not take place.  
Generally, significant decreases in penetration of MN with 0.01 mm treated skin 
were not seen, and it is possible that this relatively small amount of test product did 
not provide a consistent layer of protection. This is further evidenced by in vitro 
penetration from the 0.01 mm treated groups demonstrating higher penetration than 
the 0.05 and 0.1 mm groups and the in vivo data indicating that the 0.01 mm groups 
presented with higher erythema and blood flow than the two higher thicknesses 
tested. Another potential interference when achieving a consistent layer of barrier 
cream could be due to skin structure. The skin is not a flat uniform surface, it has 
been previously estimated that 30% of total skin surface area is due to wrinkles 
(Kligman et al., 1985b). Wrinkles have also been documented in preventing a 
uniform covering of the skin surface by a topical product (Brown and Diffey, 1986). 
As the skin is not uniform, it would be reasonable to infer that any variations in 
application of products to the skin surface (in identical amounts) could be due to this 
difference. For example, if applying a barrier cream, it may be difficult to provide a 
consistent layer due to the furrows of the skin creating more surface area than 
expected. 
In Vitro Flexing 
Although there were generally no significant differences between immobile and 
flexed skin, a difference was observed in that the amount of methyl nicotinate 
penetrating flexed skin in RD-1433 0.01 mm treated group was less than static skin. 
This may have been due to the flexing motion resulting in the furrows of the skin 
cycling between stretched and returning to a static state, in which case barrier cream 
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from treated areas may have covered an area lacking the product (Figure 5.29). In 
general, there were no consistent differences in penetration, flux or recovery of 
14
C-
MN on the skin surface in the flexed skin groups compared to the static skin groups. 
Furthermore, in vitro flexing of skin did not show differences in application of test 
products, with the noticeable exception of the 0.01 mm RD-1433 treated group. In 
this regard, the 0.01 mm RD-1433 treated group was not shown to be significantly 
different to the untreated controls when tested in vivo, which may have been due to 
the restriction of movement of the volunteers when MN was applied and biophysical 
measurements were taken. In general, although in vitro flexing did not show a 
difference to static skin, both measurements correlated well to in vivo findings, 
which would also indicate that CutaFlex
™
 is a good measure of dermal absorption 
and consistent to an OECD-compliant model. 
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Figure 5.29: Schematic Of RD-1433 Spreading On The Skin Surface After Skin Flexing. Test product RD-1433 was applied to static and 
flexed skin at nominal thicknesses of 0.01, 0.05 and 0.1 mm. When applying RD-1433 in vitro at 0.05 and 0.1 mm, the skin surface was 
consistently covered (both furrows and surface), which was not the case when applying a nominal thickness of 0.01 mm to the skin surface. 
However, when skin treated with RD-1433 at a thickness of 0.01 mm is subsequently flexed, areas which were untreated come into contact with 
areas with barrier cream, allowing for spreading of the barrier cream more consistently and increased protection against 
14
C-MN compared to 
static skin (Viegas, 2014). 
0.1 mm 0.05 mm 0.01 mm
Static
Flexed
Static
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Relative Endpoints 
It has been thoroughly documented that the use of in vitro systems is not without 
several disadvantages, most notably the absence of systemic uptake and distribution, 
limited metabolic response, lack of systemic metabolism and finally an absence of an 
inflammatory-mediated response (Pendlington, 2008).  Arguably, the absence of an 
inflammatory response limits the extent of comparison between in vitro 
measurements of methyl nicotinate to in vivo studies. To compound this, previously 
frozen porcine skin was also used, resulting in a possible decrease in enzymatic 
activities. As the mechanism of action of methyl nicotinate involves both action of 
the compounds on the papillary plexus and radial spreading through the capillaries, 
neither of the two effects would be present in vitro when using previously frozen 
skin. The active metabolism of prostaglandin molecules in skin cells (which lead to 
erythema) are not seen in vitro. However, in vitro kinetics should correlate to some 
degree with a physiological response in vivo if using skin models and experimental 
conditions that are comparable. For example, methyl nicotinate penetration should be 
similar in vitro and in vivo if in vitro skin viability was maintained and if 
concentration and exposure time were identical.  
The benefit of using methyl nicotinate is the direct and rapid action in producing a 
response, in comparison to an inflammatory response caused by resulting histamine. 
Therefore, as a histamine-mediated immune response would be a longer process to 
initiate, it is thought that methyl nicotinate may still be relevant to study in vitro as 
skin can be dermatomed or epidermal sheets created to mimic the level of the 
capillaries (i.e. level of response).  
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If using a viable porcine skin preparation, it has been noted that the phenotype of 
enzyme expression in the skin of the domestic pig is similar to human patterns 
(Meyer and Neurand, 1976). However, in vitro correlation between human and 
porcine skin with ethyl nicotinate saw a difference in dermal penetration due to a 
difference in esterase activities (Ngawhirunpat et al., 2004). Esterases are 
ubiquitously expressed in mammalian tissues and activities are known to be 
preserved after skin freezing processes (Wilkinson, 2008). As the present study used 
previously frozen porcine skin, esterase activity was not monitored or quantified 
prior to evaluation of barrier creams. It is possible that residual esterase activity in 
porcine skin may have contributed to the in vitro response to MN being similar to the 
in vivo response. 
Sensitivity Of In Vitro Detection Versus In Vivo Detection 
With the present in vitro studies, percutaneous penetration of 
14
C-methyl nicotinate 
was directly quantified with collection in the receptor chamber allowing for detection 
down to as small as 0.5% (0.05 mg) of the applied dose. Guy et al. (1983) found that 
the response of methyl nicotinate was hampered by lower drug concentrations, which 
delayed the onset and magnitude of the response as well as shortening the duration of 
which changes in the microvasculature were seen. In the present study, the lowest 
amounts of methyl nicotinate penetrated were in the 0.1 mm RD-1433 treatment 
groups, in which both erythema and blood flow were still detected above baseline. 
Therefore, the concentration and exposure duration of MN chosen for the present 
studies provided a detectable response (even when providing significant protection 
against MN penetration) using both biophysical and radiometric measurements. 
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In terms of sensitivity within biophysical measurements, in vivo measurements of 
visual erythema and tissue viability imaging found that RD-1433 was only 
efficacious from 1-4 hours, whereas laser Doppler imaging found that RD-1433 was 
efficacious up to 6 hours a result that is in agreement with the quantitative amounts 
recovered in vitro. In vivo measurements of Vaseline
® 
treated groups found 
Vaseline
®
 to be ineffective at all time periods tested a result largely consistent with 
in vitro conclusions. Laser Doppler imaging is an important measure of skin health 
due to direct links between blood flow to thermoregulation and immune defence in 
addition to providing sensitive and rapid detection of vasodilators (i.e. methyl 
nicotinate (Taylor, 2008, Wester and Maibach, 1984). Laser Doppler imaging 
measures the response of a chemical in the skin through the Doppler effect whereas 
tissue viability imaging detects a depolarisation of reflected visible light. The main 
difference between LDI and TiVi is that the former detects superficial differences in 
blood flow, while the latter identifies deeper (reticular) changes in blood flow. In 
terms of methyl nicotinate detection and quantification (i.e. papillary plexus) LDI 
may provide a superior in vivo method of detection compared to TiVi. When 
sensitivity between techniques was semi-quantified, it was found that in vitro 
radiometric analysis provided a 10-fold increase whereas biophysical measurements 
of TiVi produced a 1.4-fold increase and LDI provided a 3.5-fold increase between 
minimum and maximum values (i.e. baseline and maximum response from MN). 
This would then seem to indicate that LDI may provide a better sensitivity and a 
closer one to that found with in vitro methodology. The increased sensitivity of in 
vitro testing also supplements other such advantages of lower inter-individual 
variability, lower costs and high-throughput data methods for this type of testing. 
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In terms of experimentation, both in vitro and in vivo procedures have advantages 
and disadvantages relating to detection of methyl nicotinate response and both work 
as complimentary techniques in order to detect erythema and blood flow changes as 
well as quantify amounts penetrating through the skin. 
TEWL Measurements 
Rates of transepidermal water loss flux were not found to differ between treatment 
groups or between the untreated controls both in vitro and in vivo. No correlation was 
found between TEWL rates and tritiated water penetrated, a result also documented 
in Chapter 3. An advantage that exists when using in vitro TEWL measurements is 
that the skin sections are not prone to effects such as diurnal variation, which are 
clearly seen with the in vivo TEWL rate decrease from baseline to post-treatment 
(Chilcott and Farrar, 2000).  
In Vitro and In Vivo Measurements Of Optimal Thickness And Duration Of Efficacy 
In the optimal thickness study, skin sections treated with RD-1433 at 0.05 and 0.1 
mm showed significantly lower penetration of methyl nicotinate and accompanying 
maximum flux (in vitro) compared to the untreated control as well as RD 0.01 mm 
treated groups and all Vaseline
®
 treated groups. Comparable decreases in erythema 
and blood flow (dose-dependent) were found with RD-1433 0.05 and 0.1 mm treated 
groups when using in vivo biophysical measurements. Between the two highest 
thicknesses used, 0.1 mm consistently provided better protection, at a minimum 2-
fold greater than the 0.05 mm treated groups.  
Although Vaseline
®
 treated skin was statistically different from the untreated control, 
the values of methyl nicotinate penetrated and accompanying flux were much higher 
than RD-1433 treated skin and Vaseline
®
 was not thought to provide consistent 
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results. Most importantly, these results agree with in vivo biophysical measurement 
findings that Vaseline
®
 treated skin sites were not found to be different than the 
untreated control for both erythema and blood flow.  
In the present study, it was also noted that all RD-1433 groups contained a greater 
amount of 
14
C-methyl nicotinate in the 60 (and 120) minute swabs than the 
corresponding Vaseline treated groups. This is thought to be attributed to the 
chemical constituents making up the RD-1433 formulation. RD-1433 is an overall 
amphiphobic formulation which provides a broad-spectrum of liquid repellence from 
chemicals, whereas Vaseline
®
 is a hydrophobic formulation consisting of a mixture 
of hydrocarbon molecules 20-25 carbons in length. Results from the present studies 
have shown a small amount of methyl nicotinate (~ 5%) was still present on the skin 
surface after 60-120 minutes, with removal only taking place after washing of the 
skin. As already highlighted with the evaporation study with tritiated water (i.e. 0 mg 
left after 30 minutes), the methyl nicotinate remaining would have been spread on 
the skin surface as a fine powder.  It is conceivable that the formulation of RD-1433 
and associated low surface energy acted as a liquid repellent, and as such kept MN 
on the skin surface and available for removal. In addition, Vaseline
®
 and associated 
lipophilic chains intercalating in the stratum corneum, could have assisted the 
translocation of methyl nicotinate from the formulation into the skin.  
When contrasting both in vitro and in vivo results, it can been seen in the statistical 
table provided in Section 5.3.5 that in vitro and in vivo measurements are in broad 
agreement. However, in vitro results were found to identify additional significant 
decreases in MN penetration than in vivo findings, this was thought to be due to the 
sensitivity of the in vitro technique. Additionally, as quantitative amounts of MN 
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penetration cannot be taken from in vivo biophysical measurements (only response is 
measured), it is difficult to draw a comparison to the amount of MN penetrated in 
vitro.  
In the duration of efficacy studies, both static and flexed skin treated with RD-1433 
showed significant decreases in methyl nicotinate penetration from 1-6 hours after 
treatment. This result was similarly seen in vivo with laser Doppler blood flow. 
Furthermore, Vaseline
®
 presented with inconsistent decreases in methyl nicotinate 
penetration from 1-4 hours, in addition to static and flexed skin showed a marked 
increase in methyl nicotinate penetration (and resulting flux) in the 6 hour treated 
group. In vivo measurements demonstrated consistently that Vaseline
®
 treated groups 
did not show decreases in either erythema or blood flow that were significantly 
different to the control. The range of protective property exhibited by RD-1433 
groups at one hour through to six hours, compared to Vaseline
®
 groups, 
corresponded to a 4- to 11-fold protection.  
A significant decrease in the amount of 
14
C-MN found in the skin was also found in 
the 6 hour flexed Vaseline
®
 group. This result corresponds to a significantly higher 
penetration (and rate) of methyl nicotinate in the 6 hour group. It is thought that 
interaction of the petrolatum chains with the stratum corneum lipids may be 
responsible for this effect as this would create a disruption in the lipid bilayer of the 
stratum corneum. Previous results in the literature have documented the effect of 
Vaseline
® 
in advancing barrier repair in vivo through the same mechanism 
(intercalating hydrocarbon chains with stratum corneum lipids) (Ghadially et al., 
1992). However, biophysical measurements indicate that RD-1433 also showed 
increases in both erythema and blood flow at 6 hours (although not significant) 
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compared to groups treated from 1-4 hours. As both products showed a similar trend 
of increased methyl nicotinate penetration/response, it is reasonable to presume that a 
contact duration of 6 hours may have resulted in possible hyperhydration of the 
stratum. However, this may not have been the case with skin treated with RD-1433 
as the perfluorinated formulation is generally permeable to water vapour. Hyper-
hydration of the stratum corneum has documented in producing damage to the skin 
barrier layer (Wester and Maibach, 1995, Warner et al., 1999). As both erythema and 
blood flow are biophysical indicators of a response by MN, it is thought that the in 
vivo results (although not quantitative) are more useful, as in vitro results showed 
that Vaseline
®
 treated groups (difference between in vitro and in vivo) provided very 
inconsistent results against the penetration of methyl nicotinate.  
Therefore, after a thorough assessment of three different test product thicknesses, it 
was determined through both radiometric and biophysical confirmation of significant 
decreases in methyl nicotinate penetration, erythema response and blood flow, that a 
thickness of 0.1 mm for RD-1433 would provide the best protection of the skin. 
Additionally, after testing of both test products for duration of efficacy from 1-6 
hours it can be seen that RD-1433 provides significantly better protection through 
lower penetration (and flux) of methyl nicotinate, erythema response and blood flow 
from 1-6 hours compared to Vaseline.  
Experimental Considerations 
The dose recovery data (Figure 5.9 and Figure 5.22) demonstrated considerable loss 
of 
14
C-methyl nicotinate from all diffusion cells, with up to 80% unaccounted for in 
the (untreated) controls. This could not have be accounted for by the volatility of 
MN, which is reported to be extremely low (approximately 0.4 hPa at 25°C; Merck 
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Millipore, 2014). Therefore, the rate of vapour loss of 
3
H2O and 
14
C-MN from an 
inert surface (foil) within the diffusion cells was measured. Surprisingly, MN 
initially evaporated quickly, with approximately 80% of the applied dose evaporating 
at 45 minutes (Figure 5.1). However, there was no further measurable loss after this 
time. This unusual behaviour can be explained by the concurrent loss of tritiated 
water, which evaporated completely by 45 minutes (Figure 5.1). When there was no 
further water available, the methyl nicotinate stopped evaporating. Thus, it appears 
highly likely that the relatively low recovery of 
14
C-MN in vitro was due to co-
evaporation with the (aqueous) vehicle, resulting in considerable (80%) loss of 
radioactivity in dose recoveries.  
Due to exposure to the environment, the amount of methyl nicotinate available for 
dermal absorption after 20 minutes on untreated skin was less than half of what was 
originally applied to the skin surface. It has been previously discussed that a major 
factor affecting dermal absorption is volatility, with more volatile chemicals 
presenting with less of a dermal absorption hazard (Chilcott, 2012). This is attributed 
to the amount of chemical potentially available to penetrate through the epidermis 
being less than that of a non-volatile substance. 
In Summary 
 RD-1433 provided significantly better protection against 14C-MN than Vaseline, 
especially at a thickness of 0.1 mm.  
 RD-1433 was proven to provide a protective effect against 14C-MN up to 6 hours. 
Vaseline treated skin could not provide an adequate level of protection. 
 In vitro static and flexed skin treated with RD-1433 correlated well to in vivo 
techniques. 
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 Skin flexed in the CutaFlex™ system provided a good correlation to human skin 
treated with methyl nicotinate.  
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6.1. General Discussion 
The main aim of this Thesis was to develop and characterise a novel skin diffusion 
cell that would facilitate controlled flexing of the skin during dermal absorption 
studies. To date, all in vitro diffusion cell studies have been performed using un-
flexed (static) skin. This is clearly not representative of the real-life situation, in 
which skin may be subject to various flexional forces, especially at jointed 
anatomical locations (e.g. elbow, knee, wrist, fingers). Therefore, the successful 
introduction of skin movement within a diffusion cell would represent a substantial 
refinement of existing in vitro dermal absorption models. 
A further need to establish a flexing system exists due to the recent rise in products 
incorporating nanomaterials and the subsequent potential risk arising from dermal 
exposure to nanoparticles (Royal Society Of Chemistry, 2012, European Commision, 
2006). Whilst it is accepted that nanoparticles exceed the established molecular 
weight limit for percutaneous penetration (by several orders of magnitude) and 
inherent molecular dimensions should physically impede permeation through the 
stratum corneum, it is conceivable that skin flexion may provide the necessary 
external force to assist translocation between adjacent corneocytes. Standard (non-
flexing) diffusion cells cannot be used to test such a hypothesis, therefore further 
highlighting the need for modifying current in vitro dermal absorption models. 
A series of pilot studies (not reported in this Thesis) assessed a number of flexing 
cell prototypes before establishing the current “CutaFlex™” design. At that stage of 
development, it became crucial to address a number of issues, specifically; 
1. Does flexing of skin within the CutaFlex™ system cause damage to skin 
barrier function? 
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2. Are dermal absorption measurements of model (well-studied) compounds 
attained within the CutaFlex
™
 system in agreement with historical values? 
3. Does the CutaFlex™ system exacerbate existing damage to skin barrier 
function? 
In addressing these issues, the CutaFlex
™
 system could then be deemed appropriate 
to investigate the hypothesis that skin flexion may assist in the translocation of 
nanoparticles through the stratum corneum. In support of this aim, additional studies 
were performed which contributed to the current debate on the relationship between 
skin permeability (measured directly with tritiated water) and transepidermal water 
loss (TEWL). Furthermore, the effects of skin flexing on the performance of topical 
skin protectants such as barrier creams was investigated. 
Initial work reported in Chapter 3 addressed the fundamental issues of the CutaFlex
™
 
system in relating the effects of skin flexing on (i) normal barrier function, (ii) the 
percutaneous penetration of model compounds and (iii) exacerbation of existing skin 
damage. It was demonstrated that skin flexing (2 flexes per minute; 6 mm maximum 
amplitude for up to 8 hours) did not cause any measurable disruption in normal skin 
barrier function, as evidenced by no significant change in the skin absorption kinetics 
of 
3
H2O (Figure 3.6), benzoic acid (Figure 3.10), caffeine (Figure 3.14) and 
testosterone (Figure 3.18) to those acquired with an OECD-compliant Franz-type 
static cell. Generally, dermal absorption patterns in this Thesis agreed with historic 
model compound data (Hawkins and Reifenrath, 1986, van de Sandt et al., 2004). In 
addition, flexing of skin did not generally exacerbate prior chemical and physical 
damage (Figure 3.2 and Figure 3.3).  
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Interestingly, no correlation was shown to exist between tritiated water penetration 
and TEWL flux (Figure 3.4 and Figure 3.5), with the former method providing a 
more sensitive indicator of barrier integrity. A number of studies have been 
published purporting to support the use of TEWL as a surrogate measure of skin 
barrier integrity (Nangia et al., 1998, Fluhr et al., 2006).  In contrast, only two 
studies have indicated that TEWL does not necessarily correlate with permeability of 
the skin to water (Chilcott et al., 2002, Hui et al., 2012). The results of this present 
study tend to support the argument that TEWL is not a good indicator of skin barrier 
function. It is tempting to conclude that this may be due, at least in part, to the 
relative insensitivity of evaporimeters compared to tritiated water measurements 
(Section 3.4). 
Overall, the data presented in Chapter 3 indicated that the CutaFlex
™
 system (when 
used within current parameters) provides an equivalent measure of in vitro dermal 
absorption to the standard well-characterised Franz cell and does not impair skin 
barrier function. 
The CutaFlex
™
 system was then applied to investigate the hypothesis that skin 
flexing may facilitate translocation of nanoparticles through the skin. In Chapter 4, it 
was found that quantum dot nanoparticles (of a variety of shapes, sizes and charges) 
were not able to penetrate intact porcine skin in the presence or absence of flexing 
(Figure 4.11 and Figure 4.12). In general, flexed skin did not show differences in 
nanoparticle partitioning or penetration compared to static skin (Figure 4.4, Figure 
4.5, Figure 4.6, Figure 4.11 and Figure 4.12). However, quantum dot charge was 
indicated as a factor influencing the extent to which QDots partitioning into the 
superficial layers of the stratum corneum, with negatively charged particles being 
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superficially absorbed to a greater extent than neutral or positively charged particles.  
It needs to be emphasised that the work reported in Chapter 4 represents a pilot study 
due to the limited number of skin samples (n=3) used in each treatment group.  
Therefore, further work involving a larger population of skin samples is needed to 
substantiate these initial findings, ideally with an additional treatment group to assess 
the effects of vehicle pH to confirm the findings of Prow et al. (2012) that skin 
barrier disruption (caused by alkaline conditions) may facilitate the dermal 
absorption of nanoparticles.  
Data presented in Chapter 5, whilst relevant to finding new preventative treatments 
against incontinence-associated dermatitis (IAD), was studied to examine the 
possibility that skin flexing could potentially affect the topical distribution (and 
hence performance) of barrier creams. These studies used measurements of the 
dermal absorption of radiolabelled methyl nicotinate to quantify the protective 
effects of RD-1433 (and a comparator product, Vaseline
®
).  A particular feature of 
this study was that it was subject to replication in a human volunteer study. This 
presented an opportunity to directly compare the predictive capability of the in vitro 
CutaFlex
™
 system (containing pig skin) with indirect measurements of methyl 
nicotinate penetration through human skin in vivo (by quantification of the 
erythematous response). From a clinical perspective, the novel barrier cream RD-
1433 was found to provide consistently better protection against 
14
C-MN penetration 
than the comparator product. For example, RD-1433 provided a 3- to10-fold increase 
in protection against 
14
C-MN compared to Vaseline
®
 when used at 0.05 and 0.1 mm 
thickness and was effective for up to 6 hours in comparison to Vaseline
®
 treated skin 
(Figure 5.5 vs. Figure 5.7 and Figure 5.18 vs Figure 5.20), a conclusion which was 
reproduced in the in vivo study (Figure 5.14 and Figure 5.26). Interestingly, skin 
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flexing appeared to influence the performance of RD1433 when applied at the 
smallest (0.01 mm) thickness (Figure 5.5). This effect was tentatively ascribed to the 
cream undergoing a redistribution on the skin surface (thus providing a protective 
coating to skin which was not dosed during the application – see Figure 5.29).  Most 
importantly, the rate, duration and extent of MN penetration measured in vitro was in 
excellent agreement with the in vivo biophysical measurements, particularly blood 
flow (laser Doppler imaging). These data strongly suggest that the in vitro CutaFlex
™
 
system is predictive of the human skin absorption of MN in vivo. Moreover, the 
CutaFlex
™
 system was deemed to be more sensitive in terms of ability to quantify 
dermal absorption of MN (as opposed to biophysical measurements of the 
physiological effects of MN in vivo). 
 
6.2. Summary  
Overall, the work reported in this Thesis has successfully demonstrated the practical 
feasibility of designing, manufacturing and characterising a skin flexing diffusion 
cell system which produces measurements of dermal absorption that are generally in 
good agreement with historical values of skin permeability to a range of model 
compounds. Flexing of excised skin samples had no measurable effect on the dermal 
absorption of model compounds, quantum dot nanoparticles or efficacy of barrier 
cream protection, although some evidence of an effect was observed in the protective 
performance of a barrier cream applied at a low dose (0.01 mm thickness). 
 
6.3. Future Studies 
Although data reported in this Thesis has addressed many relevant issues, there are 
also a number of interesting questions subsequently raised regarding additional 
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flexion scenarios. In particular, it is recommended that the following work be 
performed: 
 Assessment of dermal absorption of human skin within the CutaFlex™ system 
 Further skin damage studies (e.g. SLS, punctures, tape stripping) involving 
assessment of the percutaneous absorption of benzoic acid, caffeine and 
testosterone through a damaged skin barrier layer. In addition, an evaluation 
of QDot penetration through skin compromised through chemical or physical 
means (e.g. pH damage). 
 An evaluation of an extended range of nanomaterials (e.g. metal ions, solid 
lipid nanoparticles, gold, silver) in the CutaFlex
™
 system applied to both 
flexed and static skin in the presence and absence of controlled skin damage. 
 The use of several different concentration ranges of methyl nicotinate to 
determine minimum and maximum limits of detection in terms of an in vivo 
dose-response curve (to quantify the difference in sensitivity between in vitro 
and in vivo measurements). 
 Further study to quantify the extent to which esterase activity affects methyl 
nicotinate penetration in both fresh and previously frozen porcine skin 
compared to human skin. 
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